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Introduction 
Chapter I 
Weight loss is a major problem in many types of cancer and is associated with reduced 
quality of life and a poor prognosis. Weight loss can also interfere with potentially 
curable treatment [41,561. Many uncertainties remain about the mechanisms underlying 
weight loss in patients with cancer. This thesis describes a series of studies aimed at 
defining alterations in metabolic processes that are potentially related with weight loss in 
lung cancer patients. Although in literature the terms 'cachexia' (~ a syndrome of weight 
loss and rnalnutrition) and 'weight loss' are often used interchangeably, in this thesis 
weight loss will be preferentially used. 
In this chapter, current knowledge on weight loss in cancer and its relation with 
metabolic alterations are reviewed and the aim of this thesis is presented. 
Warren already recognised in 1932 that weight loss is a major cause of death in patients 
suffering from cancer [218J. Several studies have reported negative effects of weight loss 
on quality of life [161,162J, effectiveness of anti·cancer therapy [56,106J, and survival 
[43,93,164,169,198J. Incidences of weight loss vary from 36% in breast cancer to 61% 
in lung cancer patients [22,37,56,162, 198J. The degree of weight loss is independent of 
the disease stage, suggesting that tumour presence rather than tumour load is responsi-
ble [42,154J. 
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A typical feature of weight loss in lung cancer is increased breakdown of not only fat 
tissue, but also body protein [67,94,154,191, 192J. This loss of protein is characterised by 
the predominant loss of muscle protein, whereas visceral protein tend to be preserved 
[78,94J. In fact, organs such as liver and spleen tend to be enlarged [94J, possibly due to 
increased organ activity [38J or increased extracellular water [67J. In these respects, 
weight loss in cancer differs substantially from weight loss caused by simple starvation 
[21 J where weight is predominantly lost as fat tissue. The loss of muscle protein in 
cancer bears particular clinical significance because it contributes to fatigue, loss of 
muscle strength, morbidity and rnortality. 
It is generally assumed that weight loss is caused by an imbalance between energy 
intake and energy disposal within the body. Decreased nutrient intake caused by altered 
taste perception [82J or obstruction of the gastrointestinal tract [13,161 J is commonly 
observed in weight·losing cancer patients. The tumour itself or the antitumour therapy 
could mediate both processes [52, 118J. However, hyperalimentation by use of parenter-
al nutrition often fails to restore muscle mass or to prevent weight loss [35,39,55,191 J. 
Moreover, food intake of weight-losing lung cancer patients was not different from that 
of weight-stable patients [51,89,142J. Decreased food intake in cancer patients thus 
cannot fully account for the weight loss [153, 162J. 
Increased energy expenditure in lung cancer patients could also contribute to weight 
loss. High resting energy expenditure was reported in patients with lung cancer 
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(74,106,196) or gastrointestinal cancers (73). However, other investigators did not 
observe differences in energy expenditure between weight-losing patients with lung 
cancer and healthy controls (105,142,171) or weight·losing patients with non-malignant 
illness (66,87,155). 
Since involuntary weight loss in cancer patients is not simply due to either a reduction in 
energy intake or increased energy expenditure, altered host metabolism must playa 
role. This is particularly true for patients with lung cancer, a tumour type with a high 
frequency of weight loss, which is usually not accompanied by anorexia or gastrointesti-
nal obstruction. In this thesis, lung cancer is the main tumour type studied. In view of the 
accelerated loss of muscle protein that distinguishes the weight loss in cancer patients 
from that in normal starvation, our study is focllssed upon the relation between protein 
metabolism and carbohydrate metabolism. 
Protein metabolism 
I n healthy subjects, protein turnover, including amino acid transport, RNA-synthesis and 
synthesis of non-essential amino acids, accounts for 20% (221) to 50% (226) of the 
basal metabolic rate. Protein turnover rates, usually measured using (stable) isotope 
tracers, give an estimate of the amount of protein that is ll'lObilised within the body as a 
whole, including both synthesis and breakdown of protein. 
Elevated breakdown of whole-body protein has been reported in patients with 
various tumour types with or without weight loss (62,66,84,107,116,133,141,186, 
190,199). Studies in patients with lung cancer reported elevated protein turnover in 
weight-stable as well as weight-losing patients as compared to healthy control subjects 
(89,142,171) or non-cancerous patients without weight loss (66). However, protein 
turnover in lung cancer patients was not correlated with the degree of weight loss 
(66,89). Because of the close relation between protein turnover and energy expenditure 
[226J, eleVation of protein turnover rate will increase metabolic rate. However, in lung 
cancer patients this relation is not straightforward, since no correlation between whole-
body protein turnover and energy expenditure was observed (66). Thus, elevated whole-
body protein turnover has been confirmed in several studies, whereas its relation with 
weight loss remains unclear. 
Protein turnover in specific peripheral tissues of cancer patients has been investiga-
ted in a few studies in various tumour types. Muscle protein synthesis was decreased in 
the leg of patients with mixed tumour types, resulting in a net loss of protein (131). This 
loss of protein was characterised by elevated release of amino acids, especially alanine, 
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Figure 1.1 
Schematic pathway of hepatic gluconeogenesis and related metabolic routes in muscle and the intestine. 
Many of these reactions are reversible, but for clarity only flow directions of gluconeogenesis are indicated, 
including glucose-alanine cycling and Cori cycling. BCM, branched-chain amino acids. 
Introdud/on 
as compared to healthy control subjects [24,951. In one study muscle protein synthesis 
was measured in percutaneous muscle biopsies from cancer patients in the fed state 
[641. This also revealed decreased protein synthesis, whereas no change in whole-body 
protein turnover was observed. 
Carbohydrate metabolism 
Altered glucose metabolism in the cancer-bearing host rnay have been one of the first 
metabolic alterations recognised in patients with malignancies. Marks et al [1361 repor-
ted that impaired glucose tolerance was frequent in rnalignant disease, and this was 
confirmed by others [33,34,174,1801. 
Furthermore, elevated glucose turnover was reported in cancer patients with various 
tumour types [88,96,133,202,2041. In weight-losing cancer patients, levels of glucose 
turnover were higher than in weight-stable, non-cancer patients [1331. Koea et al/1161 
found a highly significant correlation bet\veen turnour bulk and glucose turnover in 
patients with various tumour types. In another study it was shown that initially high 
glucose turnover rates in weight-losing cancer patients with mixed tumour types increa-
sed even further within one month /331. Preferential use of glucose by tumour cells has 
been reported already around 1930 /2171, and was suggested to explain the need for 
elevated glucose production in the cancer host /79,96,115,122,138,148,2081. It was 
estirnated that the elevated glucose turnover could account for up to 40% of the increa-
se in energy expenditure observed in these patients /1331. 
Proposed mechanisms underlying elevated glucose production are enhanced gluco-
neogenesis or glycogenolysis. Figure 1.1 shows a schematic pathway of hepatic gluco-
neogenesis and related metabolic routes in rnuscle and the intestine. Elevated gluconeo-
genesis from lactate, glycerol, and alanine has been reported in cancer patients. Glucose 
production from glycerol is only minor, being estimated as "-'3% of total endogenous 
glucose production in cancer [1331. Lactate produced by glycolytic activity of tumour 
cells /91,98,2201 and skeletal muscle in cancer patients [951 is transported to the liver 
where it is recycled back to glucose, though the gluconeogenic pathway. This cycling of 
glucose to lactate and back to glucose is called Cori cycling. Since the anaerobic break-
down of glucose to lactate produces 2 ~P and recycling of lactate to glucose costs 6 
energy-rich phosphate bonds, the net cost of this pathway is 4 ~P per mole glucose 
produced. In weight-losing patients with colorectal cancer [971 or solid tumours [961, 
Cori cycling accounted for 32 - 50% of the total glucose turnover, respectively. Because 
of the high energy cost of Cori cycling, it was suggested that this could contribute to 
weight loss in cancer patients [791. However, Young [226] suggested that less than 10% 
5 
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of total energy expenditure could be accounted for by Cori cycling. 
Protein and carbohydrate metabolism interrelated 
6 
Enhanced hepatic glucose production in lung cancer could also be due to increasing 
rates of gluconeogenesis from muscle-derived amino acids [116,189). It has been esti-
mated that glucose production from amino acids and glycogen accounts for 20-50% of 
total glucose production in cancer patients (204). 
The main amino acids excreted from skeletal muscle are alanine and glutamine 
which account for >50% of amino acid nitrogen released by muscle in healthy subjects 
(69). Muscle provides ~70% of the alanine released into the systemic circulation and 
thus is the major source of plasma alanine (40). Additional amounts of alanine are 
released from the gut [69,165). Alanine is synthesised by transamination of pyruvate (95) 
coupled by breakdown of branched·chain amino acids (BCAA: leucine, valine, isoleuci-
ne). Seventy percent of the alanine from muscle is pyruvate-derived, whereas 30% is 
derived by proteolysis in healthy subjects [36,40,173). 
Alanine is preferentially taken lip by the liver, whereas a major part of glutamine is 
taken up by the gut and the kidney (Figure 1.1). The liver uses alanine for glucose 
production; alanine is the principal gluconeogenic amino acid used by the liver 
[71,109,201). The conversion of glucose to alanine in muscle and back to glucose in the 
liver is called the glucose-alanine cycle (68). It is estimated that glucose-alanine cycling 
accounts for 5-12% of total gluconeogenesis [68,69). 
The first data on elevated gluconeogenesis from alanine in weight-losing cancer 
patients were obtained in a group with mixed tumour types and compared with an 
undefined group of weight-losing non·cancerous patients (219). The contribution of 
alanine to gluconeogenesis in this study was estimated at ~5% [219J. In patients with 
localised oesophageal cancer, gluconeogenesis from alanine was increased but not 
related with weight loss (25). In lung cancer patients with weight loss, both glucose 
turnover and protein breakdown were increased (89) suggesting a relation between 
these tvvo processes. In another study by the same author, decreased plasma alanine 
levels were reported (88). The authors suggested that alanine was used as a substrate for 
endogenous glucose production in these patients [881. Thus, although gluconeogenesis 
from alanine is suggested to be elevated in cancer, its significance in lung cancer and the 
relation with weight loss remains to be determined. 
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Liver energy metabolism in cancer 
Elevated gluconeogenic rates in cancer may put an increased demand on energy meta-
bolism due to the high energy costs of this pathway 11 DO]. As the liver is the main site 
for gluconeogenesis, especially so for alanine, energy utilisation in this organ may be 
particularly influenced. 
In a study in healthy rats, a close correlation between gluconeogenesis from alanine 
and hepatic ATP concentrations was reported (147]. In isolated hepatocytes from 
sarcoma-bearing rats, gluconeogenesis was increased during incubation with lactate as 
compared to hepatocytes from healthy rats (211]. This increased gluconeogenesis 
resulted in a 42% decrease in AlP levels, whereas in healthy rats, no change in AlP was 
observed during incubation with lactate. This suggests that elevated rates of gluconeoge-
nesis in the cancer-bearing host put an increased demand on hepatic energy stores 
which may contribute to weight loss. Hepatic energy status was reduced in rats bearing 
prostate carcinomas or sarcomas, as observed by decreased ATP levels and increased 
Pi ATP ratios, indicating decreased phosphorylation status (49,181,211]. Changes in 
hepatic P JATP ratios were already detected before the development of significant 
weight loss and prior to a decrease in food intake (77,1811. 
In humans with cancer, information on liver energy status is very limited. In one study 
in cancer patients with various tumour types, liver ATP levels tended to be lower in 
patients with weight loss than in healthy controls (511. As these data were obtained in 
livers without malignant infiltration, rnetabolic alterations rather than morphologic 
changes were suggested to be involved. However, whether decreases in ATP were 
related with increased gluconeogenic activity within the Hver need to be confirmed. 
I ncreasing evidence is ernerging for elevated muscle protein degradation and increased 
endogenous glucose production in cancer. These processes rnay be interrelated, 
through muscle-derived alanine as a substrate for gluconeogenesis. No information on 
gluconeogenesis from alanine is available in lung cancer and it is not known whether this 
process is related to weight loss. Also, studies in humans with cancer have not provided 
inforrnation regarding the actual localisation of the gluconeogenic process. In addition, it 
is not known whether changes in hepatic glucose metabolism are associated with 
alterations in energy metabolism in the liver. 
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Aim 
The present research project is aimed at obtaining quantitative information on gluconeo-
genesis from alanine and on liver energy metabolism in relation with weight loss in lung 
cancer patients. The following specific study questions were formulated: 
1. Is liver gluconeogenesis increased and ATP concentration decreased in lung cancer 
patients, and are these alterations related with weight loss? 
2. Can depleted liver energy stores in advanced lung cancer patients be restored by ATP 
infusion, and does this affect glucose metabolism? 
3. Do alterations in hepatic gluconeogenesis predict subsequent weight loss in cancer 
patients? 
Techniques used for investigation of substrate metabolism 
8 
Substrate metabolism in humans has been extensively investigated using (stable) isotope 
tracer infusions. More recently, magnetic resonance spectroscopy (MRS), has been used 
to study metabolism in body tissues li1 vivo. MRS provides information non-invasively on 
cellular metabolism, such as energetics and substrate turnover (44), The metabolic state 
of the liver has been studied using 31 P MRS in healthy subjects [18,19,23,46, 195J as well 
as in patients [45,48,51,58,103,143, 146,215J. 
Other applications of 3I p MRS have been the dynamic investigation of liver substrate 
metabolism such as gluconeogenesis. In studies in healthy rats [30J or humans [50,177J 
bolus infusion of L-alanine as a gluconeogenic substrate induced increasing concentrati-
ons of hepatic phosphomonoesters (PME) and phosphodiesters (PDE). The increase in 
PME was observed to be dose-dependent [50J. Liver metabolite extraction in rats after 
alanine infusion confirmed these MRS changes to be secondary to increases in 3-phosp-
hoglycerate (3PG) and phosphoenolpyruvate (PEP), respectively (Figure 1.2)[50J. Phosp· 
horus MRS has also been applied to study the dynamics of energy metabolism in human 
liver, by measuring changes in AlP levels or P/AlP ratios during a metabolic challenge 
[16,157,183 J. In Figures 1.3 and 1.4, examples of an image with the localisation used for 
31 P MRS and a hepatic 31 P MR spectrum of a healthy subject are shown, respectively, as 
obtained by the technique used in the present thesis. 
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Figure 1,2 
High-resolution 31p MR spectra of extracts from control rat liver (a) and rat liver after 11,2 mmolJkg L-
alanine infusion (b), Proton-decoupled 31p NMR spectra were acquired at SAT using a 35° excitation pulse 
with a repetition time of lOs, Peak assignments: 3PG, 3-phosphoglycerate; PE. phosphorylethanolamine; 
PC, phosphorylcholine; Pi' inorganic phosphate; GPE, glycerolphosphorylethanolamine; GPc' glycerphosp-
horyicholine', y-ATP and P.ATP, y- and p-phosphate groups of ATP, respectively; NTP/NDP, nucleotide 
tri- and diphosphates; PCr, phosphocreatine (added as an internal chemical shift and concentration stand-
ard); PEP, phosphoenolpyruvate. The approximate positions of the multi component PME and POE peaks 
are indicated [50]. 
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Figure 1.3 
Transverse one-dimensional chemical shift image (I D-CSI) of the liver of a healthy subject obtained with a 
16 cm surface coil at 2.0 Tesla showing I x4 phase-encoding steps (volume 40X I OX4 cm). A methylene 
diphosphonate (MDP) reference sample in the centre of the coil is visible Qeft). The region of interest 
(second slice from the left) is used for measurements. 
POE 
P-ATP 
P, 
PME 
10 o -10 -20 ppm 
Figure 1.4 
Representative 31p MR spectrum of a normal human liver acquired at 2.0 Tesla using a 135° excitation 
pulse (60 0 weighted average in the liver volume) vvith a repetition time of I s. Peak assignments: PME, 
phosphomonoesters; Pi' inorganic phosphate; POE, phosphodiesters; P-ATP, p-phosphate group of ATP. 
The scale represents chemical shift in ppm. 
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Outline of thesis 
In Chapter 2, a study on whole body glucose and alanine turnover, and gluconeogene-
sis from alanine in patients with lung cancer is reported, and their respective relation 
with the presence and degree of weight loss is analysed. Chapter 3 explores the questi-
on of whether phosphornonoesters in the liver of lung cancer patients, as observed by 
31 p MRS, reflect gluconeogenic intermediates. In Chapter 4, hepatic gluconeogenesis 
from alanine in lung cancer patients with or withollt weight loss is investigated dynami-
cally during intravenolls infusion of L-alanine, with special emphasis on changing concen-
trations of gluconeogenic intermediates within the liver. Hepatic energy metabolism and 
phosphorylation status in lung cancer patients before and during L-alanine infusion is 
described in Chapter 5. Effects of intravenous ATP infusion in lung cancer patients on 
hepatic energy and phosphorylation status, and glucose metabolism are described in 
Chapter 6 and Chapter 7, respectively. Chapter 8 reports on gluconeogenesis and liver 
metabolism in patients with breast cancer. In Chapter 9, the prognostic value of eleva-
ted hepatic concentrations of MRS·observed gluconeogenic intermediates for the 
development of weight loss is investigated. The results of these studies are discussed and 
placed in a broader perspective of altered metabolism and weight loss in lung cancer in 
Chapter 10. 
II 
12 
Weight loss and gluconeogenesis from alanine 
in lung cancer patients 
American Journal of Clinical Nutrition (In press) 
Susanne Leij-Halfwerk/ Pieter C Dagnelie,t,2 J Willem 0 van den Berg/ 
J Darcos L Wattirnena,' Christien H Hordijk-Luijk,' JH Paul Wilson' 
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Chapter 2 
Abstract 
The role of gluconeogenesis from protein in the pathogenesis of weight loss in lung 
cancer has remained unclear. The aim was to study gluconeogenesis from alanine in 
lung cancer patients and to analyze the relation with the degree of weight loss. In a 
cross-sectional study primed-constant infusions of 16,6-'H,]-D-glucose and [3'- C1-L-
alanine were used to assess whole body glucose and alanine turnover, and gluconeoge-
nesis from alanine in weight-losing (CaWL, IF9) and weight-stable (CaWS, IF10) lung 
cancer patients, and healthy subjects (C, IFl 5). 
Energy intake and plasma alanine concentrations were not significantly different in 
CaWL, CaWS and C. Whole body glucose production was significantly higher in CaWL 
when compared with CaWS and C (0.74 ± 0.06, mean ± SEM, I'S. 0.55 ± 0.04 and 0.51 
± 0.04 mmoljkgjh, respectively, 1'<0.01). Alanine turnover was significantly elevated in 
CaWL (0.57 ± 0.04 I'S. 0042 ± 0.05 (CaWS) and 0040 ± 0.03 (C) mmoljkgjh, respective-
ly, 1'<0.01). Also, gluconeogenesis from alanine was significantly higher in CaWL (0047 ± 
0.04 mmoljkgjh I's.0.31 ± 0.04 and 0.29 ± 0.04, respectively, P<O.Ol). The degree of 
weight loss was positively correlated with glucose and alanine turnover, as well as with 
gluconeogenesis from alanine (r= 0045, r= 0045, and r= 0.45, respectively, all P <0.01). 
Aberrant glucose and alanine rnetabolisrn exists in weight-losing lung cancer patients. 
These changes are related with the degree of weight loss and not with the presence of 
lung cancer per se. 
Introduction 
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Weight loss is frequently observed in patients with cancer. There is evidence showing 
that weight loss is related to poor therapy outcome and reduced survival 143,56,198]. 
Weight loss may occur in early stages of cancer, even before other signs of the presence 
of a tumor appear. Although animal studies suggest that the development of weight loss 
in cancer is closely related to both the presence and the size of the tumor 15], in humans 
relations with the size, extent, stage, and type of the tumor are less clear [1151. 
When cancer patients lose weight, they lose both fat and muscle mass 194]. In 
comparison with anorectic patients with the same degree of weight loss, cancer patients 
lose relatively more muscle mass 160]. Although there is no doubt that anorexia is a 
frequent phenomenon in cancer patients, reduced food intake by itself does not explain 
the loss in lean body mass observed in these patients, implicating that derangements in 
host metabolism must be a major contributing factor 143,64]. 
Metabolic alterations which have been previously reported in cancer patients include 
elevated glucose turnover and 
[88,96,115,133,204). Other studies 
We4;rht loss and gluconeogenesis 
increased endogenous glucose production 
reported net protein catabolism in weight-losing 
cancer patients, mainly frorn muscle, whereas in weight-stable cancer patients no chang-
e in protein catabolism was observed [186). It has been hypothesized that increased 
amounts of alanine, originating from muscle degradation in cancer patients, are used for 
gluconeogenesis [5,261, with loss of nitrogen through urea production as a consequen-
ce. However, studies on gluconeogenesis from alanine in tumor-bearing animals PI and 
cancer patients [25,2191 are inconclusive as far as the relation with weight loss is concer-
ned. Furthermore, studies so far do not account for anorexia as a potential confounder 
since information on food intake was usually not acquired. 
Lung cancer is a tlllllor type with a high frequency of weight loss in which anorexia 
or obstruction are less likely to be the cause of the observed weight loss. Although 
elevated protein turnover rates have been reported in lung cancer patients with weight 
loss, the role of gluconeogenesis from protein in the pathogenesis of weight loss in this 
type of cancer has remained unclear [1421. 
The aim of the present study was to study protein-derived gluconeogenesis in a well 
defined group of lung cancer patients. For this purpose alanine was selected as a precur-
sor of gluconeogenesis because alanine is the key protein-derived glucose precursor 
utilized by the liver [201). Patients with and without weight loss were included in order 
to differentiate between possible effects of lung cancer and the degree of weight loss on 
gluconeogenesis in these patients. 
Subjects and methods 
Subjects 
Patients with histologically proven non-small cell lung cancer attending the outpatient 
department of the University Hospital Rotterdam, Rotterdam, The Netherlands, were 
recruited. Two groups of lung cancer patients were studied: patients, who had>. 5% 
weight loss in the previous 6 months (weight-losing, WL). and patients without weight 
loss in the previous 6 months (weight-stable, WS). Patients were only included after an 
interval of at least 3 months after surgery, or at least 4 weeks after chemotherapy or 
radiotherapy. Patients who were in remission or apparently cured were excluded. Other 
exclusion criteria were pregnancy, metabolic disease, corticosteroid treatment, liver 
metastases as verified by CT or ultrasound, alcohol consumption of more than 10 
glasses per week, and use of a slirnming diet. Healthy control subjects without weight 
loss were included as a reference. The study was approved by the Medical Ethical 
Committee of the Erasmus University Medical Center Rotterdam, Rotterdam, the Ne-
15 
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therlands. All participants signed informed consent. 
Dietary intake 
Food intake was recorded using a standard food diary during seven days preceding the 
experiment. The subjects received oral and written information from a trained nutritionist 
(SL) about the procedures for filling in the diary and registering all consumed drinks and 
foods using household measures. Subjects were asked to maintain their usual dietary 
habits and none reported any significant changes in their diet. Subjects abstained from 
alcohol during 5 days prior to the experirnent. All medication taken was noted. 
Household measures were converted into weights using a standard food conversion 
table (Department of Hwnan Nutrition, Wageningen, The Netherlands) and a nutrition 
software program (Komeet version 2.0, B-Ware, Arnhem, The Netherlands). Average 
daily intake of energy, fat, carbohydrate and protein was calculated. 
Study design 
Body weight, height, upper~arm circumference, and thickness of four skinfolds (triceps, 
biceps, subscapular, supra iliac, using a standard skinfold caliper (Holtain Ltd., London, 
Great Britain)) were measured and the body mass index was calculated. The upper-arm 
muscle circumference was calculated as described by Frisancho [75]. 
The subjects were studied in the rnorning after an overnight fast. A cannula (0.8X 2S 
mIn) was positioned in the left cubital vein for the infusion of stable isotope tracers. In 
the contralateral cubital vein, an identical cannula was positioned for blood sampling. To 
study gluconeogenesis, a solution was prepared containing [6,6~2H2I-D-glucose, 98 
atom%, and [3-13C}-L-alanine, 99 atom% (Mass Trace, Woburn, USA), in water and this 
was sterilized by autoclavating in glass vials. A priming dose of 30 Ilmoljkg [6,6-'H,]-D-
glucose was administered followed by a continuous infusion of 10 Ilmoljkg/h [6,6-'H,]-
D-glucose for 90 minutes. Simultaneously, a priming dose of 80 Ilmoljkg [3-13q-L-alanine 
was given followed by a continuous infusion of 40 Ilmoljkg/h [3-13Q.L-alanine during 90 
® 
minutes. Both tracer solutions were infused llsing calibrated syringe pumps (Perfusor 
fm, Braun, Gerrnany). 
Venous blood sarnples \-vere drawn immediately before the isotope infusions were 
started, and at 10 min intervals from 60 to 90 min., when steady state conditions during 
the tracer infusions had been achieved. Plasma concentrations of glucose, alanine, 
insulin, glucagon, and thyroid hormones as well as isotopic enrichment of glucose and 
alanine were determined. 
We&"ht kxs and glucolleogenesis 
Analytical methods 
Blood san1l,'les were collected in tubes containing lithium heparin (Becton Dickinson 
Vaclltainer , Meylan Cedex, France) and immediately stored on ice. After centrifugation 
(10 min., 1200g, 4 " C), the plasma was collected and stored at -20"C until analyzed. An 
aliquot of the infusate was analyzed to document actual concentrations of the tracers in 
each study. 
Blood glucose concentrations were determined enzymatically with glucose-oxidase 
and peroxidase (Boehringer Mannheim, Mannheim, Germany). Plasma alanine was 
measured enzymatically as described by Williamson [223]. Plasma concentrations of 
insulin and glucagon were determined by radio imrnuno assay techniques (Biosource, 
Fleurus, Belgium and Euro-Diagnostica, Sweden, respectively). Serum total T" and T 
were measured by radio immuno assay, and total rT3 was measured according to Bauer 
[ 11]. 
Isotopic enrichments were determined using the following procedures. Plasma was 
deproteinized by adding 0.3 M barium hydroxide (Sigma Diagnostics, St.louis) and 0.3 
M zinc sulphate (Merck, Darmstadt, Germany). After centrifugation (8 min.,15000g, 
4°C) the supernatant was applied to an ion exchange column (mixed bed: AG50W-X8 
and AG1-X8, 200-400 mesh, 0.2 g each; BioRad, California). Glucose and alanine were 
eluted from the column using water and 4 M amrnonium hydroxide (Merck, Darmstadt, 
Germany), respectively, and dried under nitrogen. A glucose derivate (aldonitril penta 
acetate) was made according to Varma et al [216]. An alanine t-butyldimethylsilyl 
derivate was prepared as described by Chaves Das Neves et al [32]. 
Isotopic enrichments were rneasllred by injecting 1 ~I samples with a splil ratio of 
50:1 on a fused silica capillary column of 25 m x 0.22 mm, coated with 0.11 ~m HT5 
(SGE, Victoria, Australia). The relative isotopic enrichments of deuterated glucose and 
carbon-13 alanine were determined using a Carlo Erba GC8000 gas chromatograph 
coupled to a Fisons MD800 mass spectrometer (GC-MS) (Interscience B.V., Breda, The 
Netherlands) in electron impact ionization mode. The variation coefficient in enrichment 
was 0.2 mole% for both [6,6-'H,]-glucose and [3'-' C)-alanine, and no concentration 
effect was observed at this level of fnole% enrichment. (ons were selectively monitored 
at mass per unit charge (nVz) 187 for natural glucose and 189 for the deuterated mole-
cule. The isotopic enrichment of [3-13C)-alanine was determined at the m/z ratios 260 
and 261 for carbon-12 and carbon-13 alanine, respectively [137]. 
Total enrichment of carbon-13 glucose was measured separately (aldonitril penta-
acetate derivation) using a gas chromatograph cornbustion isotope ratio mass spectro-
meter (GC-IRMS) (Optima, Micromass UK, Middlewich, Cheshire, Great Britain). The 
{I3CJ-glucose enrichment in atom% excess (APE) was monitored after combustion to 
CO, at mass 44 for carbon-12 and 45 for carbon-13, respectively. 
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Calculations and statistics 
Whole body rate of appearance (R.) of glucose and alanine were calculated during 
steady state following a one-compartment model, using the formula: 
R. ~ F, x ((IE, /IE",) -1), (1 ) 
where F, is the isotope infusion rate (mmol/kg/h), IE the isotopic enrichment of the 
infusate (mole% excess, MPE), and IE", the isotopic enrichment of the extracellular fluid 
(plasma)(MPE)(224J_ The percentage glucose produced from alanine equals: 
( \3 I / ( \3 I . ))" ( ) IE C-g ucosepllim• IE C-a alllnep;"m. x 0.33 xl0mo 2 
where IE 13C-glucaseplasma is the isotopic enrichment in plasma (expressed 3 as 2 CO 
atam% excess, APE). Since alanine has three carbon atoms, 100% enrichment of [3-13CJ-
alanine (mole percent excess, MPE) is equivalent to 33% enrichment of B CO, from 
alanine (atom percent excess, APE). Therefore, the enrichment of alanine (MPE) is 
multiplied by 0.33 in order to obtain comparable enrichments (i.e. expressed as "CO, 
atom% excess) far bath alanine and glucose. Gluconeogenesis from alanine 
(mmol/kg/h) is then obtained as: 
% glucose from alanine x R., (I'H,J-glucose). (3) 
Finally, the percentage of alanine converted into glucose was calculated by dividing the 
rate of gluconeogenesis from alanine by the rate of appearance of alanine 140J. 
Results are presented as means ± standard error of the mean (SEM). Differences 
between group means were compared simultaneously using analysis of variance, adjus-
ting for age. Bonferroni correction was applied to allow for multiple testing. The correlati-
on between variables was analyzed using Pearson's correlation coefficient. Multiple 
linear regression was used to analyze interrelationships with adjustment for possible 
confounders. Differences were stated statistically significant at Pvalues < 0.05. 
Results 
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Study popUlation 
Nineteen lung cancer patients, nine weight-losing (7 males, 2 females) and ten weight-
stable (6 males, 4 females), and fifteen healthy control subjects (3 males, 12 females) 
were included in the study. The lung cancer patients had been diagnosed with non-srnall 
cell lung cancer stage lilA (one W5, three WL), IIIB (three W5, two WL) or IV (six W5, 
four WL) (WHO grading system). The characteristics of the study population are descri-
bed in Table 2.1. Age was significantly higher in the lung cancer patients compared to 
the healthy control subjects (P<0.05). The WL patients had lost 9.0 ± 1.4 kg or 12% 
(range 6 - 22%) of their pre-illness stable body weight within the six months preceding 
the study, in contrast with WS lung cancer patients and healthy subjects. Body weight, 
Wewht loss and gluconeogenesis 
percent of ideal body weight, body mass index, mid-upper arm circumference, and the 
sum of four skinfolds were significantly lower in WL lung cancer patients compared with 
WS patients and control subjects (f'<0.05). Upper-arm muscle circumference was 
slightly, but not significantly, lower in the WL cancer patients than in WS cancer patients 
and healthy control subjects. Albumin and transthyretin (pre albumin} concentrations 
were lower in the WL than in WS patients and healthy control subjects (P<O.Ol). 
Dietary intake 
None of the subjects reported any changes in food intake compared with pre-illness 
food intake. Carbohydrate intake preceding the experiment was at least 200 gjd in all 
subjects (Table 2.2). No significant differences in energy, carbohydrate, protein or fat 
intake were found among the groups. 
Glucose and alanine metabolism 
Baseline plasma glucose and alanine concentrations were not significantly different 
between the lung cancer patients and healthy control subjects, but glucose levels in WL 
patients were significantly higher than in WS patients (P<0.05) (Table 2.3). Steady state 
was reached within 60 minutes after the start of the isotope tracer infusions as judged 
from visual inspection of isotope enrichment profiles. Relative isotopic enrichments of 
['H,j-g[ucose, [13Cj-a[anine and [ 'ej_g[ucose in plasma during steady state were not 
statistically different between the groups .. Turnover rates of glucose and alanine are 
shown in Figure 2.1. Whole-body glucose turnover was significantly higher in the WL 
lung cancer patients than in WS patients or healthy control subjects (P<O.Ol). Simi[arly, 
alanine turnover was significantly higher in the WL lung cancer patients than in the two 
other groups (f'<0.01). Gluconeogenesis from alanine was significantly elevated in the 
WL lung cancer patients when compared with both WS lung cancer patients and hea[-
thy controls (P<O.Ol). The percentage glucose derived from alanine varied from 64.6 ± 
4.2 in the WL and 60.2 ± 11.8 in WS lung cancer patients to 55.0 ± 4.8% in healthy 
control subjects (N.S.). The percentage of alanine converted into glucose was 84.2 ± 6.9, 
70.4 ± 7.1, and 70.0 ± 7.1 %, respectively (N.S.). Glucose and alanine turnover, and 
gluconeogenesis from alanine were significantly correlated with the degree of weight 
[ass (r~0.45, 0.45, and 0.45, respectively, all f'<0.01) and inversely correlated with 
percentage of ideal body weight (r~ -0.38, -0.44, and -0.50, respectively, all P<0.05). The 
relation between gluconeogenesis from alanine in lung cancer patients and percentage 
of weight [ass is shown in Figure 2.2. 
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Table 2.1 
Characteristics of the study population' 
Control Lung cancer 
Age (y) 
Height (m) 
Weight (kg) 
% Ideal bodyweight(%) 
Weight loss (%; 6 mo) 
Body mass index (kg/m') 
Arm circumference (cm) 
Arm muscle circumference (cm) 
Sum of skinfolds (mm)' 
AJbumin (gil) 
Transthyretin (gil)' 
(n= 15) 
52 (29-72)"" 
1.74 ± 0.Q2 
77.2 ± 2.5' 
123.0±4.1' 
25.7 ± 0.8' 
32.1 ± 1.OJ 
26.1 ± 0.9 
69.6 ± 4.0' 
0.29 ± 0.01' 
WS 
(n= I 0) 
63 (38-75)' 
1.69 ± 0.D3 
73.5 ± 3.8b 
I 19.3 ± 6.4b 
-2.0 ± 1.0' 
25.6 ± 1.3° 
30.3 ± l.4b 
26.0 ± 0.9 
64.6 ± 8.4b 
44 ± Ib.4 
0.28 ± 0.02'·4 
WL 
(n=9) 
69 (53-81)' 
1.71 ± 0.03 
60.9 ± 3.5'b 
96.0 ± 5.0,b 
12 ± 2' 
20.9 ± 1.1"'" 
26.1 ± 1.2,b 
24.4 ± 1.4 
29.8 ± 3.8,b 
38 ± 2a,b.4 
0.17 ± O.02'b 
I Mean:::!::: SEM. Differences between group means were appraised by analysis of variance; WS, weight-
stable; WL, weight-losing. Means Vvithin a row with a superscript letter in common are significantly different, 
P<O.05. 
2 Mean (range). 
3 Calculated as the sum of the biceps, triceps, SUbscapular, and suprailiac skinfolds (mm). 
4 One value missing . 
.5 Prealbumin. 
Turnover measurements were not correlated with gender or age. Multivariate analysis 
showed that only the degree of weight loss was a significant predictor of glucose and 
alanine turnover as well as of gluconeogenesis from alanine. Neither energy, nor carbo-
hydrate or protein intake on the day prior to the experiment were related with plasma 
glucose and alanine concentrations nor with turnover measurements. 
Hormone concentrations 
Fasting insulin and glucagon concentrations, and insulin:glucagon ratios were not signifi-
cantly different between lung cancer patients and healthy controls (Table 2.4). Glucagon 
levels in WL patients were lower than in WS patients (P<O.Ol). Insulin / glucagon ratios 
were significantly correlated with alanine turnover (r~ ·0.36, P=0.04). 
We&ht loss and gluconeogenesis 
Table 2.2 
Daily intake of energy and selected nutrients in hea~hy control subjects, weight-stable and weight-
losing lung cancer patients. I 
Control Lung cancer 
WS WL 
(n= 15) (n= 10) (n=9) 
Energy (kJ(day) 7838 ± 401 8260 ± 405 8170 ± 644 
Fat (g/day) 77 ± 5 80 ± 5 74 ± 9 
(energy %) 37 ± I 37 ± I 34 ± 2 
Carbohydrate (g/day) 206 ± 13 224 ± 12 231 ± 16 
(energy %) 45 ± 2 46 ± I 48 ± I 
Protein (g/day) 79 ± 4 85 ± 5 81 ± 5 
(energy %) 17 ± I 18 ± I 17 ± I 
t Mean::!: SEM. Based on 7 -day food record. Differences between group means were appraised by analysIs 
of variance, adjusted for age, WS, weight-stable; WL, weight-lOSing, Means within a row with a superscript 
letter in common are significantly different, P<O.05, 
No other significant correlations between insulin or glucagon concentrations and turno-
ver rneasure- ments were observed. Thyroxine (T4 ) and T) levels did not differ between 
any of the groups. In contrast, rT, and rT, / T, ratios were significantly elevated in WL 
lung cancer patients (P<0.05) and were correlated with the degree of weight loss (r=0.47 
and FO.53, respectively, P<O.Ol). Reverse T3 concentrations were also correlated with 
glucose turnover (r=0.36, P=0.03). 
Discussion 
The present study was aimed at quantifying gluconeogenesis from alanine in both 
weight-losing and weight-stable patients with advanced lung cancer compared to heal-
thy control subjects. Although several authors have reported abnormal glucose metabo-
lism in patients with advanced malignant disease [60,96,116, 133,204J, there are few 
studies in lung cancer patients. Heber et al [88J reported elevated glucose turnover rates 
in 65% of non-small eel/lung cancer patients with weight loss. 
Furthermore, elevated whole-body protein turnover has been reported in cancer 
patients, using different amino acids {62,64, 116, 133, 1861, but data in lung cancer 
21 
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Table 2.3 
Plasma glucose and alanine concentrations, and isotopic enrichments (IE) of plasma glucose and 
alanine during turnover measurements in healthy control subjects, weight-stable and weight-
losing lung cancer patients. / 
Glucose (mmoliL) 
AJanine I)JmoliL) 
Isotopic enrichment of plasma: 
'H,-glucose (MPE)2 
13C-alanine (MPE)2 
l3C-glucose (APE)' 
Control 
(n= 15) 
5.9 ± 0.2 
347 ± 6 
2.19 ± 0.25 
8.78 ± 0.78 
1.52 ± 0.14 
Lung cancer 
WS 
(n= 10) 
5.2 ± 0.2' 
368 ± 8 
1.88 ± 0.19 
8.32 ± 0.62 
1.49 ± 0.18 
WL 
(n=9) 
5.8 ± 0.3' 
349 ± 13 
1.55±0.13 
7.22 ± 0.60 
1.53 ± 0.13 
I Mean ± SEM. Isotopic enrichments were determined under steady state conditions during primed-
constant infusions of [6,6-2H2J-D-glucose and [3 13 eJ-L-alanine. Differences between group means were 
appraised by analysis of variance, adjusted for age; WS, weight-stable; WL, weight-losing. Means within a 
row with a superscript letter in common are significantly different, P<O.OS. 
1 Mole% excess. 
3 13C02 Atom% excess. 
patients are sparse and inconclusive regarding the role of weight loss. Richards et al 
[1711, using a primed·constant infusion of [I5NI_glycine, reported increased protein 
turnover rates in patients with advanced lung cancer with weight loss. Melville et al 
[1421 also reported elevated protein turnover in newly diagnosed, non-metastatic lung 
cancer patients using !13CHeucine, but these authors did not observe any relation with 
weight loss. Fearon et al [661 studied lung cancer patients (stage II/III) both with and 
without weight loss; whole body protein turnover rates as measured by [I5NI-glycine 
\-vere elevated in all cancer patients, but again, no relation with weight loss was obser-
ved. Heber et al [891 reported elevated protein turnover in lung cancer patients as 
measured by [14q_lysine, which was inversely correlated with percent of ideal body 
weight but not with the degree of weight loss. In the present study in lung cancer pa-
tients alanine turnover was significantly correlated with both the degree of weight loss 
and percent ideal body weight. 
So far, gluconeogenesis from alanine in cancer patients has only been studied using a 
single bolus infusion of ['-tel-alanine, i.e. in non-steady state conditions. Waterhouse et 
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Figure 2.1 
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We&"ht loss and gluconeogenesis 
D Control 
r=I Lung cancer, WS 
• lung cancer, WL 
Gluconeogenesis 
from alanine 
Whole body rate of appearance (turnover) of glucose and alanine, and gluconeogenesis from alanine in 
healthy control subjects (n= 15), weight-stable \!'IS. n= I 0), and weight-losing 0NL. n=9) lung cancer 
patients. Turnover rates were assessed using primed--constant infusions of [6,6-2HJ-glucose and [3 J3 q-
alanine. Bars and error bars represent means ± SEM. **Significantly different from WS lung cancer patients 
and healthy controls, P<O.O I (ANOVA, adjusted for age). 
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Figure 2.2 
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20 
Gluconeogenesis from alanine in lung cancer patients plotted against the degree of weight change from pre-
illness stable weight in the previous 6 months (n= 19). Gluconeogenesis from alanine was assessed using 
primed--constant infusions of [6,6-2H2}glucose and [3- 13C}alanine. r, Pearson's correlation coefficient. 
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Table 2.4 
Fasting hormone concentrations in hea~hy control subjects. weight-stable and weight-losing lung 
cancer patients.' 
Insulin (mU;L) 
Glucagon (ngiL) 
Insulin 1 Glucagon 
T4 (nmol;L) 
T, (nmol;L) 
rT, (nmol;L) 
rT,/T, 
Control 
(n~ 15) 
9.3 ± 1.2 
20 ± 2 
0.5 ± 0.1 
100 ± 10 
1.85 ± 0.12 
0.26 ± 0.02' 
0.15 ± 0.02' 
Lung cancer 
WS WL 
(n~ 10) (n~9) 
11.2 ± 2.9 8.3 ± 2.22 
28 ± 3' n±Y 
0.4 ± 0.1 0.8 ± 0.3 
107 ± 5 103 ± 8 
1.87 ± 0.06 1.63 ± 0.17 
0.30 ± om' 0.40 ± 0.05" 
0.16±0.02 0.27 ± 0.05" 
I Mean.:::!:: SEM. Differences between group means were appraised by analysis of variance, adjusted for age; 
WS, weight-stable; WL, weight-losing. Means within a row with a superscript letter in common are signifi-
cantly different. P<O.OS. 
'lOne value missing. 
al [219J reported elevated rates of alanine-to-glucose conversion in WL cancer patients 
with mixed tumor types and metastatic disease when compared with undernourished 
subjects without cancer. Dietary intake was not reported in that study. Burt et al [25J 
reported elevated alanine turnover in patients with localized esophageal cancer, which 
was not related with the degree of weight loss. The present study, which was performed 
under steady state conditions with infusion of [2H21-glucose and [I3Cl-alanine, demonstra-
ted that gluconeogenesis frolll alanine was elevated in weight-losing but not in weight-
stable lung cancer patients. 
It should be noted that the approach using ["C)-alanine underestimates gluconeoge-
nesis due to dilution of I3C in intracellular pyruvate pools and at oxaloacetate, caused by 
exchange with the TCA cycle [224J. We assumed that the the yield of transfer of "c 
from alanine to glucose via the oxaloacetate turnover in liver and the extent of 13C02 
reincorporation via gluconeogenesis into carbons 3 and 4 of glucose are identical in all 
three groups. Furthermore, due to rapid exchange of 13C between alanine and pyruva-
te/lactate, gluconeogenesis may include a contribution from Cori cycling. We were able 
to n1easure 13C enrichment of lactate and found no differences between healthy sub-
jects, weight-stable or weight-losing lung cancer patients. Food intake was carefully 
We~ht loss and gluconeogenesis 
monitored in all subjects by rneans of a dietary record on the seven days preceding the 
turnover measurements. Results revealed no significant differences in energy intake 
between weight-losing and weight-stable lung cancer patients, or healthy control sub-
jects; in fact lung cancer patients tended to have higher energy intakes than healthy 
controls. In other words, weight loss and the difference in turnover measurements in our 
study population of lung cancer patients were unrelated with reduced food intake. 
Several mechanisms may be responsible for an elevated gluconeogenesis from 
alanine in weight-losing lung cancer patients. Increased gluconeogenesis could be 
caused by decreased insulin or increased glucagon concentrations [101,174). However, 
in our study and studies by others [60,88,89J fasting insulin concentrations were not 
decreased in weight-stable or weight-losing lung cancer patients. Furthermore, no diffe-
rence in glucagon concentrations between lung cancer patients and healthy controls 
was observed. Rofe et al [174) reported an altered insulin response and insulin: gluca-
gon ratio in cancer patients with various tumor types, although there was no consistent 
relationship with the degree of weight loss in these patients. Clearly, it is not possible to 
define mechanisms on the basis of plasma concentrations of insulin or glucagon alone; 
however, our data do not support a predominant role for insulin or glucagon concentra-
tions in the observed alterations in gluconeogenesis in weight-losing fung cancer pa-
tients. 
A second hypothesis is that elevated gluconeogenesis from alanine is due to increa-
sed substrate availability or increased transport of alanine into the liver. In animal studies 
in vivo, alanine concentrations in the liver of tumor-bearing hosts were elevated [1 72J, 
but plasma concentrations were normal [4) or decreased [101), suggesting elevated 
uptake of alanine by the liver. Reduced plasma alanine concentrations in weight-losing 
lung cancer patients have been reported by some authors [28,88). However, in the 
present study we did not detect differences in plasma alanine concentrations between 
weight-losing and weight-stable lung cancer patients and healthy controls, despite a 36% 
increase in alanine flux in the weight-losing cancer patientsi moreover, no correlation 
between plasma alanine concentrations and alanine turnover was observed (r= -0.08, 
P=0.67). Based on our results, it would therefore appear that elevated alanine turnover 
would be simply caused by increased plasrna alanine concentrations; however, based 
on our data the possibility of an increased alanine uptake by the liver cannot be ruled 
out. 
Yet other possible mechanisms are the acute-phase response and circulating cytoki-
nes [135,182,207) and/or elevated activity of one or more gluconeogenic enzymes 
within the liver, as demonstrated for phosphoenolpyruvate carboxykinase, glucose-6-
phosphatase [83), and pyruvate carboxylase [128) in in vitro models. In weight-losing 
lung cancer patients, hydrazine sulphate reduced glucose production [34) and increased 
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plasma alanine levels [2031, probably by inhibiting phosphoenolpyruvate carboxykinase. 
However, no data on hepatic gluconeogenic enzyme activities in hurnans with lung 
cancer are available. 
Gluconeogenesis from alanine is an energy consuming process and enhanced 
conversion of alanine into glucose could act as an energy depleting mechanism. Though 
elevated gluconeogenesis Illay be an important factor in the pathology of weight loss in 
lung cancer, this does not preclude contributions from other energywwasting processes 
to weight loss in lung cancer. Nevertheless, increased gluconeogenesis from alanine 
could result in loss of body protein. It is thought that loss of muscle mass contributes to 
impaired muscle function and decreased survival [56,1541. 
In summary, elevated rates of glucose and alanine turnover as well as gluconeogenew 
sis from alanine have been detected in advanced lung cancer patients with weight loss. 
These metabolic abnormalities are neither related with the presence of lung cancer nor 
with reduced energy intake. Prospective studies on the relation between elevated 
gluconeogenesis from alanine and weight loss in lung cancer and the underlying n1echa-
nisms are warranted. 
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Abstract 
Stable isotope tracers were used to assess whether levels of phosphomonoesters (PME) 
and phosphodiesters (POE) in the liver of lung cancer patients, as observed by "P 
magnetic resonance (MR) spectroscopy, reflect elevated whole body glucose turnover 
and gluconeogenesis from alanine. Patients with advanced non-small cell lung cancer 
without liver metastases (n=24), weight loss 0-24%, and healthy control subjects (n=13) 
were studied after an overnight fast. 31 P MR spectra of the liver li7 vivo were obtained 
and glucose turnover and gluconeogenesis from alanine were determined simultaneous-
ly using primed-constant infusions of (6,6-'H,I-glucose and !3-l3q-alanine. 
Liver PME concentrations were 6% higher in lung cancer patients cornpared to 
controls (NS); PME levels in patients with ;,5% weight loss were significantly higher than 
in patients with <5% weight loss (P<0.01). POE did not differ between the groups. In 
lung cancer patients, whole body glucose production was 19% higher (NS) and glucone-
ogenesis from alanine 42% higher (P<0.05) compared to healthy subjects; turnover rates 
in lung cancer patients with::?: 5% weight loss were significantly elevated compared to 
both patients with <5% weight loss and healthy subjects (P<0.05). PME levels were 
significantly correlated with glucose turnover and gluconeogenesis frorn alanine in lung 
cancer patients (r=0.48 and r=0.48, respectively, P<0.05). 
In conclusion, elevated PME levels in lung cancer patients appear to reflect increased 
glucose flux and gluconeogenesis frorn alanine. These results are consistent with the 
hypothesis that elevated PME is due to contributions from gluconeogenic intermediates. 
Introduction 
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'A/eight loss is a common phenomenon in patients with cancer and significantly contri-
butes to the high morbidity and mortality in this disease [43,56,1981. Since it was sugge-
sted that anorexia alone cannot fully account for the occurrence of weight loss in several 
tumor types including lung cancer, attempts have been made to investigate underlying 
mechanisms in the cancer-bearing host. Profound alterations in host metabolism inclu-
ding elevated protein breakdown [1711, increased gillcose turnover (891 and endoge-
nous glucose production 12191 have been reported and were suggested to contribute to 
the obselVed weight loss in cancer. 
It has been argued that the liver may play an important role in the metabolic alterati-
ons which contribute to weight loss in cancer (20,1151. Altered enzyme activities 
(6,83,92,1751 as well as decreased phosphorylation and energy status 16,491 were 
reported in the liver of tumor-bearing rats. Increasing tumor burden was shown to be 
Hepatic sugar phosphates and gluconeogenesis 
correlated with decreasing phosphorylation status (181 J and increasing gluconeogenic 
enzyme activity in the liver (156J. In contrast, in humans information on liver metabolism 
in cancer is extrelnely scarce. In human hepatomas, activities of pyruvate carboxylase, 
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, all regulatory enzymes 
of gluconeogenesis, were elevated compared to normallfver tissue [86]. 
In order to understand alterations in liver fnetabolism in cancer patients it is essential 
to obtain information on liver in vivo. Although non-specific changes in 31 p magnetic 
resonance (MR) spectra have been detected in various liver diseases including primary 
and secondary hepatic cancer, systemic effects of cancer on tumor-free host liver have 
rarely been investigated in humans in vivo. In a previous 31 p MRS study markedly eleva-
ted phosphomonoesters (PME) and reduced phosphodiesters (POE) in the tumor-free, 
i.e. non-111etastatic, liver of weight-losing cancer patients with various tumor types were 
observed (51 J. 
Since PME and POE resonances contain contributions from phospholipid intermedia-
tes, mernbrane precursors, as well as sugar phosphates such as glucose-6-phosphate 
(G6P), 3-phosphoglycerate (3PG), and phosphoenolpyruvate (PEP) (145]. it has been 
difficult to interpret changes in 31 p MRS·detected components in terms of metabolic 
alterations. 
We recently observed elevated glucose turnover and gluconeogenesis from alanine 
in weight-losing (WL) lung cancer patients (126J. Since gluconeogenesis from alanine 
occurs predorninantly in the liver [201 J it was suggested that elevated concentrations of 
gluconeogenic intermediates caused the increased PME levels in these patients. In the 
present study 31 p MRS of the liver and turnover measurements were combined in order 
to relate hepatic and systemic alterations in lung cancer patients. The aim was to investi-
gate whether elevated PME and POE levels in tumor-free liver as observed with 31 p MRS 
are correlated with elevated glucose flux and gluconeogenesis from alanine. 
Methods 
Subjects 
The study was approved by the Medical Ethical Committee of the Erasmus University 
Medical Center Rotterdam, Rotterdam, The Netherlands. Patients with non-small cell 
lung cancer stage IIiA/B or IV (WHO grading system) attending the outpatient depart-
ment of the University Hospital Rotterdam, The Netherlands, were recruited. Patients 
who were in remission or apparently cured were excluded. Additional exclusion criteria 
were: liver metastases (as checked for by CT /lIltrasollnd), metabolic disease, corticoste-
roid treatment, elective surgery <3 months, chemo- or radiotherapy <4 weeks prior to 
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study, alcohol consumption of more than 100 gjweek (~1 0 glasses); pregnancy; extre-
me anorexia or artificial weight reduction by dieting. Healthy subjects without weight 
loss were included as a control group. All participants signed informed consent. 
Experimental design 
The subjects were studied in the morning after an overnight fast. A cannula (0.8X25 mOl) 
was placed in the left cubital vein for the infusion of stable isotope tracers. In the contra-
lateral cubital vein, an identical cannula was introduced for blood sampling. To study 
gluconeogenesis, a solution was prepared containing [6,6~2H2]-D-glucose, 98 atom% and 
[3-"Cj-L-alanine, 99 atom% (Mass Trace, Woburn, USA) in water and this was sterilized 
by autoclaving in glass vials. A priming dose of 30 "mol/kg [6,6-'H,)-D-glucose was 
administered followed by a continuous infusion of 10 "mol/kg!h [6,6-'H,)-D.glucose for 
90 minutes. Simultaneously, a priming dose of 80 "mol/kg [3-13Cj-L-alanine was given 
followed by a continuous infusion of 40 I1mol/kgjh [3-13Cj-L-alanine during 90 minutes. 
® 
Both tracer solutions were infused using calibrated syringe pumps (Perfusor fill, Braun, 
Germany). 
Venous blood samples were drawn immediately before the isotope infusions were 
started, and at 10 min intervals after steady state conditions during the tracer infusions 
had been reached. Based on observations by others [102) and in our laboratory steady 
state was obtained between 60-90 min of the tracer infusions. Isotopic enrichments of 
deuterium and carbon-13 glucose, and carbon-13 alanine in plasma were determined. 
Biochemistry and turnover measurements 
Blood san~les were collected in tubes containing lithium heparin (Becton Dickinson 
Vacutainer , Meylan Cedex, France) and immediately stored on ice. After centrifugation 
(10 min, 1200 g 4°C), the plasma was collected and stored at _20°C until analysed. An 
aliquot of the infusate was analysed to document actual concentrations of the tracers in 
each study. 
Isotopic enrichrnents were determined using the following procedures. Plasma was 
deproteinized by adding 0.3 M barium hydroxide (Sigma Diagnostics, St.Louis, USA) and 
0.3 M zinc sulphate (Merck, Darmstadt, Germany). After centrifugation (8 min., 15000 g 
4°C) the supernatant was applied to an ion exchange column (mixed bed: AG50W-X8 
and AG1-X8, 200-400 mesh, 0.2 g each; BioRad, California, USA). Glucose and alanine 
were eluted from the column using water and 4 M ammonium hydroxide (Merck, 
Darmstadt, Gerrnany), respectively, and drieclunder nitrogen. A glucose derivate (alcloni-
tril penta acetate) was made according to Varma et al [216). An alanine t-butyldimethyl-
silyl derivate was prepared as described by Chaves Das Neves et al [32). 
Isotopic enrichments were measured by injecting 1 111 samples with a split ratio of 
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50:1 on a fused silica capillary column of 25 m x 0.22 mm, coated with 0.11 ~m HT5 
(SGE, Victoria, Australia). The relative isotopic enrichments of deuterated glucose and 
carbon-13 alanine were determined using a Carlo Erba GC8000 gas chromatograph 
coupled to a Fisons MD800 mass spectrometer (GC-MS) (Interscience B.V., Breda, The 
Netherlands) in electron impact ionization mode. The variation coefficient in enrichn1ent 
was 0.2 mole% for both 16,6-'H,J-glucose and 13- 'tJ-alanine, and no concentration 
effect was observed at this level of mole% enrichment. Ions were selectively monitored 
at mass per unit charge (m/z) 187 for natural glucose and 189 for the deuterated mole-
cule. The isotopic enrichment of 13-"q·alanine was determined at the m/z ratios 260 
and 261 for carbon-12 and carbon-13 alanine, respectively 1137J. 
Total enrichment of carbon-13 glucose was measured separately (aldonitril penta-
acetate derivation) using a gas chromatograph combustion isotope ratio mass spectro-
meter (GC-IRMS) (Optima, Micromass UK, Middlewich, Cheshire, Great Britain). The 
[13C}-glucose enrichment, as atom% excess (APE) was monitored after combustion to 
CO, at mass 44 for carbon-12 and 45 for carbon-13, respectively. 
Whole body rate of appearance (Ra) of glucose and gluconeogenesis from alanine 
were calculated during steady state assuming an one-co mpartment model as described 
by Wolfe 1224J and were expressed as mmol.kg·'. h". It was assumed that the dilution of 
13 C in intracellular pyruvate pools and at oxaloacetate, caused by exchange with the 
TCA cycle 1224J, would be similar in lung cancer patients and healthy subjects. 
lip MR spectroscopy of the liver 
Hepatic 31-phosphorus MR spectra were obtained during steady state of the isotope 
tracers. Spectroscopy studies were performed with a whole·body MR system equipped 
with a Helicon magnet operating at 2.0 Tesla (Vision Magneton, Siemens AG, Erlangen, 
Germany). A 16 cm diameter transmit/receive 'H/'P surface coil was used for MRI 
localization, shimming, and 31 p MR spectroscopy. Elastic bands were used for positio-
ning the coil lateral to the liver in the mid·axillary plane. Field homogeneity achieved in 
shimming resulted in water peak line widths which were usually less than 40 Hz ("0.5 
ppm). After obtaining an image of the region of interest, an one-dimensional chemical 
shift imaging (1 D-CSI) sequence was applied on a transverse slice of 4 cm centered on 
the surface coil and the liver (1 x4 phase·encoded matrix, field of view 40x40 cm'), 
yielding volumes of 40x1 Ox4 cm' (195J. Five spectra were collected with a 640 ~s 
Hanning·sinc shaped radio frequency pulse resulting in a flip angle of 135° in the center 
of the coil, and 60° (weighted average) in the liver volume with a repetition time (TR) of 
1 s (40 acquisitions). We previously demonstrated 151 J that use of TR~1 s and TR~20 s 
gives similar differences for PME in weight-losing or weight-stable cancer patients, and 
healthy control subjects. Furthermore, the saturation at TR~1 s and a pulse angle of 60° 
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used in our study is maximally 15% for PME (relative to f3-A TP) and 30% for POE (relati-
ve to f3-ATP)[195). 
Time domain data were Fourier transformed after Gaussian Illllltiplication (center: 0 
ms, width 30 ms) and phase corrected. Quantification of spectral peak areas was perfor-
med using Numaris-3 software package (Siemens AG, Eriangen, Germany) including 
polynomial baseline correction followed by frequency domain curve fitting (194). Meta-
bolite concentrations were calculated from peak areas and expressed relative to total 
MR-detectable phosphate as described elsewhere (51). In each experiment the average 
of five subsequent 31 p MR spectra was used for calculations. 
Statistics 
Results are presented as means ± standard error of the mean (SEM). Differences be-
tween group means were compared llsing Student's. t-test for independent groups. 
Reported correlations between variables are Pearson's correlation coefficients. Differen-
ces were considered statistically significant at Pvalues < 0.05. 
Results 
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Twenty-four patients with non-small cell lung cancer, stage IIiA/B or IV (WHO grading 
system), and thirteen healthy control subjects were included in the study. In lung cancer 
the rnean age was 66 y (range 38-85y) which was significantly higher than in controls 
(46 y, range 25·69) (1'<0.05). Body weight was significantly less in cancer patients than 
in healthy controls (65.7 ± 2.5 1'5. 75.3 ± 2.7 kg, respectively, 1'<0.05). The patients had 
lost 5 ± 1 kg or 7% (range 0 -24%) of their pre·illness body weight in the previous 6 
months. 
Whole-body turnover rates measured in lung cancer patients and healthy controls 
are shown in Table 3.1. Since it was previously shown that turnover rates are correlated 
with the degree of weight loss (1261, data of all lung cancer patients are presented 
together as well as data of patients with <5% (weight-stable, WS) or ;- 5% of weight loss 
(weight-losing, WL) separately. Gluconeogenesis from alanine was significantly higher in 
lung cancer patients than in control subjects (P<O.05). Both turnover rates of glucose 
and gluconeogenesis from alanine were significantly elevated in WL lung cancer patients 
compared with WS patients and healthy controls (P<O.Ol). Age did not significantly 
influence these results (data not shown). 
Examples of MR spectra from a healthy control subject, a weight·stable and a 
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Table 3.1 
Rate of appearance (turnover) of glucose and gluconeogenesis from alanine in healthy control 
subjects and lung cancer patients. f 
Control (n = 13) 
Lung cancer (n=24) 
< 5% weight loss (n= 12)' 
L 5% weight loss (n= 12) 
I Mean :t SEM. 
Glucose 
(mmol;kgih) 
0.52 ± 0.05 
0.62 ± 0.04 
0.53 ± 0.05 
0.71 ± 0.06 "'t 
Gluconeogenesis from 
alanine 
(mmol;kgih) 
0.28 ± 0.04 
0.41 ±0.04* 
0.32 ± 0.05 
0.51 ± 0.04 *** 
1 Weight loss was defined as percentage weight loss from pre-illness stable weight in the six months prior to 
the study. 
Statistically significant differences (Student's t-test for independent groups): compared to healthy subjects 
*P<O.05, *-~P<O.O I; compared to lung cancer patients 'Nith < 5% weight loss tP<O.05; :f:P<O.OI. 
Table 3.2 
Hepatic metabolite levels as observed by 31 P magnetic resonance spectroscopy in healthy control 
subjects and lung cancer patients,' 
PMEJP,ooJ 7 POEJP,o~ PMEJPOE 
Control (n = 13) 0.079 ± 0.007 0.298 ± 0.018 0.275 ± 0.029 
Lung cancer (n=24) 0.084 ± 0.005 0.293 ± 0.015 0.319 ± 0.027 
< 5% weight loss (n= 12)3 0.069 ± 0.004 0.279 ± 0.024 0.289 ± 0.037 
L 5% weight loss (n= 12) 0.098 ± 0.008 * 0.306 ± 0.019 0.349 ± 0.040 
I Mean ± SEM. 
2 Metabolite levels are expressed as percentage of total MR-detectable phosphate. 
3 Weight loss was defined as percentage weight loss from pre-illness stable weight in the six months prior to 
the study. 
Statistical significant different from lung cancer patients 'Nith < 5% weight [ass: :f:P<O.O I (Student's t-test 
for independent groups). 
weight-losing lung cancer patient are shown in Figure 3.1. Phosphomonoesters (PME) 
were significantly elevated in WL lung cancer patients when compared with WS patients 
(P<O.Ol) (Table 3.2). No significant differences in POE levels were observed between 
the groups. Although PMEjPOE ratios were higher in lung cancer patients than 
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CmcerWL 
C1ncerWS 
POE Control 
I3-ATP 
P, 
PME 
10 o -10 -20 ppm 
Figure 3.1 
Phosphorus MR spectra of the liver of a healthy control subject ("control"), a weight-stable lung cancer 
patient ("cancer WS") and a weight-losing lung cancer patient ("cancer WL"). Spectra were acquired at 2,0 
T es!a using a 135" excitation pulse (60 0 weighted average in the liver volume) vvith a repetition time of 
I s, PME, phosphomonoesters; P" inorganic phosphate; POE, phosphodiesters; P-ATP, p-phosphate group 
of adenosine triphosphate. The scale represents chemical shift in ppm, 
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in controls the difference did not reach statistical significance. Again, age did not signifi-
cantly influence the results. 
In Figure 3.2, correlations between liver metabolites and turnover measurements in 
lung cancer patients are shown. PME was significantly correlated with glucose turnover 
and gluconeogenesis from alanine in lung cancer patients (r=0.48 and r=0.48, respecti-
vely, P<0.05). In healthy subjects no significant correlations were observed (r= -0.19 and 
r= -0.24, respectively, P>0.42). PDE was neither correlated with glucose turnover nor 
with gluconeogenesis from alanine in lung cancer patients (r= -0.30 and r= -0.39, respec-
tively, P>0.05) or control subjects (r = -0.04 and r= -0.22, respectively, P>0.47). Positive 
correlations between PME/PDE ratio and glucose turnover or gluconeogenesis from 
alanine were observed in lung cancer patients (r= 0.47 and r=0.55, respectively, P<0.05), 
but not in healthy controls (r= ·0.18 and r= ·0.02, respectively). 
Discussion 
Phosphorus MR spectroscopy is a promising tool for the non-invasive study of diseased 
states [104,146]. However, one limitation to its application in human disease has been 
the difficulty in interpretating 31 p MR spectra in terms of metabolic alterations. To our 
knowledge, no previous studies combining 31 P MR spectroscopy with turnover measure-
ments have been reported, in cohtrast to studies using "c MRS (166,178]. In the pre-
sent study, quantitative information on hepatic substrate metabolisrn in lung cancer 
patients was obtained by simultaneous application of 31 p MRS and turnover measure-
ments. Specifically, the relation between hepatic concentrations of PME and PDE as 
observed by 31 p MR spectroscopy and glucose turnover and gluconeogenesis from 
alanine using stable isotope tracers was assessed. 
Several authors have used 31 p MR spectroscopy for the characterization of variolls 
disease states in humans and animal models. Elevated PME levels have been reported in 
diseased liver, for instance in patients with liver cirrhosis [103,149,205,206), chronic 
alcohol abuse (143], or hepatic malignancies (45].11 was suggested that this was caused 
by contributions of glycerol·3-phosphate or intermediates in the pathway of phospholi-
pid biosynthesis, phosphorylcholine (PC), or phosphorylethanolamine (PE). Furthermore, 
31 p MRS studies revealed reduced hepatic PDE levels in cirrhotic patients (103,205,206] 
and hepatic malignancies (45], and elevated PDE levels in subjects with alcohol abuse 
depending on the type and severity of the disease (143]. Decreased levels of glycerop· 
hosphorylcholine (GPe) and glycerophosphorylethanolamine (GPE), both products of 
phospholipid breakdown, or decreased levels of endoplasmic reticulum within the 
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Figure 3.2 
Metabolite concentrations as observed by 3tp magnetic resonance spectroscopy of the liver plotted against 
flux measurements as assessed by primed-constant infusion of stable isotope tracers in lung cancer patients 
(n=24). r, Pearson's correlation coefficient; PME, phosphomonoesters; PDE, phosphodiesters. 
Scheme 3.1 
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Pathway of hepatic gluconeogenesis from alanine Vvith some of the intermediates contributing to the 
phosphomonoester (PME) and phosphodiester (PDE) resonances in 31p MR spectra indicated. Numbers are 
gluconeogenic key-enzymes: I, pyruvate carboxylase: 2, phosphoenolpyruvate carboxykinase; 3, fructose-
1 ,6-bisphosphatase; 4, glucose-6-phosphatase. 
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hepatocytes were suggested as possible contributors to these changes. In the present 
study 31 P MR spectroscopy was performed in lung cancer patients with healthy livers, 
thus comprising a distinct Inetabolic situation. The absence of liver metastases in all 
cancer patients was verified by CT j ultrasound; furthermore, all patients had normal 
liver function tests. Hepatic PME levels were increased in lung cancer patients with 
weight loss, confirming previous studies in mixed tumor types {51 If but no difference in 
POE levels was observed between lung cancer patients and healthy controls. Even 
though mean age in lung cancer patients was higher than in healthy subjects, the age-
ranges largely overlapped. Furthermore, we checked our data for significant correlations 
between metabolite levels and age. No significant correlations were observed between 
age and PME (r~0.16, "'"0.33), POE (r~-O.OI, "'"0.98) or PMEjPOE (r=0.21, "'"0.22). In 
addition, in a study by Bourdel-Marchasson et al. 119] it was reported that hepatic PME, 
POE and PMEjPOE in young healthy subjects (age 30.5 ± 2.1 y) and elderly healthy 
subjects (age 8004 ± 6.3 y) were not significantly different. Glucose turnover and gluco-
neogenesis frorn alanine were elevated in WL lung cancer patients as reported previous-
ly 1126]. 
The pathway of gluconeogenesis from alanine is shown in Scheme 3.1. In the cyto-
sol, alanine is converted into pyruvate, which in turn is transported into the mitochondria 
and converted into oxaloacetate by pyruvate carboxylase. Liu et aI., using BC MRS, 
suggested that the activity of pyruvate carboxylase was increased in the liver of tumor-
bearing rats 1128]. The next step is the conversion of oxaloacetate into phosphoenolpy-
ruvate (PEP) by phosphoenolpyruvate carboxykinase (PEPCK), a regulatory enzyme in 
the gluconeogenic pathway, in humans present in the mitochondria and in the cytosol 
1139]. In rats bearing sarcomas the activity of PEPCK was about twice that of healthy rats 
183,156J and increased with increasing tumor burden 1211]. When PEP enters the 
gluconeogenic pathway it is converted into glucose via a number of intermediates 
including 3-phosphoglycerate (3 PG), fructose-l,6·bisphosphate (Fl,6P), fructose-6-
phosphate (F6P), and glucose·6·phosphate (G6P). Two other regulatory enzymes of the 
gluconeogenic pathway, fructose-l,6-bisphosphatase and glucose·6-phosphatase, cataly-
se the reactions from Fl,6P to F6P and G6P to glucose, respectively. Elevated activity of 
glucose-6-phosphatase was detected in the liver of sarcoma-bearing rats, whereas the 
activity of fructose-l ,6-bisphosphatase was only slightly increased 183]. 
Since the interpretation of PME or POE concentrations alone is not straightforward, in 
the present study a comparison with turnover measurements was made. PME was 
correlated with glucose turnover and gluconeogenesis from alanine in lung cancer 
patients, but not in healthy controls. The elevated PME levels observed in WL lung 
cancer patients could be a result of accumulation of MR-detectable gluconeogenic 
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intennediates within the liver. It has previously been shown that infusion of a gluconeo-
genic substrate caused 31 p MRS-detectable changes in the PME and POE resonances 
due to increased concentrations of 3PG and PEP, respectively, within the liver of healthy 
humans and rats [30,49,1771. So far, MR spectroscopy data on tumour-free livers in 
hurnans or animal models are extremely lirnited. 3'p MRS metabolite profiles of biopsy 
samples of histologically normal liver tissue from patients bearing hepatomas showed 
elevated contributions of PE and PC; however, changes in sugar phosphate concentrati-
ons could not be quantified in that study due to the significant period of ischemia which 
arises during the collection of human biopsies [121. In tumour-free liver of rats bearing 
the Dunning prostate tumour, decreased levels of G6P and F6P compared to control 
rats were reported [491. It was suggested that the decreased values of G6P could have 
been caused by elevated G6P-ase activity. 
I n contrast to PME levels, POE levels in lung cancer patients in the present study 
were inversely correlated with gluconeogenesis from alanine, possibly indicating increa-
sed conversion of PEP into 2-phosphoglycerate and further. PME!POE ratios were 
significantly correlated with whole-body glucose turnover and gluconeogenesis from 
alanine in lung cancer. We cannot exclude contributions of PC, PE, GPC, GPE or end-
oplasmic reticulum to the PME and POE resonances. However, bearing in mind that the 
liver of the lung cancer patients examined in the present study was apparently healthy 
(verified by CT!ultrasound and liver function tests), elevated phospholipid turnover 
would not be likely. Moreover, the elevated PME levels were specific for weight-losing 
lung cancer patients, they were absent in weight-stable patients. There is no hypothesis 
present in literature linking PC, PE, GPC or GPE to weight loss in cancer. In contrast, 
there is a clear hypothesis linking weight loss and elevated gluconeogenesis in cancer. 
Therefore, it seems unlikely that elevated PME and POE were caused by PC, PE, GPC or 
GPE. The fact that in healthy control subjects hepatic PME levels are not significantly 
correlated with glucose flux or gluconeogenesis, would suggest that metabolites other 
th an gluconeogenic intermediates, such as PC and PE, are the predominant contributors 
to the PME resonance in these subjects. 
In summary, this combined turnover and 3'p MRS study in humans Ii] vivo would 
suggest that elevated hepatic PME levels in lung cancer patients reflect increased gluco-
se flux and gluconeogenesis from alanine in these patients. Our data are consistent with 
the hypothesis that elevated PME is due to high contributions from gluconeogenic 
intermediates, possibly 3-phosphoglycerate. In healthy controls no such correlation was 
observed. Dynamic studies could provide further information on hepatic metabolislll 
and enzyme activities in Illng cancer patients li1 vivo. 
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Profound alterations in host metabolism in lung cancer patients with weight loss have 
been reported, including elevated phosphomonoesters (PME) as detected by 31 P magne-
tic resonance spectroscopy (MRS). In healthy subjects, infusion of L-alanine induced 
significant increases in hepatic PME and phosphodiesters (POE) due to rising concentrati-
ons of 3-phosphoglycerate and phosphoenolpyruvate, respectively. The aim of the 
present study was to monitor these changes in the tumor-free liver of lung cancer pa-
tients during L-alanine infusion by means of simultaneous 31 p MRS and turnover measu-
rements. Twenty-one lung cancer patients without liver metastases with (CaWL) or 
without weight loss (CaWS), and twelve healthy control subjects (C) were studied during 
an i.v. L-alanine challenge of 1.4-2.8 mOlal/kg followed by 2.8 mmol/kg/h for 90 min. 
Plasma L-alanine concentrations increased during alanine infusion, from 0.35 - 0.37 
mM at baseline to 5.37 ± 0.14 mM in CaWL, 6.67 ± 0.51 mM in CaWS, and 8.47 ± 
0.88 mM in C (difference from baseline and between groups during alanine infusion, all 
P<O.OOl). Glucose turnover and liver PME levels at baseline were significantly elevated 
in CaWL. Alanine infusion increased whole-body glucose turnover by 8 ± 3% in CaWS 
(?c0.03), whereas no significant change occurred in CaWL and C. PME levels increased 
by 50 ± 16% in C (area under the curve, P<0.01) and by 87 ± 31 % in CaWS (P<O.OS) 
after 45-90 min. In contrast, no significant change in PME was observed in CaWL. 
Plasrna insulin concentrations increased during L-alanine infusion in all groups to levels 
which were lower in CaWL than in CaWS and C (P<0.05). In lung cancer patients, but 
not in C, changes in PME and POE levels during alanine infusion were inversely correla-
ted with their respective baseline levels (r~ -0.82 and r~ -0.86, respectively, P<O.OOl). 
Also, changes in PME during alanine infusion in lung cancer patients were inversely 
correlated with the degree of weight loss (r~ -0.54, P<0.05). 
In conclusion, this study demonstrates the presence of major alterations in the 
pathway of hepatic gluconeogenesis in weight-losing lung cancer patients, as shown by 
elevated glucose flux before and during L-alanine infusion, and by the increased PME 
and POE levels which reffect accumulation of gluconeogenic intermediates in these 
patients. Weight-stable lung cancer patients show accelerated rise in PME and POE 
levels during L-alanine infusion, suggesting enhanced induction of the gluconeogenic 
pathway. Our results suggest altered gluconeogenic enzyme activities and elevated 
alanine uptake within the liver of WL/WS lung cancer patients. 
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Introduction 
Weight loss in lung cancer is associated with both impaired therapy outcome (56) and 
reduced survival (37,43,56,198). Characteristic features of weight loss in lung cancer are 
breakdown of both fat mass and skeletal muscle, whereas visceral organs are typically 
spared or even enlarged (38,94). Although profound alterations in host substrate meta· 
bolisrn in cancer patients have been reported, Inechanisms responsible for the observed 
weight loss are yet poorly understood. Isotope tracer studies showed elevated protein 
breakdown and glucose turnover in lung cancer patients using isotope tracers 
(89,142,171). Increased gluconeogenesis from alanine was observed in tumor-influen-
ced hepatocytes [175), in tumor-bearing animals if) vivo [129), and in cancer patients 
with various tumor types (219). We recently reported increased whole-body gluconeo-
genesis from alanine in lung cancer patients with weight loss (126). A significant correla-
tion between gluconeogenesis from alanine and the degree of weight loss was also 
observed. 
Since the liver is the main site for gluconeogenesis [2011, the observed increase in 
gluconeogenesis form alanine as observed in weight-losing lung cancer patients is likely 
to be partly related with altered liver metabolism (20,115). In animal models, altered 
hepatic enzyme activities (6,92) and decreases in liver phosphorylation status [49) and 
energy balance (6) were correlated with tumor burden [181). Furthermore, elevated 
concentrations of gluconeogenic intermediates such as glucose-6-phosphate were 
observed within the liver of these animals (6). Another experimental study revealed 
altered hepatic metabolism in response to fructose infusion even in rats with minimal 
tumor burden (77). These alterations preceded the onset of cachexia and it was sugge-
sted that they were related to elevated hepatic gluconeogenesis in these animals. 
Due to lack of non-invasive techniques, data on altered liver rnetabolism in humans 
with lung cancer are limited. In recent studies using 31 p magnetic resonance spectrosco-
py (MRS), elevated concentrations of phosphomonoesters (PME) were observed in the 
liver of weight-losing cancer patients with various tumor types [51) and lung cancer 
(125). In contrast, liver PME levels in weight-stable cancer patients were not significantly 
different from those in healthy subjects. Furthermore, hepatic PME levels were signifi-
cantly correlated with the rate of gluconeogenesis from alanine in lung cancer patients, 
but nOI in healthy subjects [125). MRS sludies have also been used to obtain dynamic 
information on liver metabolism by monitoring changes in hepatic metabolite concentra-
tions during infusion of a gluconeogenic substrate. Changes in PME and AlP levels were 
reported using 31 p MRS with L-alanine infusion if) vivo in healthy rats [30) as well as in 
rals after ischemia (147) or surgery [200(. In healthy humans, 31 p MRS with either a 
bolus (50( or continuous (177( infusion of L-alanine was shown to provide information 
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on changes in concentrations of gluconeogenic interrnediates within the liver. However, 
information on liver gluconeogenic intermediates during a metabolic challenge in lung 
cancer patients is lacking. 
The aim of the present study was to monitor glucose metabolism in tumor-free liver 
of lung cancer patients with and without weight loss by means of 31 P MRS, with infusion 
of L-alanine as a gluconeogenic substrate. Data were compared with flux measurements 
using stable isotope tracers before/during alanine infusion. 
Materials and methods 
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Subjects 
The study was approved by the Medical Ethical Committee of the Erasmus University 
Medical Center Rotterdam, Rotterdam, The Netherlands. Patients with non-small cell 
lung cancer stage IIiA/B or IV (WHO grading system) attending the outpatient depart-
ment of the University Hospital Rotterdam, The Netherlands, were recruited. Patients 
who \overe in remission or apparently cured were excluded. Additional exclusion criteria 
were: liver 111etastases (as checked for by CT/ultrasound), metabolic disease, corticoste-
roid treatment, elective surgery <3 months, chemo- or radiotherapy <4 weeks prior to 
study, alcohol consumption of more than 1 OOg/week (~1 0 glasses), pregnancy, extreme 
anorexia or artificial weight reduction by dieting. Healthy subjects without weight loss 
were included as a control group. All participants signed informed consent. 
Experimental design 
All subjects kept a dietary record during 7 days and refrained from alcoholic drinks for 
three days prior to the MRS measurernents. Data on pre-illness stable weight, current 
weight, and weight loss over the previous 6 months were taken from hospital records 
supplemented with oral information from patients. The subjects were studied between 
7:30 a.m. and 1 :00 p.m. after an overnight fast (12-14 h). Body weight was measured to 
the nearest 0.1 kg on an electrical weighing scale (Seca 707, Hamburg, Germany), 
height was measured to the nearest 0.1 cm, and thickness of four skinfolds (triceps, 
biceps, subscapular, supra iliac) were measured to the nearest 0.2 nlln using a standard 
skinfold caliper (Holtain ltd., London, Great Britain). A cannula (0.8X25 mm) was placed 
in the left cubital vein for the infusion of the stable isotope tracer and unlabeled L-alani-
ne. In the contralateral cubital vein, an identical cannula was positioned for blood 
sampling. To determine whole-body glucose turnover a solution was prepared contai-
ning 16,6-'H,]-D-glucose, 98 atom% (Mass Trace, Woburn) in water, sterilized by autocla-
ving in glass vials. A solution of (unlabeled) L-alanine in water (100g per liter, Bufa B.v., 
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Uitgeest, The Netherlands) was prepared, sterilized by autoelaving in glass bottles, and 
warmed to ...... 30°C. 
The study consisted of two phases. During the first phase (baseline), a priming dose 
of 30 ~moljkg of 16,6-'H,I-glucose was administered followed by a continuous infusion 
of 1 0 ~moljkgjh for 90 min. During the second phase, a priming dose of 1.4 - 2.8 
mmoljkg unlabeled L-alanine was administered in 5-8 min and followed by a continuous 
infusion of 2.8 mmoljkgjh L-alanine for 90 min in order to reobtain a steady state; 
simultaneously the isotope tracer infusion was continued. Venous blood samples were 
collected as follows: phase 1) one sample immediately before the isotope tracer infusion 
was started (for determination of background enrichment of 'H-glucose) and at 10 min 
intervals from 30 to 90 min during isotope tracer infusion, after steady state was re-
ached; phase 2) at 15 min intervals during continuous L-alanine infusion. Phosphorus 
MR spectra of the liver were obtained at baseline and at 3 min intervals during l-alanine 
infusion. 
lip MR spectroscopy of the liver 
Spectroscopy studies were performed with a whole-body MR system equipped with a 
Helicon magnet operating at 2.0 Tesla (Vision Magneton, Siemens AG, Erlangen, Germa-
ny). A 16 cm diameter transmit/receive 'HI"P surface coil was used for MRI localizati-
011, shimming and 3tp MR spectroscopy. Elastic bands were lIsed for positioning the coil 
lateral to the liver in the mid-axillary plane. Field homogeneity achieved in shimming 
resulted in water peak line widths which were usually less than 40Hz (~0.5 ppm). After 
obtaining an image of the region of interest, a one-dimensional chemical shift imaging 
(1D-CSI) sequence was applied on a transverse slice of 4 cm centered on the surface 
coil and the liver (1 x4 phase-encoded matrix, field of view 40x40 cm'), yielding volumes 
of 40x1 Ox4 cm3 11951. Spectra were collected with a 640 ~s Hanning-sinc shaped radio 
frequency pulse resulting in a flip angle of 135 0 in the center of the coil, and 60° 
(weighted average) in the liver volume with a repetition time (TR) of 1 s (40 acquisiti-
ons). 
Time domain data were Fourier transforrned after Gaussian multiplication (center: 0 
ms, width 30 ms) and phase corrected. Quantification of spectral peak areas was perfor-
med using Numaris-3 software package (Siemens AG, Eriangen, Germany) ineluding 
polynomial baseline correction followed by frequency domain curve fitting [1941. Meta-
bolite concentrations were calculated from peak areas and expressed relative to total 
MR-detectable phosphate as previously described 1511. Total MR-detectable phosphate 
did not change during l-alanine infusion (data not shown). 
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Substrate concentrations and glucose turnover 
Blood samples were collected in tubes containing lithium heparin (Becton Dickinson 
Vacutainer@, Meylan Cedex, France) and immediately stored on ice. After centrifugation 
(10 min, 1200 g, 4'C), the plasma was collected and stored at -20'C until analyzed. 
Blood glucose concentration was measured enzymatically with a glucose-oxidase/ 
peroxidase assay (Boehringer Mannheim, Mannheim, Germany). Plas!)1a alanine concen-
tration was determined enzymatically as described by Williamson [223J. Isotopic enrich-
ment of deuterium-glucose (mole% excess, MPE) in plasma was determined by gas 
chromatography-mass spectrometry as described previoLisly [126}. Plasrna concentrati-
ons of insulin and glucagon were determined at two time points during baseline and two 
time points during L-alanine infusion by radio immuno assay techniques (Biosource, 
Fleurus, Belgium and Euro-Diagnostica, Sweden, respectively). 
Statistical analysis 
Results are reported as means ± standard error of the mean (SE). In each experiment the 
average of five subsequent MR-spectra was used as baseline value for calculations. Mid-
time points of MRS data acquisition at 15 min intervals during L-alanine infusion (7.5, 
22.5,37.5 min, etc.) were used for graphical representation, with values being expressed 
relative to the baseline value of healthy control subjects (~1 00%). As a measure of 
overall spectral response, integrals of time-response curves (area under the curve, AUC) 
of peak areas over 0-45 min, 45-90 min, and 0-90 min intervals during L-alanine infusion 
were calculated and expressed relative to the baseline values. Between-group differen-
ces in baseline values and response to alanine infusion were analyzed using ANOV A. 
Changes from baseline values were analyzed using Student's paired i-test. Differences 
between groups were appraised by multiple regression analysis, including age and 
priming dose of L-alanine as covariates. Pearson's correlation coefficients were calcula-
ted between baseline metabolite concentrations (expressed relative to total MR-detecta-
ble phosphate) and absolute metabolite change (AUC) per minute during L-alanine 
infusion. Pvalues <0.05 indicate statistical significance. 
Results 
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Study population 
Twenty-one patients with non-small cell lung cancer were included in the study: nine 
weight-losing (,. 5% weight loss, CaWL) and twelve weight-stable patients « 5% weight 
loss, CaWS). Twelve healthy subjects were included as controls (C). Characteristics of 
the study population are listed in Table 4.1. Mean age of lung cancer patients was 
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Table 4.1 
Characteristics of study population.' 
Control Lung cancer P Value 
Age (y) 
Gender (mlf) 
Disease stage (1IIA/1I1BfiV) 
Previous therapy (n)J 
Weight (kg) 
Surgery 
Radiotherapy 
Chemotherapy 
Weight change (kg) 
Weight change (%) 
% Idea! body weight 
Body mass index (kg/m2) 
Sum of skinfo!ds (mm)4 
Albumin (gfiiter) 
Prealbumin (gfiiter) 
I Mean ± SE. 
2 Range 
(n ~ 12) 
37-69 ' 
2/10 
a 
a 
a 
77.0 ± 3.0 
a 
a 
124 ± 5 
25.8 ± 1.0 
71 ;±:; 6 
46 ± 15 
0.30 ± 0.01 
WS 
(n ~ 12) 
38-76 
7/5 
1/5/6 
2 
6 
6 
72.8 ± 3.4 
I ± I 
I ± [ 
117 ± 5 
25.1 ± 1.0 
63 ± 6 
43 :t: [5 
0.29 ± 0.015 
WL 
(n ~ 9) 
53-81 
7/2 
3/2/4 
2 
4 
a 
60.9 ± 3.5 
-9.0 ± 1.4 
-12 ± 2 
96 ± 5 
20.9 ± 1.1 
30 ± 4 
38 ± 25 
0.17 " 0.02' 
Ca vs. WLvs. 
c WS 
<0.01 0.20 
0.36 0.02 
0.56 <0.001 
0.59 <0.001 
0.33 <0.01 
0.62 0.01 
0.29 <0.001 
0.34 <0.01 
0.47 <0.001 
3 Antitumor treatment surgery> 3 months, radio- and chemotherapy. 4 weeks prior to the MRS study 
(number of patients) 
4 Sum of four skinfo!ds: biceps, triceps, supra iliac, subscapular (mm) 
5 One value missing 
higher than in C, although age ranges largely overlapped. Disease stage was sirnilar in 
the WLfWS lung cancer patients. The previous antitumor treatment was also compara-
ble in both groups, except for chemotherapy which had been given as a previous 
treatment in six CaWS but in none of the CaWL. Note that none of the patients received 
any antitumor therapy at the time of the study. The WL lung cancer patients had lost 9.0 
± 1.4 kg (mean ± SE) or 12% (range 6 - 22%) of their pre-illness stable body weight 
within the six months preceding the study. Body weight, body mass index and sum of 
skinfolds were significantly lower in CaWL when compared with CaWS and C (/'<0.05). 
Albumin and prealbumin levels were also significantly decreased in CaWL. Liver function 
tests were normal in all subjects. All patients had a history of smoking compared to 42% 
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Figure 4.1 
Plasma alanine concentrations in healthy control subjects (--0--; n = ! I), weight-stable (-e-; n = I I) and 
weight-losing (-... - ; n = 9) lung cancer patients before and during a primed-constant infusion of I A-2.8 
mmolJ1<g + 2.8 mmol;1<gIh L -alanine. Curves and error bars represent means ± SE. 
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Figure 4.2 
# 
L-alanine 
[JControl 
ElCaWS 
IICaWL 
Whole body rate of appearance (turnover) of glucose before and during primed-continuous L-alanine 
infusion in healthy control subjects (Control, n~ I 0), weight-stable (CaWS, n~ 12), and weight-losing 
(CaWL, n=6) lung cancer patients. Turnover rates were assessed using a primed-constant infusion of [6,6-
2H2]-g!ucose. Bars and error bars represent means ± Sf, Significantly different from WS lung cancer patients 
and healthy controls: *p<O.OS, ii:-*P<O.OI (ANOVA, adjusted for age), 'Significantly different from baseline, 
P<O.05 (Paired t-test). 
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of the healthy subjects. Actual smokers at the time of study were 38% of WL, 33% of 
WS cancer patients, and 33% of healthy control subjects. No differences in energy 
intake were detected between any of the groups. Because of the difference in age 
between the groups, all data were checked for potential confounding by age. Although 
in no case significant confounding by age was observed, all presented statistical analyses 
are adjusted for age. 
Plasma substrate concentrations and flux measurements 
Fasting blood glucose levels were similar in lung cancer patients (CaWL, 5.8 ± 0.3 mM 
(mmoljliter); CaWS, 5.3 ± 0.2 mM) and healthy subjects (5.7 ± 0.2 mM) and did not 
change during L-alanine infusion (CaWL, 5.7 ± 004 mM; CaWS, 5.0 ± 0.1 mM; C, 5.5 ± 
0.2 rnM). Baseline plasma alanine concentrations were similar in lung cancer patients 
and healthy controls (0.35 - 0.37 mM, Figure 4.1). L-Alanine infusion caused a sharp and 
highly significant rise in plasma alanine concentrations to an average of 5.37 ± 0.14 111M 
in CaWL, 6.67 ± 0.51 mM in CaWS, and 8047 ± 0.88 mM in C (CaWL I'S. CaWS and 
CaWS I's. C: P<0.001). These post-alanine plasma concentrations were significantly 
different between all groups (P<O.OOl). Turnover rates of glucose at baseline and during 
L-alanine infusion are presented in Figure 4.2. Whole-body glucose turnover at baseline 
was 35% higher in CaWL as compared to both CaWS and C (P<0.01). During alanine 
infusion glucose turnover slightly increased by 0.03 ± 0.02 mmoljkg/h in CaWL 
(~0.19), 0.05 ± 0.02 mmoljkg/h in CaWS (P<0.05), and 0.09 ± 0.04 mmoljkg/h in C 
(~0.08). Glucose turnover during alanine infusion was still 36% higher in CaWL than in 
CaWS and C (P<0.05). 
Hepatic concentrations of gluconeogenic intermediates 
Baseline phosphomonoesters (PME) were significantly elevated in CaWL (10.5 ± 1.0 %) 
when compared with CaWS and C (6.7 ± 0.5 and 7.9 ± 0.7, respectively, P<0.01, 
corrected for age), as previously reported. No differences in POE (CaWL, 30.6 ± 1.9; 
CaWS, 27.8 ± 2.2; C, 3104 ± 2.0) were observed between the groups. 
In Figure 4.3 changes in hepatic metabolite concentrations during L-alanine infusion 
are shown. PME increased gradually in C and reached statistical significance at 60 min 
(P<O.Ol). In CaWS, PME showed a sharp and highly significant rise during the first 30 
min and was still significantly elevated at 75 min of L-alanine infusion (P<0.05). The slope 
of PME from 0-30 min was significantly steeper in CaWS than in C (2048 ± 0.50% / min 
I's. 0.77 ± 0045% / min; ~0.01). In contrast, PME concentrations in CaWL did not 
change significantly during alanine infusion. Phosphodiesters (POE) initially decreased in 
C but increased in both CaWS and CaWL, with significantly different slopes of POE 
curves between 0-30 min between WL!WS lung cancer patients I's. 
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Figure 4.3 
Metabolite concentrations in the liver of healthy control subjects ( __ 0 __ : n = 9), as well as weight-stable 
(-e-; n = 10) and weight-losing (_.t._ ; n = 7) lung cancer patients during a primed-constant infusion of 
1.4-2.8 mmol/l<g + 2.8 mmol/l<gJh L-alanine: a) phosphomonoesters (PME). b) phosphodiesters (PDE). 
Curves and error bars represent means ± SE. Baseline values are means from 5 spectra acquired in each 
subject before L-alanine infusion. Values are expressed as percentage of mean baseline value of healthy 
subjects (= 100%). Times during L-alanine infusion are mid-time points of 31 p MRS data collection referen-
ced to the start of the L-alanine infusion (O=baseline). Significance of changes during L-alanine infusion 
compared to baseline (Student's paired t-test): *P<0,05, **P<O.O I, 
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healthy subjects (0.62 ± 0.33% j min and 1.20 ± 0.77 % j min I'S. ·0.57 ± 0.33% j min, 
respectively; ."=0.02). POE levels as such were not significantly different from baseline at 
any time point in either of the three groups. 
Overall changes during LMalanine infusion: area under the curve 
Overall changes in metabolite concentrations during L-alanine infusion relative to baseli-
ne are presented in Table 4.2. During the first 45 min of alanine infusion the increase in 
PME concentrations was significantly less in CaWL than in CaWS and C (."=0.02). At 45· 
90 min of alanine infusion this difference in response between CaWL and CaWSjC 
remained although it was no longer statistically significant. 
Table 4.2 
Hepatic phosphoric metabolite levels after primed-constant infusion of L-alanine in healthy 
control subjects and lung cancer patients.' 
Control Lung cancer P Value2 
Time of alanine WS WL Cays. WLvs. 
infusion (n = 9) (n = 10) (n = 7) C WS 
PME 0-45 min 21 ± 9 58 ± 14 ** 7±8 0.29 0.02 
45-90 min 50 ± 16 ** 87 ± 31 • 7±9 0.54 0.17 
0-90 min 33 ± II * 69 ± 19 ** II ± 10 0.41 0.09 
POE 0-45 min -5 ± 7 32 ± 20 23 ± 15 0.58 0.16 
45-90 min -3 ± 10 40 ± 33 9 ± 12 0.51 0.14 
0-90 min -8 ± 5 30 ± 22 12 ± II 0.55 0.06 
I Area under the curve during L-alanine infusion expressed as change from baseline (%, mean ± SE). 
') For between group differences in response to alanine infusion adjusted for age and L-alanine prime dose. 
Difference from baseline values (Student's paired t-test): *P<O.05, **P<O.O I, 
Hormone levels 
Plasrna insulin and glucagon levels are presented in Figure 4.4. Baseline insulin concen-
trations were lower in CaWL than in CaWS and C (P<0.05). Insulin levels showed a 
strong increase at 45 min of L-alanine infusion (P<0.01) and were still significantly eleva-
ted from baseline at 90 min in all groups (P<0.01). In CaWL, insulin levels remained 
significantly lower than in both CaWS and C during the 90 min of alanine infusion 
(P<0.01). Baseline glucagon levels were similar in WLJWS lung cancer patients and 
control subjects. L-alanine infusion caused a substantial rise in plasma glucagon at 45-
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Figure 4.4 
Plasma insulin (a) and glucagon (b) concentrations in healthy control subjects ( __ 0 __ ; n = 10), weight-stable 
(-e-; n = 10) and weight-losing (-... - ; n = 6) lung cancer patients before and during a primed-constant 
infusion of 1.4-2.8 mmol,lkg + 2.8 mmollkg;11 L-alanine. Curves and error bars represent means ± SE. 
90 min in all groups (P<0_01). No significant differences in glucagon concentrations 
during alanine infusion were observed between any of the groups. 
Correlations 
Spectral changes in PME and PDE during alanine infusion were strongly dependent on 
their respective baseline concentrations in lung cancer patients (r=-0.82 and r=-0.86, 
respectively; P<O.OOl) but not in C (r=-0.07 and r=-0.30, respectively) (Figure 4.5). 
Furthermore, patients with a higher degree of weight loss sho\oved less increase in PME 
levels during alanine infusion (r= -0.54, P<0.05). 
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Figure 4.5 
Changes in metabolite concentrations in the liver of healthy control subjects (n=9) and lung cancer patients 
(n= 17) during a primed-constant infusion of L-alanine plotted againsttheir respective baseline values for: a) 
PME, b) POE, both expressed relative to total MR-detectable phospate (%), r, Pearon's correlation coeffi-
cient. 
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Discussion 
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In the present study, hepatic gluconeogenesis from alanine in lung cancer patients was 
monitored by means of 3I p MR spectroscopy during an i.v. L-alanine challenge, and 
information on gluconeogenic intermediates was obtained non-invasively. Simultaneous-
ly, glucose turnover before and during L-alanine infusion was measured using stable 
isotope tracers. 
Glucose flux was found to be significantly elevated in WL lung cancer patients at 
baseline as compared to WS lung cancer patients and control subjects, confirming other 
studies [89,126). Changes in glucose turnover during L-alanine infusion were minimal, as 
could be expected in view of the autoregulatory mechanisms which control hepatic 
glucose output [57,108,225). Liver PME levels increased during alanine infusion both in 
CaWS and C, confirming studies performed in healthy animals [30) and humans 
[50,177) in which this rise in PME was attributed to increased concentrations of 3-phosp· 
hoglycerate (3PG) [30,50). Our finding in the present study that in WS lung cancer 
patients PME increased significantly faster and reached twice as high levels as in healthy 
subjects may reflect a more rapid rise in concentrations of 3PG in the liver of these 
patients. In contrast, in weight-losing lung cancer patients, PME was already elevated at 
baseline and did not increase any further during alanine infusion. Moreover, a strong 
negative correlation between baseline PME levels and rise in PME during alanine infusi-
on was observed in lung cancer patients, but not in healthy controls, suggesting that 
levels of 3PG in WL patients were maximal at baseline and could not be increased any 
further by an i.v. alanine challenge. 
Even though rnean POE concentrations were similar in lung cancer patients and 
healthy controls both at baseline and during alanine infusion, a significant difference in 
slope between patients (increase) and healthy subjects (decrease) was detected in the 
first 30 minutes of alanine infusion. As for PME, changes in POE during alanine infusion 
were negatively correlated with baseline POE levels in lung cancer patients but not in 
healthy subjects. The POE resonance contains components of phospholipid membranes, 
such as glycerophosphorylethanolamine and glycerophosphorylcholine, and the gluco-
neogenic intermediate phosphoenolpyruvate [146). In liver extracts of healthy rats, post-
alanine infusion phosphoenolpyruvate concentrations were significantly elevated 
[30,50], suggesting that the increase in POE in lung cancer patients observed in the 
present study is most likely due to elevated accumulation of phosphoenolpyruvate. 
The rnechanisms involved in the increasing levels of PME before and during alanine 
infusion in lung cancer patients could be enhanced uptake of alanine within the hepato· 
cytes and/or elevated gluconeogenic enzyme activity. In animal studies li1 vivo, alanine 
concentrations in the liver of tumor·bearing hosts were elevated [172), whereas plasma 
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alanine concentrations were decreased [101 J, suggesting elevated uptake of alanine by 
the liver. Some authors reported reduced plasrna alanine concentrations in weight-losing 
lung cancer patients [28,88). In the present study, we did not detect any differences in 
baseline plasma alanine levels between WL!WS lung cancer patients and healthy sub-
jects. This indicates that elevated alanine flux previously reported in weight-losing lung 
cancer patients [126) is counterbalanced by increased alanine uptake in the liver, resul-
ting in similar plasma levels in CaWL, CaWS, and C. It is noteworthy that, even though 
plasma alanine concentrations increased significantly in all groups during infusion of a 
standardized alanine dose, they did not increase to the same extent but in the order 
CaWL < CaWS < C (P<0.001). This would imply that alanine uptake by the liver during 
alanine infusion is increased in lung cancer patients, and especially so in weight-losing 
patients. 
Elevated activities of gluconeogenic key enzymes in the liver of turnor-bearing hosts 
have been reported by several authors, which could explain the elevated PME levels in 
WL lung cancer patients at baseline, as well as the faster and larger increase in PME 
observed in CaWS during alanine infusion. Increased POE and PME levels during alanine 
infusion, most likely reflecting elevated phosphoenolpyruvate and 3PG concentrations, 
could be explained by enhanced activities of pyruvate carboxylase (converting pyruvate 
into oxaloacetate) and/or phosphoenolpyruvate carboxylase (converting oxaloacetate 
into phosphoenolpyruvate). The observed increase in glucose production could also be 
the result of enhanced glucose-6-phosphatase activity. Indeed, animal studies showed 
elevated activities of pyruvate carboxylase in the liver of rats bearing marnmary adeno-
carcinomas [128), and phosphoenolpyruvate carboxykinase [156) and glucose-6-phosp-
hatase [83) in the liver of sarcoma-bearing rats. Factors which may be involved in the 
enhanced activities of gluconeogenic enzymes are decreased insulin or increased 
glucagon concentrations [10,101,174), stimulating gluconeogenic key enzymes [160). 
Relatively higher glucagon:insulin ratios were observed in CaWL in comparison to WS 
patients. 
In surnmary, this study demonstrates the presence of major alterations in gluconeo-
genesis in the tumor-free liver of lung cancer patients both with and without weight loss. 
Weight-losing lung cancer patients have markedly elevated glucose flux before as well as 
during L-alanine infusion. This is also confirmed by elevated PME and POE levels within 
the liver which reflect accumulation of gluconeogenic intermediates in these patients 
both before and during alanine infusion. Neither glucose flux nor concentrations of 
gluconeogellic intermediates within the liver show any ch ange during alanine infusion in 
WL cancer patients, suggesting that gluconeogenesis is already maxirnally induced at 
baseline in these patients. Weight-stable lung cancer patients, having a normal glucose 
flux, show an accelerated rise in PME and PDE levels during L-alanine infusion. Our 
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results suggest that both altered gluconeogenic enzyme activities within the liver and 
elevated alanine uptake are involved in these abnormalities. 
Acknowledgments 
56 
We are grateful to CHK Hordijk-Luijk and JDL Wattimena for performing biochemical 
analyses and mass spectrometry, and HJ Agteresch, CCM Bartels, M Heijsteeg, F Lager-
waard, AST Planting, MJM van Mierlo, S Senan, R Slingerland, G Stoter, MMA Tilanus-
Linthorst, J Verweij, and AG Zwanenburg for their co-operation in the patient recruit-
ment. We are grateful to W Schneijderberg and C Onna for their assistance during the 
experiments. 
Decreased energy and phosphorylation status 
in the liver of lung cancer patients 
with weight loss 
Submitted for publication 
Susanne Leij~Halfwerk/'.2 Pieter C Dagnelie/,3 Malthijs Oudkerk/ Paul E Sijens2 
1 Department of Internal Medicine II, Erasmus University Medical Center Rotterdam, Rotterdam, 
:2 Dcpartrnent of Diagnostic Radiology, Daniel Den Hoed Cancer Center, Rotterdam and 
3 Department of Epidemiology, University Maastricht, Maastrich t, TIle Netherlands 
Chapter 5 
Abstract 
Altered energy status has been reported in the liver of tumour-bearing animals, but data 
on energy status in humans are scarce. Therefore, bioenergetics in tumour~free liver of 
lung cancer patients were monitored using 31 p magnetic resonance spectroscopy (MRS) 
with infusion of L~alanine as a gluconeogenic challenge. 
Twenty-one overnight-fasted lung cancer patients without liver metastases, with 
(CaWL) or without weight loss (CaWS), and twelve healthy control subjects (C) were 
studied. Hepatic energy status was monitored before and during an Lv. L~alanine infusion 
of 1.4-2.8 mmol/kg + 2.8 mmol/kg/h for 90 min. by "P MR spectroscopy. 
Baseline levels of A TP in WL lung cancer patients, expressed relative to total MR-
detectable phosphate, were reduced (CaWL, 9.5 ± 0.9% vs. CaWS, 12.6 ± 0.8% and C, 
12.4 ± 0.8%; 1'<0.05) and inversely correlated with the degree of weight loss in lung 
cancer patients (r = -0.46, ~0.03). Pi /ATP ratios were increased (P<O.OS), indicating 
reduced liver phosphorylation status. During L-alanine infusion, ATP levels decreased in 
all groups (P<O.OS); in CaWL, ATP levels were lower at all time-points between 0-90 min 
as compared to both CaWS and C (1'<0.05). PJATP ratios Were significantly higher after 
70-90 min of L-alanine infusion in CaWL compared to CaWS and C (P<O.OS). 
Hepatic ATP and phosphorylation status are reduced in weight-losing lung cancer 
patients, in contrast with WS patients and healthy subjects, and continue to decrease 
during infusion of a gluconeogenic substrate, suggesting impaired energy regenerating 
capacity in these patients. 
Introduction 
58 
Weight loss is a common phenomenon in advanced cancer patients which affects both 
outcome of anti-tumour therapy [S6J and survival [43, 198J. Alterations in intermediary 
host metabolism have been frequently described, including elevated protein breakdown 
[89[, increased glucose production [26,96,133J, and enhanced Cori cycle activity 
[5, 116J. Since these processes put a continuous demand on energy stores of the cancer-
bearing host, energy reserves may become depleted which could contribute to weight 
loss. Although the mechanisms are not fully understood, it has been suggested that the 
liver is involved with rnetabolic alterations causing weight loss in cancer (20,115]. 
In animals bearing experimental tumours, reduced liver phosphorylation status has 
been reported [49J. In sarcoma-bearing rats, liver ATP levels progressively decreased 
[211 J and Pi /ATP ratios increased [181 J with increasing tumour-burden, suggesting 
intracellular energy depletion. Moreover, changes in intracellular Pi /ATP ratios were 
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already detected before the development of significant weight loss and prior to a decre-
ase in food intake (77,181]. [t was suggested that elevated P, release during fructose 
infusion was a result of increased g[uconeogenic (77]. Hepatocytes from tumour-rats 
also showed elevated gluconeogenesis from lactate and a dramatically decreased 
energy regenerating capacity during this elevated metabolic process (211]. 
Due to lack of non-invasive techniques, data on altered energy metabolism in the 
liver of humans with cancer are scarce. In a recent study, 31 p magnetic resonance spec-
troscopy (MRS) was used as a first attempt to measure hepatic energy status in cancer 
patients in vivo (511. Resu[ts suggested reduced concentrations of ATP and P, depen· 
ding on the technique utilised, in cancer patients with various tumour types, even 
though P, / A TP ratios were not different from healthy subjects (51]. 
The aim of the present study was to monitor ATP and Pi levels in tumour-free liver of 
a well-defined group of lung cancer patients with or without weight loss using 31 P MRS. 
L-alanine was infused in order to assess the energy generating capacity of the liver 
during a g[uconeogenic challenge. 
Subjects and methods 
Subjects 
The study was approved by the Medica[ Ethica[ Committee of the Erasmus University 
Medica[ Centre Rotterdam, Rotterdam, The Netherlands. Patients with non-small cell 
lung cancer stage [IIA/B or [V (WHO grading system) attending the outpatient depart-
ment of the University Hospita[ Rotterdam, The Netherlands, were recruited. Patients 
who were in remission or apparently cured were excluded. Additional exclusion criteria 
were: liver metastases (as checked for by CT/u[trasound), metabolic disease, corticoste-
roid treatment, elective surgery <3 months, chemo- or radiotherapy <4 weeks prior to 
study, alcoho[ consumption of more than 100g/week (=10 glasses), pregnancy, extreme 
anorexia or artificial weight reduction by dieting. Healthy subjects without weight loss 
were included as a control group (C). All participants signed informed consent. 
Twenty·one patients with non·small cell lung cancer were included in the study: nine 
weight-losing (weight loss 9.0 ± 1.4 kg (mean ± SEM) or 1 2% (range 6-22%), CaWL) and 
twelve weight-stable patients « 5% weight loss, CaWS). Twelve healthy subjects without 
weight loss were included as a control group (C). [n lung cancer patients mean age was 
higher (CaWL: 69 y (mean), range 53·81; CaWS: 63 y, range 38-76) as compared to C 
(49 y, range 37-69) although age ranges largely overlapped. Similar disease stages 
(CaWL: 3 lilA, 2 IIIB, 4 IV; WS: 1 lilA, 5 IIIB, 6 IV) and previous anti tumour treatment 
(surgery: 2 WL, 2 WS; radiotherapy: 4 WL, 6 WS; chemotherapy: OWL, 6 WS) were 
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observed in the WLfWS lung cancer patients. Minimal time period between the previ· 
ous therapy and MRS study was 3 months for surgery and 4 weeks for radio· and che-
rnotherapy. None of the patients received any therapy at the time of the study. Data on 
pre-illness stable weight, current weight, and weight loss over the previous 6 rnonths 
were taken from hospital records supplemented with oral information form patients. 
Body weight was measured to the nearest 0.1 kg on an electrical weighing scale (Seca 
707, Hamburg, Germany), height was measured to the nearest 0.1 em, and thickness of 
four skinfolds (triceps, biceps, subscapular, supra iliac) were measured to the nearest 0.2 
mm using a standard skinfold caliper (Holtain Ltd., London, Great Britain). Body weight, 
body mass index, and sum of skinfolds, as well as albumin and prealbumin levels were 
significantly decreased in CaWL as compared to CaWS and C (P<O.Ol). Liver function 
tests were normal in all subjects. No differences in energy intake between the lung 
cancer patients and healthy controls were detected as calculated from a dietary record 
during 7 days prior to the study. 
Experimental design 
All subjects refrained from alcoholic drinks for three days prior to the MRS measure-
ments. The subjects were studied between 7:30 a.m. and 1 :00 p.m. after an overnight 
fast (12-14 hours). A cannula (0.8x25 mm) was positioned in the left cubital vein for the 
infusion of L-alanine. In the contralateral cubital vein, an identical cannula was positioned 
for blood sampling. Blood samples were obtained for the determination of plasma 
substrate concentrations just before the L-alanine infusion was started and during alanine 
infusion. A solution of L-alanine in water (10% w/v) was prepared (Bufa B.V., Uitgeest, 
The Netherlands), sterilised by autoclavating in glass bottles, and warmed to -30°C, 
After obtaining five baseline lip MR spectra, a priming dose of 1.4 - 2.8 mmol/kg L-
alanine was administered in 5-8 min and followed by a continuous infusion of 2.8 
mmol/kg/h L-alanine for 90 minutes in order to obtain steady state conditions. Plasma 
alanine concentrations were determined enzymatically as described by Williamson 
(2231. Blood glucose concentrations were measured enzymatically with glucose-oxidase 
and peroxidase (Boehringer Mannheim, Mannheim, Germany). 
lip MR spectroscopy of the liver 
Spectroscopy studies were performed with a whole-body MR system equipped with a 
Helicon magnet operating at 2.0 T esla (Vision Magneton, Siemens AG, Erlangen, Germa-
ny). A 16 cm diameter transmit/receive IHtP surface coil was used for MRI localizati-
on, shimming and lip MR spectroscopy. Elastic bands were used for positioning the coil 
lateral to the liver in the mid-axillary plane. Field homogeneity achieved in shimming 
resulted in water peak line widths which were usually less than 40Hz (~0.5 ppm). After 
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obtaining an image of the region of interest, a one-dimensional chemical shift imaging 
(1 D-CSI) sequence was applied on a transverse slice of 4 cm centered on the surface 
coil and the liver (1 x4 phase-encoded matrix, field of view 40x40 cm'), yielding volumes 
of 40x1 Ox4 cm' [195J. Spectra were collected with a 640 flS Hanning-sinc shaped radio 
frequency pulse resulting in a flip angle of 135 0 in the centre of the coil, and 60 0 
(weighted average) in the liver volume with a repetition time (TR) of 1 s (40 acquisiti-
ons). Spectra were obtained at baseline and sequentially at 3 min intervals during the 
continuous L-alanine infusion. 
Time domain data were Fourier transformed after Gaussian multiplication (centre: 0 
ms, width 30 rns) and phase corrected. Quantification of spectral peak areas was perfor-
med using Numaris-3 software package (Siemens AG, ErJangen, Germany) including 
polynomial baseline correction followed by frequency domain curve fitting [194J. Meta-
bolite concentrations were calculated from peak areas and expressed relative to total 
MR-detectable phosphate as previously described [51J. Total detectable MR-phosphate 
did not change during L-alanine infusion (data not shown). Intracellular pH values were 
calculated from the chemical shift difference between the Pi and a-AlP resonances 
[134J. 
Statistical analysis 
Results are reported as Illeans ± standard error of the mean (SEM). In each experiment 
the average of five subsequent spectra was used as baseline value for calculations. Mid-
time points of MRS data acquisition at 15 rnin intervals during L-alanine infusion (7.5, 
22.5, 37.5 rnin, etc.) were used for graphical representation, and values expressed 
relative to the mean baseline value of healthy control subjects (~1 00%). Integrals of 
time-response curves (area under the curve) of absolute peak areas over 0-45 min, 45-90 
min, and 0-90 min intervals during L-alanine infusion were calculated as a measure of 
overall spectral response and expressed relative to baseline values (AUC). Directions of 
response were analysed by calculation of the slope of sequential spectra between 0-30 
min of L-alanine infusion. Changes from baseline values were appraised using Student's 
paired I-test Between-group differences in baseline values and in response to alanine 
infusion were analysed by ANOV A. Multiple regression analysis was used to analyse 
interrelationships with adjustment for age and L-alanine priming dose. Pearson's correlati-
on coefficients between baseline metabolite concentrations (expressed relative to total 
MR-detectable phosphate) for baseline values and absolute metabolite change (AUC) 
per rllinute during L-alalline infusion were calculated. P values <0.05 indicate statistical 
significance. 
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Fasting blood glucose levels were similar in lung cancer patients and did not change 
during L-alanine infusion. Baseline plasma alanine concentrations were similar between 
lung cancer patients and healthy controls (0.35 - 0.37 mM) and increased significantly 
during L-alanine infusion to 5.4 ± 0.1 mM in CaWL, 6.7 ± 0.5 mM in CaWS, and 8.5 ± 
0.9 mM in C (change from baseline and difference between all groups: P<O.OOl). 
lip MRS at baseline and during L-alanine infusion 
Table 5.1 shows hepatic baseline values of ATP and inorganic phosphate (P;) in lung 
cancer patients and healthy control subjects. Liver A TP concentrations were significantly 
lower in CaWL than in CaWS and C (1'<0.01, adjusted for age). ATP levels in CaWS and 
C were not significantly different. No significant differences in Pi levels were observed 
between the groups, although P; was slightly higher in CaWL. P; IATP ratios were signifi-
cantly increased in CaWL when compared with both CaWS and C (1'<0.05), indicating a 
decreased liver phosphorylation status. Again, P; IATP ratios in CaWS and C did not 
differ significantly. 
Table 5.1 
Baseline hepatic metabolite levels expressed relative to total MR-detectable phosphate in healthy 
control subjects and lung cancer patients.' 
Control Lung cancer P Value
2 
WS WL Cays. WLvs. 
(n = 12) (n = 12) (n = 9) C WS 
ATp J 12.4±0.8 12.6 ± 0.8 9.5 ± 0.9 0.60 0.01 
P," 8.4 ± 0.7 8.5 ± 0.4 9.1 ± 1.1 0.90 0.98 
P,IATP 0.72 ± 0.08 0.72 ± 0.06 1.07 ± 0.19 0.68 0.03 
I Mean:::!:: SEM. 
2 Differences between group means were analysed by ANOVA adjusted for age; Ca, lung cancer; C. healthy 
control; W5, weight-stable; WL, weight-losing 
, Percent of total MI\-detectable phosphate. 
Changes in ATP and Pi concentrations during L-alanine infusion are presented in Figure 
5.1. ATP levels showed a slow but steady decrease in all groups which became statisti-
cally significant from baseline values after 20 min of alanine infusion in CaWL (P<0.05) 
Figure 5.1 
a) 120 
100 
80 
60 
10 
20 
b) 110 
120 
100 
c) 
ri-- 80 
60 
200 
e 160 
120 
80 
Hepatic energy status In fung cancer 
•• 
-10 0 10 20 30 40 50 60 70 80 90 
Time (min) 
Energy metabolite concentrations in the liver of healthy control subjects (--0-_; n = 9), as well as weight-
stable (-e-; n = J 0) and weight-losing (-... - ; n = 7) lung cancer patients during a primed-constant infusion 
of 1.4-2.8 mmo!;kg + 2.8 mmol;kg/h L-alanine; a) ATP, b} Pi' c) Pi /ATP. Curves and error bars represent 
means :.t SEM. Baseline values are means from 5 spectra acquired in each subject before L-alanine infusion. 
Values are expressed as percentage of mean baseline value of healthy subjects (= I 00%). Times during L-
alanine infusion are mid-time points of 31p MRS data collection referenced to the start of the L-a1anine 
infusion (O=baseline). Significance of changes during L-alanine infusion compared to baseline (Student's 
paired t-test): *P<0.05, is:-$P<O.O I. Significant difference between CaWL and CaWS/C: tP<0.05, 
tP<O.O I (ANOVA). 
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Table 5.2 
Overall response of hepatic metabolite levels to primed-constant infusion of L-alanine in healthy 
control subjects and lung cancer patients.' 
Control Lung cancer 
WS WL 
(n = 9) (n = 10) (n = 7) 
ATP 0-45 min - 6 ± 3 *.,;; -5 ± 4 -16 ± 5 * 
45-90 min -12 ± 5 ** -13 ± 5 * -21 ± 7 * 
0-90 min -12 ± 3 ** -9 ± 4 * -17 ± 5 * 
P, 0-45 min -21 ± 6 "* I ± 10 -II ± II 
45-90 min -9 ± 13 9 ± 18 -16 ± 5 * 
0-90 min -18 ± 8 -I ± II -9 ± 9 
P,IATP 0-45 min -12 ± 8 II ± 14 4 ± 14 
45-90 min 9 ± 16 30 ± 24 26 ± 15 
0-90 min -6 ± II 13 ± 15 21 ± 12 
I Area under the curve during L-alanine infusion expressed as change from baseline (%, mean ± SEM). 
Difference from baseline values (Student's paired t-test): *P<O.05, **P<O,O!. 
and after 35-40 min in CaWS (P<0.05) and C (P<O.Ol). In CaWL, ATP levels were 
significantly lower at all time points between 0·90 min when compared with both CaWS 
and C (P<0.05). Between 60-90 min of alanine infusion, partial recovery of ATP was 
observed in both C and CaWS, but not in CaWL where ATP continued to decrease. P; 
levels in C decreased sharply during the first 30 min (P<O.Ol), but recovered to baseline 
values between 60 and 90 min of alanine infusion. In contrast, no significant change in PI 
was observed in CaWS throughout alanine infusion, whereas in CaWL PI showed a slow 
but continuous decrease which became statistically significant at 60 min of alanine 
infusion, with a sudden recovery thereafter. Pi fATP ratios did not change significantly 
during the first 60 min of alanine infusion in either patients or healthy subjects, even 
though P; IATP tended to decrease in C during the first 30 min. After 60 min of alanine 
infusion Pi fATP ratios showed a sudden significant rise in CaWL when compared with 
CaWS and C (P<O.Ol). This difference remained statistically significant (P<0.05) until 90 
min when the alanine infusion was discontinued. 
Overall changes during L-alanine infusion 
Overall changes in metabolite concentrations during L-alanine infusion relative to baseli-
ne are presented in Table 5.2. Although ATP decreased relatively more in CaWL and 
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almost three times as much as in CaWS and C between 0-45 Inin, the difference compa-
red to CaWS and C was not statistically significant. Changes in Pi after alanine infusion 
were also not significantly different between lung cancer patients and healthy subjects at 
either 0-45 or 45-90 of alanine infusion. P,IATP ratios in lung cancer patients tended to 
increase during alanine infusion whereas in control subjects a trend to decrease was 
observed (NS), but again the changes were not significantly different between the 
groups. Alanine infusion did not change liver pH in any of the groups (data not shown). 
Correlations 
Baseline levels of ATP were inversely correlated with the degree of weight loss in lung 
cancer patients (r~-0.46, "'"0.03). Furthermore, baseline ATP levels were inversely 
correlated with Pi at baseline (r~-0.38, "'"0.03). Changes in ATP during L-alanine were 
significantly correlated with baseline Pi (r~0.50, 1'<0.01), but no significant correlation 
between changes in ATP and Pi during alanine infusion was detected (r~-0.168, "'"0.41). 
Discussion 
In the present study, bioenergetics in the tumour-free liver of lung cancer patients during 
an Lv. L-alanine challenge were monitored using 31 p MR spectroscopy. Alanine infusion 
is known to stimulate gluconeogenesis [57,59,2251, and a standardised dose can be 
llsed to investigate gluconeogenic and energy metabolism within the liver by 31 p MRS 
directly and non-invasively [501. In the present study, primed-constant infusion of 1.4-2.8 
mmol/kg L-alanine + 2.8 mmol/kg/h induced a steady decrease in ATP levels in healthy 
controls. This decrease in liver ATP was also reported after bolus infusion of 5.6 ml110l 
alanine/kg in healthy rats [301, but was not observed at a lower dose of 2.8 mmol/kg 
alanine in healthy rats [301 or humans [501. 
Baseline ATP levels were significantly reduced in weight-losing lung cancer patients, 
whereas ATP levels in weight-stable lung cancer patients were not different frofn those in 
healthy control subjects. Furthermore, phosphorylation status was significantly decrea-
sed in weight-losing cancer patients, as shown by elevated Pi JATP ratios. During L-
alanine infusion, ATP levels in WL cancer patients decreased to a greater extent than in 
WS patients and healthy control subjects. It is remarkable that, between 60-90 min of L-
alanine infusion, ATP levels in WS cancer patients and healthy subjects showed some 
recovery, whereas in WL cancer patients the decrease in ATP concentrations continued 
thoughout the 90-min infusion period. 
In sarcoma-bearing rats progressive decrease in liver ATP levels was detected be-
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tween 5 and 20% of tumour~burden [211 I, whereas significant weight loss and anorexia 
were only detected at 20% tumour-burden_ In liver from rats bearing sarcomas, decrea-
sed phosphorylation potential was detected biochemically [61 and by 31 p MRS in vivo 
[1811_ Phosphorylation status was also negatively correlated with tumour-burden, and 
reduced phosphorylation status was most prominent at a high tumour~burden when also 
weight loss and anorexia were present [1811_ A study in cancer patients with mixed 
tumour types suggested apparently decreased ATP levels in the tumour-free liver [511_ 
The loss of hepatic ATP during alanine infusion could be caused by different mecha-
nisms. Since gluconeogenesis frorn alanine is an energy consuming process which 
requires 6 moles of A TP per mole glucose produced, an increase in gluconeogenesis 
puts a demand on the energy stores in the hepatocyte_ If ATP is utilised at a higher rate 
than A TP is resynthesised, an energy deficit in the hepatocyte would occur. Furthermore, 
complete metabolism of alanine includes the urea cycle in addition to gluconeogenesis, 
requiring an additional 4 ~P per mole of glucose produced [1511_ The energy-dependent 
uptake of alanine into the hepatocyte could also be involved in the decrease in ATP 
levels during alanine infusion [1 70,2141_ 
The observed bioenergetic derangements in lung cancer patients may be related to 
the presence of a distant tumour 1211} causing increased metabolic activity in the liver 
[261_ Elevated gluconeogenesis from alanine has previously been reported in weight-
losing lung cancer patients [851_ When compared with healthy rats, P,/ATP ratios during 
fructose infusion were increased in the liver of rats with minimal turnour burden (771, 
prior to the onset of cachexia. It was suggested that the increase in P r was caused by 
elevated hepatic gluconeogenesis in these rats resulting in increased release of Pj in the 
conversion of glucose-6-phoshate to glucose [771_ In tumour-influenced rat hepatocytes 
it was demonstrated that elevated gluconeogenesis during incubation with lactate 
resulted in a 42% drop in ATP levels, whereas in hepatocytes from healthy animals no 
change in ATP levels was observed, suggesting decreased energy regenerating capacity 
in tumour-bearing liver [2111_ Furthermore, this progressive loss of liver ATP levels was 
correlated with decreased insulin levels [2111_ Brauer et al. showed that the tumour-
induced reduction of phosphorylation in the host liver of rats bearing sarcomas was 
prevented by short-term as well as chronic insulin administration [201_ Moreover, insulin-
treated rats did not develop weight loss, possibly due to inhibition of gluconeogenesis 
[201_ This would suggest that in weight-losing lung cancer patients the reduced ATP 
levels within the liver rnay be correlated with the increased gluconeogenesis, and that an 
impaired adaptation to the metabolic stress induced by infusion of a gluconeogenic 
substrate exists in these patients. 
In summary, this study has shown decreased ATP levels and phosporylation status in 
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weight-losing lung cancer patients. During alanine infusion, A TP levels decrease to a 
greater extent in WL lung cancer patients, and do not show the recovery seen in WS 
patients and healthy subjects. Further studies on the mechanisms responsible for the 
observed alterations in liver energy metabolism are warranted. 
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Abstract 
Decreased liver ATP levels and phosphorylation status have recently been observed in 
Illng cancer patients with weight loss. The airn of the present study was to investigate 
whether ATP infusion restores liver energy status in advanced lung cancer patients lIsing 
3l p magnetic resonance spectroscopy (MRS). 
Nine patients with advanced non·small cell lung cancer were studied one week 
before (baseline) and at 22-24 hours of continuous ATP infusion (37-75 ~g/kg/min). 
After an overnight fast, localised hepatic Jl p MR spectra (repetition time 15 s) were 
obtained and analysed for ATP and P; content. Ten healthy subjects (without ATP infusi· 
on) were studied as a control. 
Liver ATP levels in lung cancer patients increased from 8.8 ± 0.7 % (of total MR-
detectable phosphate; mean ± SE) at baseline to 12.2 ± 0.9 % during ATP infusion 
(P<0.05). These levels were similar to those in healthy subjects (11.9 ± 0.9%). In patients 
with >5% weight loss, the increase in ATP levels was most prominent (from 7.9 ± 0.7 to 
12.8 ± 1.0%, 1'<0.01). 
In conclusion, ATP infusion restores hepatic energy levels in patients with advanced 
lung cancer, especially in weight·losing patients. These changes could have beneficial 
effects on the nutritional status of weight-losing lung cancer patients. 
Introduction 
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Weight loss is a common phenomenon in lung cancer patients and contributes signifi-
cantly to the high morbidity and mortality in this disease (56, 198J. Alterations in interme-
diary host metabolism have been frequently described, including elevated protein 
turnover (89,1311, glucose production (116,204J and Cori cycle activity [96J. In an in 
vitro study, gluconeogenesis in isolated hepatocytes frorn sarcoma-bearing rats was 
increased during incubation with lactate as compared to hepatocytes from healthy rats 
(211 J. This increased gluconeogenesis resulted in a 42% decrease in ATP levels, whereas 
in healthy rats no change in ATP was observed (211 J. This suggests that elevated rates of 
gluconeogenesis in the cancer-bearing host rnay put an increased demand on the 
energy stores and may contribute to weight loss. 
Alterations in hepatic energy status have been well docurnented in animal models of 
various tumors. Decreased liver phosphorylation status, as observed by increased P /ATP 
ratios, was detected in rats bearing prostate tumors (491 or sarcomas [6,20,1811 and was 
correlated with increasing tumor burden (1811. It is noteworthy that these alterations in 
liver energy status were already detected before the development of weight loss (77J. 
A TP infusion and liver energy status 
Decreased liver ATP levels as detected by 31 p magnetic resonance spectroscopy (MRS) 
were reported in patients with various tumor types {S 1 J. Recently, we reported decrea~ 
sed hepatic ATP and phosphorylation status in weight-losing lung cancer patients, when 
compared with weight-stable patients and healthy controls [1241. 
In mice bearing colon tumors daily intraperitoneal ATP injections increased total liver 
and erythrocyte ATP pools [1681. These increases were associated with a significant 
inhibition of host weight loss [1681. The present study was aimed at investigating whe-
ther continuous ATP infusion increases hepatic ATP levels and phosphorylation status in 
advanced lung cancer patients. 
Subjects and methods 
Subjects 
The study was approved by the Medical Ethical Committee of the Erasmus University 
Medical Center Rotterdam. All patients signed informed consent. Eligible for the study 
were patients with histological or cytologically proven non-small cell lung cancer, stage 
IIiB or IV (WHO grading system) without curative options, and Karnofsky index of 60% 
or more. Patients with cognitive dysfunction or liver, renal, respiratory, or heart failure, 
and patients undergoing surgery, concurrent chemotherapy, or radiotherapy involving all 
lesions were excluded. Ten healthy subjects (age range 37-69 y; body weight 76.4 ± 3.6 
kg (mean ± SE)) where included as a control. 
Study design 
In nine patients (7 males, 2 females) liver energy and phoshorylation status were studied 
using 31 p magnetic resonance spectroscopy (MRS) one week before (baseline) and 
during continuous ATP infusion, i.e. 22~24 hours after starting ATP infusion. The patients 
received ATP infusion doses varying from 37 to 75 flgjkgjmin. Clinical characteristics of 
these patients are listed in Table 6.1. Healthy control subjects were only studied at 
baseline. ATP infusions (6.1 mg ATP-Na,.3H,O in 1 ml NaCI 0.9%)(Merck, Darmstadt, 
Germany) were sterilised by filtration and given with initial dose of 20 flgjkgjmin and 
increased by increments of 1 0 ~g/kg/min every 30 min until a Inaximurn dose of 7S 
flgjkgjmin, or until the maximally tolerated dose had been reached. If any side effects 
occurred, the dose was reduced to the last given dose or further until side effects disap~ 
peared, usually within minutes after lowering the ATP dose. Thereafter, ATP was infused 
at a continuous rate. The most frequently occurring side effects were chest discomfort 
and 'Ineeding to take a deep breath II. 
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Table 6.1 
Characteristics of non-small cell lung cancer patients. 
Patient Gender Age Tumor Weight Weight change' ATP infusion 
(no.) (m;1) (y) stage (kg) (%) (jJgA<g/min) 
m 31 4 71.6 -20.4 67 
2 m 76 38 91.1 - I 1.7 42 
3 m 85 3B 54.9 -10.2 75 
4 f 52 4 64.2 -9.0 75 
5 f 57 4 56.6 -22.5 40 
6 m 75 38 70.8 - 1.7 67 
7 m 49 38 77.1 -1.0 75 
8 m 71 3B 71.8 -4.2 75 
9 m 68 4 65.1 -0.3 37 
Mean 63 69.2 -9.0 61 
SE 6 3.7 2.7 6 
I Prior to MRS 
lip MR spectroscopy 01 the liver 
Subjects were studied after an overnight fast. MR Spectroscopy studies were performed 
with a whole-body MR system equipped with a Helicon magnet operating at 2 T (Vision 
Magnetom, Siemens AG, Erlangen, Germany). A 16 em diameter transmit/receive lH/lp 
surface coil was used for MRI localization, shimming and 31 p MR spectroscopy. Elastic 
bands were used for positioning the coil lateral to the liver in the mid·axillary plane. Field 
homogeneity achieved in shimming resulted in water peak line widths which were 
usually less than 40Hz ("0.5 ppm). After obtaining an image of the region of interest, a 
one·dimensional chemical shift imaging (1 D·CSI) sequence was applied on a transverse 
slice of 4 cm centered on the surface coil and the liver (1 x4 phase-encoded matrix, field 
of view 40x40 cm'), yielding volumes of 40x1 Ox4 cill 11951. Spectra were collected 
with a 640 fJS Hanning-sinc shaped radio frequency pulse resulting in a flip angle of 
135 0 in the center of the coil, where a methylene diphosphonate reference sample was 
positioned, and 60° (weighted average) in the liver volume. Spectra with repetition time 
of 15 s (10 acquisitions) were obtained in each patient examination. Time domain data 
A TP infusion and liver energy status 
were Fourier transformed after Gaussian multiplication (center: 0 ms, width 30 fns) and 
phase corrected. Quantification of spectral peak areas was performed using Numaris-3 
software package (Siemens AG, Erlangen, Germany) including polynomial baseline 
correction followed by frequency domain curve fitting (194J. Metabolite concentrations 
were calculated from peak areas and expressed relative to total MR-detectable phospha-
te as previously described (51 J. 
Statistics 
Results are presented as means ± standard error of the mean (SE). Changes of liver ATP 
concentrations and PJATP ratios during ATP infusion were tested for significance using 
Student's paired t-test. Between-group differences were compared using the Student's t-
test for independent groups. Pearson's correlation coefficients were calculated to investi-
gate possible relationships between parameters. P-values of <0.05 indicated statistical 
significance. 
Results and discussion 
Baseline ATP levels in the liver of lung cancer patients were significantly lower than in 
healthy subjects (1'<0.05, Table 6.2). When patients were stratified for presence of 
weight loss, it was shown that ATP levels in patients with :<! 5% weight loss were as much 
as 34% lower than in healthy subjects (P<0.05, Table 6.2). In contras~ ATP concentrati-
ons in patients with <5% weight loss were not significantly different from healthy con-
trols. During ATP infusion, liver ATP levels in lung cancer patients increased by 48 ± 
15% (P<0.05) reaching levels similar to those in healthy subjects (Table 6.2). In lung 
cancer patients with >5% weight loss, ATP increased by 64 ± 9% (1'<0.01). P/ATP ratios 
during A TP infusion decreased to levels close to those in healthy subjects, although none 
of these changes were statistically significant. No significant correlations were observed 
between ATP-dose and the change in liver ATP or phosphorylation status (r~0.08 and 
r~0.28, respectively). 
To our knowledge, no earlier studies have addressed the effect of ATP infusion on 
ATP concentrations in the liver of human subjects. In tumor-bearing mice, single intrape-
ritoneal injections of ATP increased total liver ATP pools from 3.2 to 8.3 mM (168J. 
Following this expansion of liver ATP pools, erythrocyte ATP levels increased from 0.6 to 
2.4 mM (168J. In patients in the present study we measured whole blood ATP concen-
trations of 0.71 ± 0.02 mM at baseline. After 22-24 hours of ATP infusion, blood ATP 
levels increased to plateau levels of 53 ± 3 to 69 ± 2% above baseline, depending on 
the ATP-dose given. 
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Table 6.2 
Liver energy and phosphorylation status as observed by 31 P MRS in healthy subjects and advanced 
lung cancer patients before and during infusion of adenosine triphosphate (37-75 pgA<g/min).' 
Healthy Lung cancer 
Total <5% weight loss ~5% weight loss 
(n= 10) (n=9) (n=4) (n=5) 
ATP' 
Baseline 11.9 ± 0.9 8.8 ± 0.7' 10.3 ± 1.3 7.9 ± 0.7* 
During ATP infusion 12.2 ± 0.9t I 1.5 ± 1.5 12.8± l.at 
P/ATP 
Baseline 0.73 ± 0.16 0.94 ± 0.15 0.77 ± 0.21 1.07 ± 0.21 
During ATP infusion 0.68 ± 0.11 0.68 ± 0.11 0.68±0.19 
I Mean ± standard error of the mean (SE) 
2 Expressed as percentage of total MR-detectable phosphate 
Significance of difference from healthy subjects: *P<O,Q5; significance of difference from baseline: 
tP<O.05. tP<O.OI. 
It could be argued that the observed increase in liver ATP levels in the present study 
might be caused by contamination of MR spectra by ATP in blood circulating in the liver 
voxel, due to elevated erythrocyte AlP concentrations and/or vasodilation. Although 
ATP concentrations in humans are 34 times higher in liver 115,99[ than in erythrocytes 
[54,209,222[, and AlP infusions were reported to even further increase liver AlP levels 
in mice [168[, no data are available on the contribution of AlP from blood to the 31 p MR 
signal of liver ATP in humans in vivo. Therefore, an estinlation of ATP contamination 
from blood was made using in this study measured whole blood ATP concentrations of 
0.7 mM, and assuming a liver ATP concentration of 2.51 mM [99[, and a liver blood 
volume of 0.25 ml/g wet weight [81[. Results showed a relative contribution of blood 
ATP to total liver ATP in the MRS liver voxel of ~9%. During ATP infusion, whole blood 
A TP concentrations increased to 1.1 rnM which would give a s 5% increase in total 
MRS-observed AlP concentrations in the liver voxel. This is one order of magnitude less 
than the 50·60% increase in liver AlP levels. 
Yet another effect of ATP is vasodilation [2, 176[mediated by purinergic receptors P1 
and P2 which are located on endothelial cells of blood vessel walls [17,112[. Vasodilati-
on in the liver could affect the 31 P MRS measurement by increasing blood volurne within 
one liver voxel.lndeed, increased liver AlP levels were observed by 31 p MRS in rat liver 
after dopamine administration, probably due to increased hepatic blood flow [159[. 
A TP infus;cx] and liver energy status 
Based on reported maximal changes in hepatic blood volume in humans between -200/0 
[76[ and +20%[9[ depending on the stimulus used, increased blood volume in the liver 
could account for an increase in liver A TP levels by 8%. Again, this is one order of 
magnitude short of the observed effect. If liver ATP values are corrected for the highest 
possible blood contribution from combined vasodilation and raised erythrocyte ATP 
levels (18%), the increase in patients with >5% weight loss still remains highly significant 
(P<O.Ol). We therefore conclude that the increase in total liver ATP as measured by 31 p 
MRS during ATP infusion does reflect a significant rise in ATP levels in liver tissue and is 
not caused by altered ATP contamination from blood. 
In conclusion, this study shows that i.v. ATP infusion is able to restore depleted liver 
ATP pools in patients with advanced lung cancer to levels similar to or above those in 
healthy subjects. This effect is most marked in weight·losing lung cancer patients. The 
increase in liver ATP pools could have beneficial effects on the nutritional status of 
weight·losing lung cancer patients. 
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Abstract 
Cancer cachexia is associated with elevated lipolysis, proteolysis, and gluconeogenesis. 
Recently, adenosine 5'-triphosphate (ATP) infusion was found to significantly inhibit loss 
of body weight, fat mass and fat-free rnass in advanced lung cancer patients. The present 
study was aimed at exploring the effects of ATP on whole body glucose turnover, 
alanine turnover, and gluconeogenesis from alanine. Twelve patients with advanced 
non-small cell lung cancer were studied one week before and at 22-24 hours of continu-
ous ATP infusion. After an overnight fast, turnover rates of glucose and alanine, and 
gluconeogenesis from alanine were determined using primed-constant infusions of 
[6,6-'H,]-glucose and 13-13C]-alanine. High-dose ATP infusion (75 ~g/kg/min) induced an 
increase in glucose turnover from 0.44 ± 0.13 to 0.62 ± 0.07 mmoljkg/h (1"=0.059), and 
in gluconeogenesis from alanine from 0.30 ± 0.16 to 0.37 ± 0.13 mmoljkg/h (1"=0.056). 
At lower ATP doses (37-50 ~g/kg/min) these effects were not detected. The increase of 
glucose turnover during ATP infusion compared to baseline showed a significant correla-
tion with the ATP dose (r=0.58, AO.05). No change in alanine turnover was observed at 
any ATP dose. The percentage glucose derived from afanine showed an increase from 
59 ± 26% to 75 ± 17% at high-dose ATP (P<0.05) which was not detected at lower ATP 
dose. Results of this study indicate an increase in whole-body glucose turnover rate and 
gluconeogenesis from alanine during high-dose ATP infusion (75 ~g/kg/min) in advan-
ced lung cancer patients, with a significant dose-response relationship for A TP dose and 
glucose turnover. 
Introduction 
78 
Cachexia is a cornmon phenomenon in lung cancer patients, and contributes significant-
ly to morbidity and mortality [43,56,198]. Cancer cachexia is associated with metabolic 
alterations including elevated lipolysis [61,188], protein breakdown [132,154,171], and 
increased glucose turnover [89J. In patients with advanced cancer increased glucose 
production has been shown from lactate [185], glycerol [133], and alanine [85,219]. 
It has been argued that the liver plays an important role in the metabolic alterations 
contributing to the development of weight loss in cancer [20,115]. In liver [49,181,211] 
and skeletal muscle [181] of tumour bearing rats, significantly reduced adenosine 
5'-triphosphate (ATP) levels have been demonstrated which were associated with increa-
sed gluconeogenesis [211] and increased gluconeogenic enzyme activity [156]. In mice 
bearing CT26 colon tumours, daily intraperitoneal injections of ATP, AMP or adenosine 
for 1 0 consecutive days significantly inhibited host weight loss [168]. This inhibition was 
A TP infusion and glucose tumover 
associated with elevated hepatic A TP pools 1167, 168J. 
In a randomised clinical trial in patients with advanced non-small cell lung cancer we 
recently demonstrated beneficial effects of ATP infusions on body weight, skeletal 
muscle mass, muscle strength, and body cell mass 11 J. The present study was aimed at 
exploring effects of ATP infusion on whole-body glucose turnover, alanine turnover and 
gluconeogenesis from alanine. Based on the beneficial clinical outcomes we expected 
that A TP would have an inhibitory effect on these processes. Alanine was selected as a 
substrate because this amino acid is the key protein-derived precursor of glucose utilized 
by the liver 1201], and a component of muscle protein degradation. 
Subjects and methods 
Subjects 
Patients with histologically or cytologically proven non-small cell lung cancer, stage IIIB 
or IV without curative options, and a Karnofsky index of 60% or more were eligible for 
the study. Patients with cognitive dysfunction or liver, renal, respiratory, or heart failure, 
and patients undergoing surgery, concurrent chemotherapy, or radiotherapy involving all 
lesions were excluded. The study was approved by the Medical Ethical Committee of 
the Erasmus University Medical Center Rotterdam. All participants signed informed 
consent. 
Study design 
In the clinical trial 28 patients were randomised to receive a maximum of 10 ATP cour-
ses of 30 hours each: 7 courses at 2-week intervals, followed by 3 ATP courses at 
4-week intervals. ATP infusions (6.1 mg ATP-Na,.3H,O in 1 ml saline 0.9%)(Merck, 
Darmstadt, Germany) were sterilised by filtration and started with an initial dose of 20 
~g/kg/min and were increased by increments of 1 0 ~g/kg/min every 30 minutes until a 
maximum dose of 75 ~g/kg/min, or until the maximally tolerated dose had been re-
ached. I f any side effects occurred, the dose was reduced to the last given dose or 
further until side effects disappeared, usually within minutes after lowering the ATP dose. 
Thereafter, ATP was infused at a continuous rate. The most frequently occurring side 
effects were chest discomfort and the need to take a deep breath. 
In 12 out of the 28 ATP-allocated patients, glucose and alanine turnover and gluco-
neogenesis from alanine were studied one week before (baseline) and during a ATP 
course (22-24 hours after starting ATP infusion). Seven patients received low-dose 
infusions of 37-50 ~g/kg/min ATP, and five high-dose infusions of 75 ~g/kg/min ATP. 
The subjects were studied in the morning after an overnight fast. A cannula (0.8x25 
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mm) was placed in the left cubital vein for the infusion of stable isotope tracers. In the 
contralateral cubital vein, an identical cannula was positioned for blood sampling. To 
study gluconeogenesis, a solution was prepared containing [6,6.'H,I·D.glucose, 98 
atom%, and [3-13CJ-L-alanine, 99 atom% (Mass Trace, Woburn, USA), in water and this 
was sterilised by autoclaving in glass vials. A priming dose of 30 I-Imoljkg 
[6,6.'H,I·D.glucose was administered followed by a continuous infusion of 10 I-Imoljkg/h 
[6,6.'H,I·D.glucose for 90 minutes. Simultaneously, a priming dose of 80 I-InlOljkg 
[3.13 q.L.alanine was given followed by a continuous infusion of 40 I-InlOljkg/h 
[3.13 q.L·alanine during 90 minutes. Both tracer solutions were infused using calibrated 
syringe pumps (PerfusortD fm, Braun, Germany). Venous blood samples were drawn 
immediately before the isotope infusions were started, and at 10 min intervals from 30 
to 90 min., i.e. after steady state conditions during the tracer infusions had been achie-
ved. 
Analytical methods 
Blood samples were collected in tubes containing lithium heparin (Becton Dickinson 
Vacutainer®, Meylan Cedex, France) and immediately stored on ice. After centrifugation 
(10 min., 1200 g, 4°C), the plasma was collected and stored at ·20°C until analysed. An 
aliquot of the infusate was analysed to docllment the actual concentrations of the 
tracers in each study. Blood glucose concentrations were determined enzymatically with 
glucose·oxidase and peroxidase (Boehringer Mannheim, Mannheim, Germany). Plasma 
alanine was measured enzymatically as described by Williamson (223). Isotopic enrich-
ments were determined using the following procedures. Plasma was deproteinized by 
adding 0.3 M barium hydroxide (Sigma Diagnostics, St.Louis) and 0.3 M zinc sulphate 
(Merck, Darmstadt, Germany). After centrifugation (8 min, 15000 g, 4°C) the superna· 
tant was applied to an ion exchange column (mixed bed: AG50W·X8 and AG1·X8, 
200·400 mesh, 0.2 g each; BioRad, California). Glucose and alanine were eluted from 
the column using water and 4 M ammonium hydroxide (Merck, Darmstadt, Germany), 
respectively, and dried under nitrogen. A glucose derivative (aldonitril penta acetate) 
was prepared according to Varma et al [2161. An alanine t·butyldimethylsilyl derivative 
was prepared as described by Chaves Das Neves et al [321. 
Isotopic enrichments were measured by injecting 1 1-11 samples with a split ratio of 
50:1 on a fused silica capillary column of 25 m x 0.22 mm, coated with 0.11 I-Im HT5 
(SGE, Victoria, Australia). The relative isotopic enrichments of deuterated glucose and 
carbon· 13 alanine were determined using a Carlo Erba GC8000 gas chromatograph 
coupled to a Fisons MD800 mass spectrometer (GC-MS) (Intersience B.V., Breda, The 
Netherlands) in electron impact ionisation mode. In general, the variation coefficient in 
enrichment was 0.2 mole% for both [6,6.'H,I·glucose and [3.lJq.alanine measurement, 
A TP infusion and glucose turnover 
and no concentration effect was observed at this mole% enrichment level. Ions were 
selectively monitored at mass per unit charge (m/z) 187 for natural glucose and 189 for 
the deuterated molecule. The isotopic enrichment of [3-"q-alanine was determined at 
the m/z ratios 260 and 261 for carbon-12 and carbon-13 alanine, respectively [13 71. 
Total enrichment of carbon-13 glucose was measured separately (aldonitril pen-
ta-acetate derivation) using a gas chrornatograph combustion isotope ratio mass spectro-
meter (GC-IRMS) (Optima, Micromass UK, Middlewich, Cheshire, Great Britain). The 
[I) C]-glucose enrichrnent in atom% excess (APE) was monitored after cOlnbustion to 
CO, at mass 44 for carbon-12 and 45 for carbon-13, respectively. 
Calculations 
Whole body rates of appearance (R) of glucose and alanine were calculated during 
steady state following a one-compartrnent model, using the equation: 
R, = F, X ((IE, /IE,) -1), (1 ) 
where F, is the isotope infusion rate (mmol/kg/h), IE the isotopic enrichment of the 
infusate (mole% excess), and IE,cr the isotopic enrichment of the extracellular fluid 
(mole% excess)[2241. The percentage glucose produced from alanine equals: 
13 13. (IE C-glucosep",m, / (IE C-alanmep",m, x 0.33)) xl 00% (2) 
The correction factor in formula (2) is applied in order to correct for the number of 
carbons in both glucose and alanine. Gluconeogenesis from alanine (mmol/kg/h) is then 
obtained as: 
% glucose from alanine x R, (['H,I-glucose). (3) 
Finally, the percentage of alanine converted into glucose was calculated by dividing the 
rate of gluconeogenesis from alanine by the rate of appearance of alanine [40J. 
Statistical analysis 
Results are presented as means ± standard deviation (SD). Changes in turnover between 
baseline and ATP infusion were tested for significance by Student's paired t-test. The 
correlation between variables was analysed using Spearrnants rank correlation coeffi-
cient. Results were considered to be statistically significant with a Pvalue <0.05. 
Results 
Study population 
Twelve lung cancer patients (9 males, 3 females) with a mean age of 64 ± 13 yrs and 
weight of 72.7 ± 13.0 kg participated in the study. Mean weight loss at baseline was 7.1 
± 9.0 kg. Clinical details of the patients studied are shown in Table 7.1. Patients had 
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already an average of 2.3 (range 0-7) previous AlP courses_ 
Table 7.1 
Clinical details of patients with non-small cell lung cancer-_ 
Patient Sex Age Stage Weight change Weight at Weight Previous AlP AlP dose 
(y) at baseline (%) rando (kg) (kg) courses (IlgJkg/min) 
M 68 4 -104 65.5 65.1 37 
2 F 57 4 -23.5 57.5 56.6 40 
3 M 66 4 3.0 6804 69.0 40 
4 M 76 38 -10.7 89.6 91.1 4 42 
5 M 54 38 -22.6 74.5 72.0 4 50 
6 M 41 38 2.3 87.9 98.2 7 50 
7 M 77 38 3.6 81.6 82.9 50 
8 M 71 38 -4.3 71.0 71.8 75 
9 M 48 38 -4.8 79.7 77.1 5 75 
10 M 85 38 -8.5 53.9 54.9 2 75 
II F 53 4 -7.7 69.0 69.2 0 75 
12 F 52 4 -10.8 65.0 64.2 75 
Glucose and alanine metabolism 
8aseline plasma glucose and alanine concentrations were 4_9 ± 0.8 and 0.36 ± 0.02 
mmol/I, respectively, and did not change during AlP infusion. When data were analysed 
for all subjects combined, turnover rates of glucose and alanine, and gluconeogenesis 
from alanine during AlP infusion did not differ significantly from baseline. However, as 
shown in Table 7.2, stratification for ATP dose revealed remarkable differences accor-
ding to AlP dose. In patients with low-dose AlP infusion (37-50 ~g/kg/min), no change 
was detected in glucose turnover or gluconeogenesis from alanine. In patients with 
high-dose AlP infusion (75 ~g/kg/min) glucose turnover increased by 50 ± 50% 
(POOO.059), and gluconeogenesis from alanine by 40 ± 35% (POOO.056). Mean baseline 
glucose turnover rates and gluconeogenesis from alanine in patients receiving the 
high-dose AlP infusions tended to be lower than in the low-dose AlP group for glucose 
turnover (P=O.07j Student's t -test). The change of glucose turnover from baseline was 
significantly correlated with the AlP dose (r~0.58, P<0.05). No such dose-effect relation 
A TP ,;l(usioll and glucose turnover 
was demonstrated for alanine turnover or gluconeogenesis from alanine. 
The percentage glucose derived from alanine increased significantly during high-dose 
ATP infusion (baseline, 59 ± 26%; ATP, 75 ± 17%; P<0.05), but not at low-dose ATP 
(baseline, 67 ± 29%; ATP, 68 ± 33%; n.s.). No difference in the percentage of alanine 
converted into glucose was observed between baseline and during ATP infusion at 
either high-dose A TP (baseline, 63 ± 18%; A TP, 61 ± 21 %; n.s.) or low-dose A TP (baseli-
ne, 59 ± 33%; ATP, 60 ± 34%; n.s.). 
Table 7.2 
Glucose turnover and gluconeogenesis from alanine in twelve lung cancer patients before and 
during ATP infusion.' 
Low-dose A TP High-dose ATP 
(37-50 pgA<g/min) (75 pgA<g/min) 
(n=5) (n=7) 
Glucose turnover 
baseline (mmolil<gJh) 0.58 ± 0.10 0.44 ± 0.13 
during ATP infusion (mmolil<gJh) 0.56 ± 0.13 0.62 ± 0.07 
change (mmolil<g/n)' -0.02 ± 0.12 0.18 ±0.15 
change (%)2 
-2.8 ± 19.0 50.1 ± 49.6 
P value of change 0.67 0.059 
Gluconeogenesis from alanine 
baseline (mmolil<gJh) 0.34 ± 0.17 0.30 ± 0.16 
during ATP infusion (mmolil<gJh) 0.35 ± 0.24 0.37±0.12 
change (mmolil<gJh)' 0.01 ±0.14 0.07 ± 0.06 
change (%)' 1.9 ± 34.3 39.3 ± 35.1 
P value of change 0.87 0.056 
I Scores expressed as mean ± SO 
2 Change from baseline 
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The aim of the present pilot study was to explore effects of intravenous ATP infusion on 
whole-body glucose turnover, alanine turnover, and gluconeogenesis from alanine, as 
possible pathways contributing to the reported benefici al effects of A TP on body weight 
and body composition in advanced lung cancer patients. The effect of ATP on gluconeo-
genesis from the amino acid alanine was studied because ATP was shown to inhibit loss 
of skeletal muscle mass and muscle strength [1]. Turnover measurements were perfor-
med at 22-24 hours after starting ATP infusion, i.e. after ATP had reached plateau levels 
in erythrocytes [1]. All but one patients were studied during one of the subsequent ATP 
infusions. During high·dose ATP infusion (75 Ilg/kg/min) whole-body glucose turnover 
increased by approximately 40%, whereas no change whatsoever was shown at 
low-dose ATP infusion (37-50 Ilg/kg/min). The ATP·induced increase of gluconeogenesis 
from alanine explained only part of the increase in total hepatic glucose production. This 
would suggest that ATP may also stimulate gluconeogenesis from other substrates and 
glycogenolysis. In vitro studies show that ATP administration stimulated gluconeogenesis 
from lactate [63,179J, pyruvate [29,179J, and glutamine [63,117,179, 197J. Studies in 
isolated hepatocytes [31,47,114J and perfused rat liver [27,123J showed that ATP also 
stimulated glycogenolysis by activating glycogen phosphorylase. It is conceivable that 
high-dose ATP infusion evoked stimulation of glycogenolysis in our patients since turno-
ver measurements were performed after an overnight fast of 10-12 hours. Glycogen 
stores in healthy subjects were reported to be depleted only after 36 hours of fasting 
[152J; no data on glycogen stores in cancer patients are available. 
The mechanisms responsible for increased glucose turnover and gluconeogenesis 
during high-dose ATP infusion remain to be elucidated. Potential mechanisms include 
receptor-stimulating and catecholamine hormone-stimulating effects of ATP. Studies in 
isolated hepatocytes showed that extracellular ATP induced phosphatidylinositol hydro-
lysis, intracellular Ci+-mobilization, and extracellular Ci+-influx by stimulation of surface 
purinergic P2 receptors [31, 158J which are involved in the control of gluconeogenesis 
[8J and glycogenolysis [113J. Furthermore, ATP was shown to act as a cotransmitter of 
the catecholamine noradrenaline in the nervous system, and was suggested to modulate 
the release of other neurotransmitters [BOJ. Noradrenaline is an activator of gluconeoge-
nesis {53,179J and glycogenolysis {53J. 
Notably, baseline glucose turnover rates in the present study tended to be lower in 
patients receiving high-dose ATP infusions than in those receiving low-dose ATP. Since 
patients in the high-dose group had already undergone an average of two ATP courses 
before the present turnover measurements, the possibility cannot be excluded that the 
previous ATP infusions had induced a reduction in whole body glucose turnover on a 
A TP infusion and glucose tumover 
longer term, which would be consistent with the observed attenuation of weight loss in 
our patients. In contrast, baseline gluconeogenesis from alanine did not differ significant-
ly between low- and high· dose ATP groups. This would be consistent with the finding in 
several experimental in vivo studies that the ATP degradation product adenosine inhibi-
ted gluconeogenesis from lactate 1120,121, 130J, pyruvate [121, 130J and glutamine 
1121,130J, but not from alanine 1120,121 J. In the present human study, direct effects of 
ATP on glucose turnover and gluconeogenesis cannot be separated from potential 
effects of adenosine. 
In conclusion, our study demonstrates that ATP infusion causes a dose-dependent 
increase in whole-body glucose turnover in advanced lung cancer patients. During 
high·dose ATP infusion (75 ~g/kg/min) the increase in glucose turnover was partly 
accounted for by increased gluconeogenesis from alanine. Despite the direct stimulating 
effects of ATP on glucose production and gluconeogenesis from alanine, inhibitory 
effects at longer term cannot be excluded. Further studies will have to show whether 
differences between direct and long-term effects of ATP infusions 011 glucose turnover 
do exist. 
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Observations on gluconeogenesis and 
liver metabolites in 
breast cancer patients 
Chapter 8 
Introduction 
Weight loss is a common phenomenon in cancer patients and it contributes to the high 
morbidity and mortality in this disease. The reported incidence of weight loss varies 
widely between different tumour types, ranging from 36% in patients with breast cancer 
to 61 % in patients with lung cancer and 83% in patients with pancreatic cancer 156]. 
Though reduced food intake may be a contributing factor in the etiology of weight loss, 
it cannot solely explain the OCCllrrence of weight loss. Alterations in host metabolism 
have been reported, such as elevated glucose turnover, protein catabolism, and increa-
sed gluconeogenesis from lactate or protein-derived amino acids. Since these processes 
put a demand on host reserves, it has been suggested that this elevated metabolism 
contributes to the weight loss in these patients. 
We previously reported elevated rates of glucose turnover and gluconeogenesis 
from alanine in lung cancer patients, which were dependent on the degree of weight 
loss in these patients. Moreover, alterations in liver metabolism, sllch as elevated alanine 
uptake and high acculllulation of gluconeogenic intermediates, were already found 
before weight loss had occurred. Patients with breast cancer also lose weight, though to 
a lesser extent than lung cancer patients. It is possible that the difference in the inciden-
ce of weight loss between these tUlllour types is caused by differences in host metabo-
lism. However, information on substrate metabolism in breast cancer patients is limited. 
The objective of the present study was to investigate endogenous glucose producti-
on in breast cancer patients using stable isotope tracers and 31 p rnagnetic resonance 
spectroscopy (MRS). In addition, hepatic ATP levels Were monitored. 
Subjects and methods 
88 
Subjects 
The study was approved by the Medical Ethical Committee of the Erasmus University 
Medical Center Rotterdam, Rotterdam, The Netherlands. Patients with breast cancer 
attending the outpatient department of the University Hospital Rotterdam, The Nether-
lands, Were recruited. Patients who were in rernission or apparently cured were exclu-
ded. Additional exclusion criteria were: liver metastases (as checked for by 
CT jultrasollnd), metabolic disease, corticosteroid treatment, elective surgery <3 months, 
chemo- or radiotherapy <4 weeks prior to study, hormonal therapy, except for Nolva-
dex(T amoxifen of LHRH-replacements, alcohol consumption of more than 100 g/week 
(~1 0 glasses), pregnancy, extreme anorexia or artificial weight reduction by dieting. 
Healthy female subjects without weight loss were included as a control group. All 
Gluconeogenesis in breast cancer 
participants signed an informed consent form. 
Experimental design 
All subjects kept a dietary record during 7 days and refrained from alcoholic drinks for 
three days prior to the MRS measurements. Data on pre-illness stable weight, current 
weight, and weight loss over the previous 6 1l1Onths were taken from hospital records 
supplemented with oral information form patients. The subjects were studied between 
7:30 a.m. and 1 :00 p.m. after an overnight fast (12-14 h). Body weight was measured to 
the nearest 0.1 kg on an electrical weighing scale (Seca 707, Hamburg, Germany), 
height was measured to the nearest 0.1 cm, and thickness of lour skinfolds (triceps, 
biceps, subscapular, supra iliac) were measured to the nearest 0.2 mm using a standard 
skinlold calliper (Holtain Ltd., London, Great Britain). A cannula (0.BX25 mm) was placed 
in the left cubital vein for the infusion of stable isotope tracers. In the contralateral 
cubital vein, an identical cannula was introduced for blood sampling. To study gluconeo-
genesis, a solution was prepared containing 16,6-'H,)-D-glucose, 98 atom% and 13-13C)-L-
alanine, 99 atom% (Mass Trace, Woburn, USA) in water and this was sterilised by 
autoelaving in glass vials. A solution of (unlabeled) L-alanine in water (100 g per litre, 
Bufa B.V., Uitgeest, The Netherlands) was prepared, sterilised by autoelaving in glass 
bottles, and warmed to ~30°C. 
The study consisted of two phases. During the lirst phase (baseline), a priming dose 
of 30 (Jmol/kg 16,6-'H,)-D-glucose was administered followed by a continuous infusion 
of 10 (Jmol/kg/h 16,6-'H,)-D-glucose for 90 minutes. Simultaneously, a priming dose of 
80 (Jmol/kg 13-13C)-L-alanine was given followed by a continuous infusion of 40 
(Jmol/kg/h 13-"C)-L-alanine during 90 minutes. Both tracer solutions were infused using 
calibrated syringe pumps (Perfusor® frn, Braun, Germany). During the second phase, a 
priming dose of 1.4 - 2.8 mmol/kg unlabeled L-alanine was administered in 5-8 min and 
followed by a continuous infusion of 2.8 mmol/kg/h L-alanine for 90 min in order to 
reobtain a steady state; simultaneously the isotope tracer infusion of deuterated glucose 
was continued for calculation of glucose turnover. 
Venous blood samples were collected as follows: Phase 1) one sample immediately 
before the isotope tracer infusions were started (for determination of background enrich· 
ments) and at 10 min intervals after steady state conditions during the tracer infusions 
had been reached. Based on observations in our lab and by others [102) steady state 
was usually obtained between 60-90 min of the tracer infusion; Phase 2) at 15 min 
intervals during continuous L-alanine infusion. Phosphorus MR spectra of the liver were 
obtained at baseline and at 3 min intervals during L-alanine infusion. 
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Biochemistry and turnover measurements 
Blood san]t'les were collected in tubes containing lithium heparin (Becton Dickinson 
Vacutainer ,Meylan Cedex, France) and immediately stored on ice. After centrifugation 
(10 min, 1200 g, 4°C), the plasma was collected and stored at _20°C until analysed. 
Isotopic enrichment of deuterium-glucose and 13C~alanine (rnole% excess, MPE), and 
BC-glucose (atom% excess, APE) in plasma was determined as described previously 
[126]. 
Whole body rate of appearance (RJ of glucose an d gluconeogenesis from alanine 
were calculated during steady state assuming an one-compartment model as described 
by Wolfe [102,224] and were expressed as mmol/kg/h. It was assumed that the unde-
restimation of the gluconeogenic rate due to dilution at oxaloacetate and TeA-cycle 
[224] would be similar in lung cancer patients and healthy subjects. 
lip MR spectroscopy of the liver 
Spectroscopy studies were performed with a whole-body MR system equipped with a 
Helicon magnet operating at 2.0 Tesla (Vision Magneton, Siemens AG, Eriangen, Germa-
ny). A 16 cm diameter transmit/receive 'H/'P surface coil was used for MRllocalisation, 
shimming and 31 p MR spectroscopy. Elastic bands were used for positioning the coil 
lateral to the liver in the mid-axillary plane. Field homogeneity achieved in shimming 
resulted in water peak line widths which were usually less than 40 Hz ("0.5 ppm). After 
obtaining an image of the region of interest, an one-dimensional chemical shift imaging 
(1 D-CSI) sequence was applied on a transverse slice of 4 cm centered on the surface 
coil and the liver (1 x4 phase-encoded matrix, field of view 40x40 cm'), yielding volumes 
of 40x1 Ox4 cm3 [195]. Five spectra were collected with a 640 fJs Hanning-sinc shaped 
radio frequency pulse resulting in a flip angle of 135° in the centre of the coil, and 60° 
(weighted average) in the liver volume with a repetition time (TR) of 1 s (40 acquisiti-
ons). 
Time domain data were Fourier transformed after Gaussian rnultiplication (center: 0 
ms, width 30 ms) and phase corrected. Quantification of spectral peak areas was perfor-
med using Numaris-3 software package (Siemens AG, Eriangen, Germany) including 
polynomial baseline correction followed by frequency domain curve fitting [194]. Meta-
bolite concentrations were calculated from peak areas and expressed relative to total 
MR-detectable phosphate as described previously [51]. In each experiment the average 
of five subsequent 31 P MR spectra was used for calculations. 
Statistics 
Results are presented as means ± standard error of the mean (SEM). In each experiment 
the average of five subsequent MR-spectra was used as baseline value for calculations. 
Gluconeogenesis in breast cancer 
Mid-time points of MRS data acquisition at 15 min intervals during L-alanine infusion 
(7.5, 22.5, 37.5 min, etc.) were Llsed for graphical representation, with values being 
expressed relative to the baseline value of healthy control subjects (=100%)_ As a mea-
sure of overall spectral response, integrals of time·response curves (area under the curve, 
AUC) of peak areas over 0-90 min intervals during L-alanine infusion were calculated 
and expressed relative to the baseline values. Between-group differences in baseline 
values and response to alanine infusion were analysed using Student's Hest for unpaired 
groups. Changes from baseline values were analysed using Student's paired t-test. Pear-
son's correlation coefficients were calculated for interrelationship between various 
variables. Differences were considered statistically significant at Pvalues < 0.05. 
Results 
Eleven patients with breast cancer and 12 age-matched healthy control subjects, all 
females, were eligible for the study. Their anthropometric and clinical characteristics are 
listed in Table 8.1. No differences in age and anthropometry were observed. One of the 
breast cancer patients had lost 7% of her pre-illness stable weight. Albumin levels in 
breast cancer patients were significantly lower (43 ± 1 gil) compared to healthy subjects 
(47 ± 1 gil, P<O.Ol), whereas no differences in prealbumin and liver function tests were 
observed. No differences in total energy, protein, fat, and carbohydrate intake were 
observed between the groups (data not shown). 
Table 8.1 
Characteristics of study popUlation. 
Ivge (y) 
Weight (kg) 
Weight change (kg) 
Weight change (%) 
% Ideal body weight 
Body mass index (kg/m~ 
Sum of skinfolds (mm)" 
I Mean ± SEM, 
Control 
(n = 12) 
52 ± 3 
76.1 ± 2.6 
128 ± 5 
26.3 ± 1.1 
75 ± 5 
Breast cancer 
(n = ") 
53 ± 4 
67.7 ± 3.5 
O±I 
O±I 
128 ± 7 
26.6 ± 1.4 
77 ± 10 
Significant difference from healthy control subjects (Students unpaired t-test): * P<O,OS, 
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Turnover measurements 
Plasma glucose and alanine concentrations, isotopic enrichment of glucose and alanine, 
glucose and alanine turnover, and gluconeogenesis from alanine were not significantly 
different between breast cancer patients and healthy control subjects (Table 8.2). 
During L-alanine infusion, plasma glucose levels decreased although this was only 
significant in healthy control subjects. Isotopic enrichment of glucose slightly decreased 
in both groups, but this was only significantly in breast cancer patients. 
Table 8.2 
Isotopic enrichments and turnover rates in breast cancer patients and healthy, age-matched 
female subjects at baseline and during L-alanine infusion,' 
Control (n= II) Breast cancer (n=8) 
Glucose (mmoIJl) 
Alanine (mmoIJl) 
'H,-glucose (MPE) 2 
"C-alanine (MPE) 
"C-glucose (AIPE) J 
Baseline 
5.6 ± 0.2 
0.35 ± 0.07 
1.87 ± 0.15 
7.75 ± 0.80 
1.37 ±0.17 
Glucose turnover (mmoIJl<gJh) 0.55 ± 0.04 
Alanine turnover (mmoIJl<gJh) 0.43 ± 0.03 
Gluconeogenesis from alanine 0.32 ± 0.04 
I Mean ± SEM 
2 Mo!e% eXcess 
3 Atom% excess 
(mmoIJl<gJh) 
During L-alanine 
5.4 ± 0.2 * 
8.0 ± 0.9 ** 
1.73 ± 0.24 
0.62 ± 0.06 
Baseline 
5.1 ± 0.2 
0.35 ± 0.07 
1.84 ± 0.18 
9.06 ± 0.60 
1.77±0.17 
0.55 ± 0.06 
0.38 ± 0.03 
0.32 ± 0.04 
Significantly different from baseline value (Paired t-test): *p<O.OS, * P<O.O! . 
"p MR spectroscopy 
During L -alanine 
4.9 ± 0.3 
6.4 ± 1.0 ** 
1.63 ± 0.19* 
0.65 ± 0.08 
Baseline values of phosphomonesters (PME) were not significantly different between 
breast cancer patients and healthy subjects (6.2 ± 0.9 VS. 8.8 ± 1.1 %, respectively, 
1"=0.09). No differences in baseline levels of POE, P, and ATP were observed between 
the groups. 
In Figure 8.1 changes in hepatic metabolite concentrations during L-alanine infusion 
Gluconeogenesis in breast omcer 
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Figure 8.1 
Metabolite concentrations in the liver of healthy control subjects (~-O--; n = 7) and weight-stable breast 
cancer patients (-e-; n = 6) during a primed-constant infusion of lA-2.8 mmol,kg + 2,8 mmol,kglh L-
alanine: a) phosphomonoesters (PME), b) phosphodiesters (PDE), c) ATP. d) inorganic phosphate (P;). 
Curves and error bars represent means:::!:: SE. Baseline values are means from 5 spectra acquired in each 
subject before L-alanine infusion. Values are expressed as percentage of mean baseline value of healthy 
subjects (= I 00%). Times during L-alanine infusion are mid-time points ofJ'p MRS data collection referen-
ced to the start of the L-alanine infusion (O=baseline). Significance of changes during L-alanine infusion 
compared to baseline (Student's paired t-test): *P<O.OS, **P<O.OI. 
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are shown. PME levels increased gradually in healthy subjects and reached statistical 
significance at 60 min (P<O.Ol) (Figure 8.1). In breast cancer patients, PME showed a 
sharp rise during the first 20 min, but was only significantly different from baseline at 60 
min of L-alanine infusion (P<0.05) after which PME decreased. POE levels as such were 
not significantly different from baseline at any time point in either of the two groups. 
ATP levels showed a slow but steady decrease in both groups which became statisti-
cally significant from baseline values after 40 min of alanine infusion in healthy subjects 
(P<0.01), but never in breast cancer patients. Between 60·80 min of alanine infusion, 
partial recovery of ATP was observed in healthy control subjects. Pi levels in healthy 
subjects decreased sharply during the first 30 min (P<0.05), but recovered to baseline 
values between 30 and 90 min of alanine infusion. In contrast, Pi levels in breast cancer 
patients showed a sharp initial rise (NS), but slowly decreased to baseline values during 
alanine infusion. 
The overall increase PME levels in healthy control subjects was 41 ± 12% (1'=0.02), 
whereas in breast cancer patients the increase was 67 ± 34% (1'=0.09). ATP levels 
significantly declined in healthy subjects (-13 ± 4%, 1'=0.01), whereas in breast cancer 
patients no change was observed (-4 ± 6,1'=0.39). 
Correlations 
Gluconeogenesis from alanine was inversely correlated with percentage of ideal body 
weight and body mass index (r~-0.67 and r~-0.68, respectively, 1'<0.05) in healthy 
subjects, but not in patients with breast cancer (r~-0.27 and r~-35, respectively, P>OAO). 
In breast cancer patients, both hepatic PME and POE levels were correlated with percen-
tage of ideal body weight (r~0.67 and 0.93, respectively, 1'<0.05) and body mass index 
(r~0.68 and 0.94, respectively, 1'<0.05), whereas P-ATP was inversely correlated with 
body mass index and percentage of ideal body weight (r~-0.89 and r~-0.88, respectively, 
P<O.Ol). In healthy subjects, only POE was correlated with percentage of ideal body 
weight (FO.63 and 0.63, respectively, P<0.05). Liver PME levels in breast cancer pa-
tients were inversely correlated with glucose turnover (r~ -0.90, P<0.05) and gluconeo-
genesis from alanine (r~-0.90, 1'<0.05), whereas in healthy subjects no such relation was 
observed (r~-0.37 and r~-0.22, respectively, P>0.33). 
Discussion 
94 
Alterations in hepatic gluconeogenesis have been previously reported in patients with 
lung cancer by 31 p MRS with L-alanine infusion (1241. In the present study, hepatic 
gluconeogenesis was investigated in patients with breast cancer using the same techni-
Gluconeogenesis in breast amcer 
que. Simultaneously, glucose turnover before and during L-alanine infusion was measu-
red using stable isotope tracers. Alanine turnover and gluconeogenesis frOIn alanine 
Were measured at baseline only. 
Glucose and alanine turnover, and gluconeogenesis in breast cancer patients were 
not different from those in healthy control subjects, confirming previous data in weight-
stable lung cancer patients [126). This suggests that whole-body glucose and alanine 
metabolism are not altered in cancer patients without weight loss. Since weight loss 
occurs less frequently in patients with breast cancer [56) only one weight-losing breast 
cancer patient could be included in the study, so that the relation between turnover 
measurements and weight loss could not be determined. Changes in glucose turnover 
during L-alanine infusion were minimal, as could be expected in view of the autoregula-
tory mechanisms which controls hepatic glucose output [57,108,225). 
PME levels in the liver of breast cancer patients and healthy control subjects were 
similar at baseline. During L-alanine infusioll, PME increased in both groups confirming 
studies performed in healthy animals [30) and humans [50,124,177). This rise in PME 
was attributed to increased concentrations of 3-phosphoglycerate (3PG) [30,50). Howe-
ver, the overall rise in PME was not significantly different in breast cancer patients 
compared to healthy subjects. This finding is in contrast with observations in weight-
stable lung cancer patients where a rapid and significant increase in PME was observed 
[124). Moreover, hepatic PME levels at baseline in breast cancer patients in the present 
study were inversely correlated with glucose production, whereas in lung cancer pa-
tients the opposite was found [125). It may be speculated that due to a high gluconeo-
genic rate during L-alanine infusion, less gluconeogenic intermediates accumulate within 
the liver of these patients resulting in lower PME levels in breast cancer patients. In 
healthy control subjects, no correlations between PME and glucose turnover or glucone-
ogenesis from alanine were observed, confirming previolls reports 1125]. 
Baseline ATP levels in the liver of breast cancer patients in the present study were 
not different from healthy subjects. During L-alanine infusion, ATP levels in healthy 
subjects decreased significantly, confirming previous observations [124). This could be 
that elevated gluconeogenesis from alanine put an increased demand on hepatic ATP 
supply. In contrast, in breast cancer patients L-alanine did not reduce liver ATP levels. It 
may be hypothesised that breast cancer patients have larger energy reserves or enhan-
ced ATP regeneration in the liver than healthy subjects. As no ATP depletion exists in 
breast cancer patients, gluconeogenic flow is not inhibited resulting in lower PME levels 
in these patients. 
It should be noted that most of the patients were on stable therapy (T amoxifen). 
Since the exact influence of Tamoxifen on hepatic glucose mechanism is not clear, an 
influence of therapy cannot be excluded. In addition, several breast cancer patients 
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showed side-effects (nausea, sweating) during L-alanine infusion, which may be due to 
decreased capacity for the L-alanine dose. 
In summary, weight-stable breast cancer patients do not show the alterations in 
hepatic glucose and energy metabolisrn observed in lung cancer patients, indicating that 
alterations in host-metabolism may be tumour-specific. 
Elevated liver phosphomonoester levels 
predict weight loss in cancer 
Susanne Leij.Haifwerk,' Pieter C Dagneiie\" 
I Department of Internal Medicine II, Erasmus University Medical Center Rotterdam, Rotterdam 
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Abstract 
Raised hepatic phospho monoester (PME) levels have been observed by lip magnetic 
resonance spectroscopy (MRS) in cancer patients with weight loss and have been 
attributed to increased gluconeogenic intermediates. The aim of the present study was 
to assess the prognostic relevance of elevated PME levels for the development of weight 
loss in cancer. 
Advanced cancer patients diagnosed with lung (n~31), breast (n~20), or cancer of 
other origin (n~5), without liver metastases, were studied after an overnight fast. Body 
weight, body rnass index, upper arm circumference, and triceps skinfold thickness were 
measured on the day of the MRS and after three months. Dietary intake was calculated 
using a seven·day food record. Localised hepatic lip MR spectra were obtained using a 
repetition time of 20 s. 
Hepatic PME levels in the cancer patients, expressed relative to total MR·detectable 
phosphate, were 10.3 ± 0.6% (mean ± SEM). Cancer patients lost 0.6 ± 0.5 kg of their 
weight within three months after MRS. After adjustment for energy intake and weight 
loss prior to MRS, an increase of 5% in PME was prognostic for a 1.8 ± 0.6 kg decrease 
in body weight and a 0.6 ± 0.2 kg/m' reduction in body mass index within three months 
after MRS (P<0.05). 
Elevated hepatic PME levels and PME/P; ratios in cancer patients predict the develop· 
ment of weight loss. Further exploration of the use of lip MRS as a non·invasive tool for 
early identification of cancer patients at risk for weight loss is warranted. 
Introduction 
98 
Weight loss frequently occurs in patients with cancer and contributes to the high morbi· 
dity and mortality in this disease [56,93,169,198[. Several mechanisms have been 
suggested to playa role in the development of weight loss in cancer, including anorexia 
[82[, increased energy expenditure [196[, and alterations in host metabolism [79[. 
Increased rates of glucose turnover [116, 133[ and gluconeogenesis [25,126,219[ have 
been observed in weight·losing cancer patients, and may be related to altered liver 
metabolism. 
Recently, lip magnetic resonance spectroscopY' ( P MRS) of the liver has been 
applied as a non·invasive tool to study liver metabolism in cancer patients. Elevated 
phospho monoester (PME) levels were observed in the tumour·free liver of weight·losing 
patients with various tumour types [51 J and lung cancer [126[. 
Although weight loss and altered liver metabolism were related in these cancer 
Hepatic PME and develcpment of weight loss 
patients, it remains to be established whether changes in liver metabolite concentrations 
are able to predict the development 01 weight loss in cancer. Therelore, the aim 01 the 
present study was to assess the prognostic relevance of P ME for weight loss in cancer. 
Subjects and methods 
Subjects 
The study was approved by the Medical Ethical Committee 01 the Erasmus University 
Medical Center Rotterdam, The Netherlands. All participants signed inlormed consent. 
Cancer patients attending the outpatient department 01 the University Hospital Rotter-
dam, The Netherlands, were recruited. Patients who were in remission or apparently 
cured were excluded. Additional exclusion criteria were: liver metastases (as checked lor 
by CT or ultrasound), metabolic disease, corticosteroid treatment, elective surgery <3 
months, chemo· or radiotherapy <4 weeks prior to study, alcohol consurnption of more 
than 100 gjweek (=10 glasses), pregnancy, extreme anorexia or artificial weight reducti· 
on by dieting. 
Dietary Intake 
Food intake was recorded using a standard lood diary during seven days preceding the 
experiment. The subjects received oral and written information from a trained nutritionist 
(PD,SL) about the procedures lor lilling in the diary and registering all consumed drinks 
and loods using household measures. Subjects were asked to maintain their usual 
dietary habits and none reported any signilicant changes in their diet. Subjects abstained 
Irom alcohol during 5 days prior to the experiment. All medication taken was noted. 
Household measures were converted into weights using a standard food conversion 
table (Department 01 Human Nutrition, Wageningen, The Netherlands) and a nutrition 
soltware program (Komeet version 2.0, B-Ware, Amhem, The Netherlands). Average 
daily intake 01 energy, lat, carbohydrate and protein was calculated. 
Study design 
Data on pre·illness stable weight, current weight, and weight loss over the previous 6 
months were taken lrom hospital records supplemented with oral inlormation from 
patients. On the day of the MRS measurements, body weight was measured to the 
nearest 0.1 kg on an electrical weighing scale (Seca 707, Hamburg, Germany), height 
was measured to the nearest 0.1 em, and body mass index was calculated. Upper arm 
circumference was measured to the nearest 0.1 cm and thickness of the triceps skinfold 
was measured to the nearest 0.2 mm using a standard skinfold caliper (Holtain Ltd., 
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london, Great Britain). The anthropometric measurements were repeated at three 
months following MRS. 
lip MR spectroscopy of the liver 
Hepatic 31·phosphorus MR spectra were obtained in the morning after an overnight fast 
between 8:00 and 12:00 a.m. Spectroscopy studies were performed with a whole·body 
MR system equipped with a Helicon magnet operating at 2 Tesla (Siemens Magnetom 
SP 4000, upgraded to Vision, Siemens AG, Erlangen, Germany). A 16 Col diameter 
transmit/receive 'H/'P surface coil was used for MRI localization, shimming, and 3'p 
MR spectroscopy. Elastic bands were used for positioning the coil lateral to the liver in 
the mid·axillary plane. Field homogeneity achieved in shimming resulted in water peak 
line widths which were usually less than 40 Hz ("0.5 ppm). After obtaining an image of 
the region of interest, an one·dimensional chemical shift imaging (1 D·CSI) sequence was 
applied on a transverse slice of 4 cm centered on the surface coil and the liver (1 x4 
phase·encoded matrix, field of view 40x40 Col'), yielding volumes of 40x10x4 cn? 
[195]. Five spectra were collected with a 640 J.ls Hanning·sinc shaped radio frequency 
pulse resulting in a flip angle of 135" in the center of the coil, and 60° (weighted avera· 
gel in the liver volume with a repetition time of 1 5 to 20 s. 
Time domain data were Fourier transformed after Gaussian multiplication (center: 0 
ms, width 30 ms) and phase corrected. Quantification of spectral peak areas was perfor· 
med using Nurnaris-3 software package (Siemens AG, Erlangen, Germany) including 
polynomial baseline correction followed by frequency domain curve fitting [194]. Meta· 
bolite concentrations were calculated from peak areas and expressed relative to total 
MR·detectable phosphate as described previously [51]. 
Statistics 
Results are presented as means ± standard error of the mean (SEM). Differences be· 
tween group means were compared using analysis of variance. The predictive value of 
PME for weight loss was examined by multivariate regression analysis with adjustment 
for energy intake and weight loss prior to MRS. Differences were considered statistically 
significant at P values < 0.05. 
Table 9.1 
Characteristics of the cancer patients. f 
Tumour type (lJB/O)2 
Age (y) 
Weight (kg) 
Previous weight change (% /6 mo) 
Body mass index (kg/m') 
Arm circumference (cm) 
Triceps skinfold (mm) 
I Mean ± SEM. 
2 L: lung; B: breast: 0; other; number of patients. 
Results 
Hepatic PME and development of weight loss 
Mean ± SEM 
31/20/5 
60.6 ± 1.6 
67.5 ± 1.6 
-5 ± I 
24.1 ± 0.6 
29 ± I 
16.4 ± 1.3 
Range 
38 - 81 
45 - 96 
-8 - 24 
16.3 - 33.3 
20 - 37 
4.4-39.4 
Fifty-six cancer patients, twenty-five males and thirty-one females, were included in the 
study (Table 9.1). Forty-four patients were eligible for follow-up. Main tumour types 
represented were non-small cell lung cancer (n~31) and breast cancer (n~20). All pa-
tients had normal liver function tests. Energy intake was 1944 ± 67 kcal/day and did not 
differ between tumour types. Though previous weight change varied considerably 
among individual patients, no systematic differences between patients with different 
tumour types were observed (1'=0.17). Albumin and prealbumin concentrations were 42 
± 1 gil (mean ± SEM) and 0.23 ± 0.01 gil, respectively. 
Hepatic PME levels in cancer patients were 10.3 ± 0.6% (range 3-18%), and PME/P, 
ratios were 1.31 ± 0.09 (range 0.39-3.59), and did not differ significantly between 
tumour types. During the three months following MRS, body weight decreased by 0.6 ± 
0.5 kg, body mass index by 0.2 ± 0.2 kglm', arm circumference by 0.5 ± 0.2 cm, and 
triceps skinfold by 1.1 ± 0.6 mm. 
After adjustment for energy intake and weight loss prior to MRS, a rise in PME levels 
of 5% significantly predicted a decrease of 1.8 kg body weight and 0.6 kglm' in body 
mass index during the following three months (Table 9.2, both P<0.05). In contrast, 
decreases in arm circumference and triceps skinfold thickness were not predicted by 
changes in PME. Plasma albumin or prealbumin did not predict weight loss in this 
population of cancer patients. Tumour type was no confounding factor in the analysis. 
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Table 9.2 
Predictive value of a 5% rise in PME,t'P for subsequent changes in anthropometric measures, 
PMEJP P Value 
Weight (kg) -1.8 ± 0.62 0.010 
Body mass index (kg/m') ·0.6 ± 0.2 0.DI5 
Arm circumference (cm) -0.6 ± 0.3 0.081 
Triceps skinfold (mm) -1.6 ±0.9 0.071 
I Multivariate analysis adjusted for energy intake and presence of weight loss prior to MRS, 
1 Change per three months after MRS (mean ± SEM). 
Discussion 
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Weight loss in cancer is known to be a prognostic factor for reduced survival in cancer 
143,93,198). Although attempts have been made to elucidate underlying mechanisms 
and to reverse the weight loss in cancer, little attention have been given to prognostic 
factors for the development of weight loss itself. 
The present study demonstrates that elevated PME levels in the non-metastasised 
liver of cancer patients significantly predict the development of weight loss within three 
months following MRS. This effect was not caused by confounding by energy intake, nor 
by weight loss prior to the MRS examination, as was shown by multivariate analysis 
including these variables. In addition, no confounding effect of tumollr type was obser-
ved. 
Phosphorus MRS has been applied in the non·invasive study of nutritional conditions 
and metabolic changes 17). However, possible applications of J1 p MRS as a prognostic 
tool for various disease states have only rarely been investigated. In patients with hepatic 
lymphoma, the degree of liver infiltration was reflected by increased hepatic PME levels 
[58). In response to chemotherapy a decrease in PME levels was observed. The authors 
suggested that lip MRS might provide a useful tool in the diagnosis of liver infiltration 
and response to chemotherapy 158). In a study in patients with primary biliary cirrhosis, 
the prognostic value of 31 P MRS was assessed in patients waiting for orthotopic liver 
transplantation 1103). Elevated PME/P, ratios in the patients with primary biliary cirrhosis 
were positively correlated with standard prognostic indices based on plasma parameters 
indicating disease severity 1103). The metabolic background for the observed hepatic 
changes was not investigated in that study. When we analysed the prognostic value of 
hepatic PMEjPi ratios in cancer patients in the present study, it was significant for weight 
loss only. It should be noted, however, that in this study only cancer patients without 
HepatIc Pf1E and development of weight loss 
infiltrated livers were studied, as was confirmed by CT/ultrasound and liver function 
tests. 
In a 31 p MRS study in weight-losing cancer patients of various tumour types, without 
hepatic malignancies, increased hepatic PME levels were observed [51[. This was sugge-
sted to be due to elevated concentrations of giuconeogenic intermediates within the 
liver [51[. Dynamic liver 31 p MRS studies in rats showed that increased liver PME levels 
coincided with increased concentrations of 3~phosphoglycerate, a gluconeogenic inter-
mediate [30,50[. Indeed, liver PME levels in lung cancer patients were reported to 
significantly correlate with rates of glucose turnover and gluconeogenesis [125[. 
Several authors have suggested that elevated gluconeogenesis observed in cancer 
could be a contributing factor in the development of weight loss [189,204[. Gluconeo-
genesis is an energy-consUlning process. The present study confirms that high concentra-
tions of gluconeogenic intermediates in the liver of cancer patients are indeed prognos-
tic for the development of weight loss. Early detection of cancer patients at risk for 
weight loss would facilitate early treatment, thus preventing or reversing the process of 
weight loss, and might therefore contribute to improved survival. We conclude that 31 p 
MRS may be useful clinically as a non-invasive prognostic tool for predicting weight loss 
in cancer patients. Further investigation in a larger cancer patient population is warran-
ted. 
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Weight loss is frequently observed in patients with cancer and contributes to the high 
morbidity and mortality in this disease. Decreased food intake cannot fully explain the 
origin of weight loss, especially so in patients with lung cancer, suggesting that alterati-
ons in host metabolism must playa role. A typical feature of the weight loss in cancer is 
that not only fat mass, but also muscle protein is degraded. In lung cancer, elevated 
protein turnover and glucose production have been reported and it was suggested that 
elevated gluconeogenesis from muscle-derived amino acids/ especially alanine, may 
contribute to the weight loss observed. It has remained unclear, however, whether 
gluconeogenesis from alanine is elevated in lung cancer patients and whether this is 
related with weight loss. Also, it is not known whether changes in hepatic glucose 
metabolism are associated with alterations in energy (ATP) metabolism in the liver of 
lung cancer patients. 
Therefore, the present research project was aimed at obtaining quantitative informali-
on on gluconeogenesis from alanine and liver energy metabolism in relation with weight 
loss in lung cancer, using turnover rneasurernents with stable isotope tracers and hepatic 
31 P magnetic resonance spectroscopy (MRS). 
Glucose turnover 
106 
Gluconeogenesis from alanine was significantly elevated in lung cancer patient with 
weight loss compared to weight-stable lung cancer patients and healthy control subjects 
(Chapter 2), and correlated with the degree of weight loss. These data were obtained 
under steady state conditions using primed-constant infusions of {6,6-2H 2]-glucose and 
(3-13C]-alanille assuming an one·compartment model. 
Total glucose production, as measured by deuterated glucose in the present study, 
did not change during L-alanine infusion in weight·losing lung cancer patients and 
healthy control subjects (Chapter 4), confirming studies in healthy subjects and dogs 
(57,108,140,2251 in which gluconeogenesis from alanine increased during L-alanine 
infusion, whereas the amount of alanine released from the gut decreased (571. It was 
also suggested that decreased glycogenolysis (108,150), or increased amounts of alani-
ne shunted to glycogen (2251 or protein (361, might playa role in the constant rate of 
endogenous glucose production. In contrast, in weight-stable lung cancer patients in the 
present study, total glucose production increased by 8% during L-alanine infusion. This 
would suggest that glucose production from other substrates was not inhibited to the 
same extent by alanine infusion as in healthy subjects. It is unlikely that increased glyco· 
genolysis played a role in the elevated glucose production during L-alanine infusion, 
since decreased glycogen stores have been observed in patients with colorectal cancer 
General discussion 
197]. One explanation for the observation that glucose production during L-alanine 
infusion did not increase in weight-losing lung cancer patients, is that gluconeogenesis 
was already maximally induced at baseline, although other explanations remain possible. 
To obtain an indication of stimulation of protein synthesis by L-alanine infusion, total 
amino acid concentrations in plasma of two weight-losing lung cancer patients and two 
healthy subjects were measured. It was shown that during L-alanine infusion, apart from 
the marked elevation in alanine levels, concentrations of glutamine, glycine, proline, 
serine, and threonine increased in both cancer patients and healthy subjects. 
The contribution of alanine to the elevated endogenous glucose production obser-
ved in weight-losing lung cancer patients was estimated based on our turnover data. The 
percentage glucose derived from alanine was not elevated in weight-losing lung cancer 
patients as compared to both weight-stable lung cancer patients or healthy control 
subjects (Chapter 2), which implies a similar relative contribution of alanine to total 
glucose production in the three groups. When comparing the data in absolute terms, 
however, total glucose turnover was 23 mmol/kg/h higher in weight-losing lung cancer 
patients than in healthy subjects, whereas gluconeogenesis from alanine in these pa-
tients was only 18 mmol/kg/h higher. This suggests that, although elevated gluconeoge-
nesis from alanine explains :::::70% of the enhanced glucose production in weight-losing 
lung cancer patients, glucose production from other substrates, such as lactate, may 
have been elevated as well. 
Information on gluconeogenesis from lactate could not be obtained in the present 
study, because this would have requested a separate labelled tracer (for example 13-14C]-
lactate). Nevertheless, we were able to measure BC-enrichment in lactate in most of the 
subjects which may provide an indication of gluconeogenesis from lactate. Results 
showed that lactate enrichment was 1.91 ± 0.30 MPE in weight-losing lung cancer 
patients, 2.49 ± 0.11 MPE in weight-stable lung cancer patients and 2.95 ± 0.16 MPE in 
healthy subjects, and did not differ significantly between the groups. Values of enrich-
ment were lower for lactate than for alanine (CaWL: 7.22 ± 0.60, CaWS: 8.09 ± 0.64, C: 
9.19 ± 1.06 MPE). This was unexpected since alanine rapidly equilibrates with pyruvate-
lactate which leads to similar 13C enrichment in these substrate at complete equilibration 
in the body pools 1109,111]. Apparently this was not the case in the present study. 
However, we may conclude that in our study the proportion of gluconeogenesis from 
lactate to total glucose production is likely to have been similar in weight-losing lung 
cancer patients compared to weight-stable patients and healthy subjects, as there were 
no differences in "e-Iactate enrichment between the three groups. Nevertheless, we 
should be aware of possibility that Cori cycling may have contributed to the gluconeoge-
nesis from alanine as measured by the present technique. 
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Mechanisms of elevated gluconeogenesis from alanine 
lOB 
Elevated gluconeogenesis from alanine as observed in weight-losing lung cancer patients 
could be driven by high precursor availability 157,70) from muscle protein breakdown 
166,94), or by elevated hepatic alanine uptake and/or increased gluconeogenic enzyme 
activity. 
Alanine availability 
It has been suggested that enhanced muscle protein breakdown and higher alanine 
release reported in weight-losing cancer patients as compared to healthy control sub-
jects [24,95} provides increasing amounts alanine for endogenolls glucose production. 
[n weight-losing lung cancer patients in the present study, alanine flux was 0.17 
mmol/kg/h higher than in healthy subjects (Chapter 2). Although this extra amount of 
alanine could be solely released from muscle protein breakdown, this is not very likely 
since alanine accounts for only 7-10% of the amino acids in muscle 169). Enhanced 
muscle alanine production 140) or glucose-alanine cycling within weight-losing lung 
cancer patients is more likely, in combination with part of the alanine being produced 
from glutamine in the gut 114,151) (Figure 1.1). The origin of the enhanced alanine 
production by muscle in weight-losing lung cancer patients is not clear. However, it has 
been reported in healthy subjects that elevated amounts of circulating lactate 140) 
and/or glucose 1173, lB7) stimulate alanine production in muscle, which explains increa-
sed release of alanine by muscle in weight-losing lung cancer patients. 
Hepatic alanine uptake 
Hepatic alanine uptake and glucose production from alanine are known to be closely 
related with alanine levels in plasma 157,70, lOB). In the present study, alanine uptake by 
the liver was estimated by calculating alanine clearance'. Weight-losing lung cancer 
patients had an alanine clearance of 1.65 ± 0.15 I/kg/h which was significantly higher 
than the rates observed in weight-stable lung cancer patients and healthy subjects (1.16 
± 0.12 and 1.19 ± O.OB, respectively; P<O.Ol). The elevated alanine clearance was also 
reflected by significant lower plasma alanine concentrations during steady state of L-
alanine infusion (l.4-2.B mmol/kg followed by a continuous load of 2.B mmol/kg/h) in 
weight-losing lung cancer patients (5.0 mM), compared to weight-stable lung cancer 
patients (6.3 mM) and healthy subjects (B.l mM)(Chapter 4). Measurements in lB lung 
cancer patients and 6 healthy subjects showed that of the total L-alanine dose infused, a 
Alanine clearance (I/kg/h) was calculated as alanine turnover (mmol/kg/h) divided by 
plasma alanine concentration (mrnoljl). 
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maximum of 3% was excreted in urine, indicating that >97% of the alanine infused had 
been taken up and metabolised by body tissues. Most of this alanine has been taken up 
by the liver, whereas splanchnic and peripheral alanine uptake may have been unchang-
ed, as reported in healthy dogs after an L-alanine load 1571. Thus, the attenuated increase 
in plasma alanine levels during constant L~alanine infusion in weight~losing lung cancer 
patients is likely to be caused by increased hepatic alanine uptake in these patients. In 
weight-stable lung cancer patients, plasma alanine concentrations during L-alanine 
infusion were also significantly lower than in healthy subjects indicating an enhanced 
hepatic alanine uptake in weight-stable patients as well. 
Gluconeogenic enzyme activities 
Various animal models suggested increased gluconeogenic enzyme activities in the liver 
in the cancer-bearing state 183,128, 144J. In our study, we did not measure gluconeoge-
nic enzymes directly. However, in addition to the turnover studies which provide infor-
mation on the whole-body level, we used 31 P magnetic resonance spectroscopy (MRS) 
to investigate gluconeogenesis non-invasively at the actual site of metabolism: the liver. 
31 P-MRS with L-alanine infusion has been applied to study gluconeogenesis in healthy 
rats 1301 and humans [50,1771, showing increasing concentrations of hepatic gluconeo-
genic intermediates, especially 3-phosphoglycerate and phosphoenolpyruvate. This was 
reflected in the present study by increased levels of phosphomonoesters (PME) and 
phosphodiesters (PDE), respectively. 
I n the present study, high hepatic PME levels in weight-losing lung cancer patients 
were observed even without stimulation of the gluconeogenic pathway (Chapter 3). 
Simultaneous turnover measurements revealed that the degree of elevation of PME in 
lung cancer patients was positively correlated with the rate of gluconeogenesis from 
alanine, confirming that elevated PME levels in the liver of weight-losing lung cancer 
patients were due to elevated concentrations of gluconeogenic intermediates. Subse-
quent L-alanine infusion in these patients (Chapter 4) did not further increase hepatic 
PME levels, suggesting that hepatic gluconeogenesis from alanine was already maximally 
induced. Weight-stable lung cancer patients expressed normal liver PME levels at baseli-
ne, but showed an enhanced increment of PME levels during L-alanine infusion compa-
red to healthy control subjects (Chapter 4). The elevated PME levels indicate enhanced 
hepatic acculllulation of 3-phosphoglycerate, which is consistent with facilitated inducti-
on of gluconeogenesis. Moreover, increasing concentrations of hepatic PDE levels 
following L-alanine administration were observed in lung cancer patients both with and 
without weight loss, in contrast to healthy subjects implicating higher accumulation of 
phosphoenolpyruvate in the liver of these patients. This observation would be consistent 
with an elevated activity of phosphoenolpyruvate carboxykinase (PEPCK, converting 
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oxaloacetate to phosphoenolpyruvate) and possibly pyruvate carboxylase (PC, conver-
ting pyruvate to oxaloacetate) as observed in the liver of tumour-bearing rats [83,1281 
(see also Scheme 3.1). 
Notably, elevated PME in the liver of lung and breast cancer patients were prognos-
tic for the development of weight loss. This is consistent with a causal relationship 
between elevated gluconeogenesis and weight loss, although other explanations cannot 
be excluded. 
Hormones 
Although enhanced gluconeogenesis from alanine observed in weight-losing lung cancer 
patients in the present study could be hormonally regulated, results showed that serum 
insulin and glucagon concentrations were not different between lung cancer patients 
with/without weight loss and healthy control subjects, nor were they correlated with 
glucose turnover or gluconeogenesis from alanine (Chapter 2), During L-alanine infusion, 
both insulin and glucagon levels increased significantly in all groups (Chapter 4). Remar-
kably, the insulin:glucagon ratio during L-alanine infusion was lower in weight-losing lung 
cancer patients (0.17 ± 0.03) than in weight-stable lung cancer patients (0.44 ± 0.09) 
and healthy subjects (0.91 ± 0.42) which implies a more gluconeogenic state in lung 
cancer patients, especially weight-losing patients, than in healthy subjects. 
Concentrations of rT3 in weight-losing lung Cancer patients were significantly increa-
sed compared to weight-stable lung cancer patients and healthy control subjects, and 
were correlated with glucose turnover. High rT3 levels are non-specific for the cancer-
bearing state but occur in other diseases as well, indicating energy depletion of the liver 
[65,901. Indeed, in the liver of weight-losing lung cancer patients in the present study 
decreased energy status was observed as discussed in the next paragraph. 
Liver energy status 
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Liver ATP levels in weight-losing lung cancer patients were lower than in weight-stable 
lung cancer patients and healthy control subjects (Chapter 5 and 6), confirming data 
from tumour-bearing animals [6,20,77,211 J. Infusion of L-alanine as a gluconeogenic 
substrate induced a drop in liver ATP levels in both weight.losing and weight-stable lung 
cancer patients and healthy control subjects (Chapter 5). This reduction in ATP could be 
due to increased ATP utilisation for alanine uptake into the hepatocyte [72,163,2121, for 
gluconeogenesis [1111, and/or for urea production [1511. Remarkably, at 75-90 min of L-
alanine infusion, hepatic ATP levels in weight-stable lung cancer patients and healthy 
control subjects were partly restored, whereas A TP levels in weight-losing lung cancer 
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patients continued to decrease. The enhanced decrease in ATP as well as the depleted 
ATP stores at baseline in weight-losing lung cancer patients, indicate elevated ATP 
utilisation for increased gluconeogenesis and/or decreased efficiency of ATP-regenerati-
on (226]. 
MRS data from the present study were analysed for a possible relation between 
hepatic A TP levels and gluconeogenesis. Unexpectedly, no correlations between hepatic 
PME levels and ATP levels were observed. In contrast, a strong inverse correlation 
between hepatic ATP and POE levels was observed in lung cancer patients (Pearson's 
r~-0.81, P<0.001), breast cancer patients (F·0.98, P<O.Ol), as well as in healthy control 
subjects (r~·0.73, 1'<0.01). Furthermore, increases in POE levels during L-alanine infusion 
were larger when ATP levels at baseline were higher (1'<0.001). As previously described, 
POE contains contributions from phosphoenolpyruvate. Alanine has an inhibitory effect 
on pyruvate kinase, converting phosphoenolpyruvate to pyruvate, and a stimulatory 
effect on PEPCK (59]. Thus, the presence of increased alanine concentrations within the 
hepatocyte would stimulate the conversion of pyruvate towards phosphoenolpyruvate 
and further to glucose. Four out of the six energy-rich phosphate bonds necessary for 
gluconeogenesis are utilised by the gluconeogenic enzymes PC and PEPCK (1 51] which 
are the rnost energy-consuming steps in gluconeogenesis [111 J. In addition, PC and 
PEPCK activities are stimulated by a high ATP content. Although we cannot exclude the 
utilisation of ATP for other energy-consuming processes, our finding that POE and ATP 
are closely related would be consistent with enhanced ATP consumption for elevated 
gluconeogenesis. 
We further tested the hypothesis that ATP infusion would be able to reverse the 31 p 
MRS-observed depletion of ATP pools in the liver of weight-losing and weight-stable lung 
cancer patients. Indeed, intravenous infusion of ATP caused a significant 390/0 rise in 
hepatic ATP levels which was independent of the ATP dose given (Chapter 6). Simulta-
neously, a dose-dependent rise in total glucose production rates and gluconeogenesis 
from alanine was observed (Chapter 7). It could be hypothesised that the restoration of 
hepatic ATP levels by ATP infusion provided energy necessary for the elevated glucone-
ogenesis in weight-losing lung cancer patients, as previously suggested by the close 
relation between POE and ATP. However, this relation does not seem straightforward 
since changes in liver ATP content during A TP infusion and glucose turnover or glucone-
ogenesis from alanine were not correlated. Other mechanisms by which A TP infusion 
could stimulate glucose production may be through binding on purinergic membrane 
receptors, or by acting as cotransmitter of noradrenaline in the nervous system thereby 
indirectly stimulating glucose production (31,80,158]. ATP was also reported to inhibit 
binding of insulin to its receptor (210], which may stimulate glucose production as well. 
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Though the precise way of action of ATP has not been clarified, we speculate that ATP 
may act predominantly on the liver rather than on muscle, since ATP infusion did not 
have any effect on alanine flux in lung cancer patients in our study. The stimulatory 
action of ATP on glucose production may be acute, since glucose turnover and glucone-
ogenesis from alanine appeared lower in lung cancer patients one week after they had 
received an ATP course. A breakdown product of A TP, adenosine, has been reported to 
inhibit gluconeogenesis [121,1301. 
Conclusions 
From the results of the studies described in this thesis, the following conclusions can be 
drawn: 
1. Hepatic gluconeogenesis from alanine is elevated, whereas liver energy status is decrea-
sed in lung cancer patients with weight loss. These alterations are correlated with the 
degree of weight loss. Nevertheless, even in patients without weight loss alterations in 
hepatic gluconeogenesis are observed. There is evidence for elevated hepatic alanine 
uptake and gluconeogenic enzyme activity in the early steps of the gluconeogenesis 
occurring even in the absence of weight loss. 
2. Depleted ATP levels in the liver can be restored by intravenous infusion of ATP in lung 
cancer patients, especially weight~losing patients. High·dose ATP infusion also stimulates 
glucose turnover and gluconeogenesis from alanine during the infusion, but may lead to 
a reduction in gluconeogenesis after the ATP infusion has been stopped. 
3. Elevated hepatic PME levels predict the development of weight loss in cancer patients 
in the next three months. This would be consistent with the hypothesis that elevated 
gluconeogenesis contributes to weight loss in these patients. 
Future perspectives 
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Though the present study has clarified some of the metabolic changes involved in 
weight loss in lung cancer, underlying mechanisms remain to be investigated. As eleva· 
ted hepatic gluconeogenesis is prognostic for developing weight loss in cancer, further 
research on aberrations in the gluconeogenic pathway may help develop new therapeu· 
tic strategies. 
The following issues would appear to be especially relevant. First, it would be impor· 
tant to analyse the underlying mechanisms of the elevated glucose production in weight· 
losing lung cancer patients, which appeared to occur from both alanine as well as 
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lactate. Though in the present study evidence for alterations in liver metabolism in lung 
cancer was observed, its relation with other organs, especially in skeletal muscle, needs 
to be clarified. There may exist a regulating mechanism between altered liver and mus-
cle metabolism involving alanine, glucose and lactate. Selective labelling of lactate, 
alanine and glucose would permit to investigate metabolism of these substrates simulta-
neously 140,110, 150J. In addition, the forearm balance technique could be applied in 
order to investigate the fractional extraction of lactate, alanine, and glucose by muscle 
140J. Total glucose production by gluconeogenesis could be assessed simultaneously 
using 'H,O as described by Landau et a11119J. 
In addition, measurement of concentrations of individual gluconeogenic intermedia-
tes and activities of gluconeogenic enzymes within the liver would be of interest. Alt-
hough chemical analysis of liver biopsies is possible 112], the use of non-invasive techni-
ques is to be preferred in patients. We have shown that Jl p MRS can be a valuable tool 
for this especially if combined with turnover measurements. Additional information 
could be obtained by "c MRS of the liver. This method allows not only the determinati-
on of concentrations of gluconeogenic substrates, but also the flow through the variolls 
steps of gluconeogenesis or cycling 11 78,200J. Another advantage of this technique is 
that glycogen formation can be measured simultaneously 1166,184,213J. This is of 
particular interest since glycogen depletion could be another driving force in the enhan-
ced glucose production in cancer 197, 127J. Moreover, 13C and 31 P MRS could be used 
simultaneously for the investigating glucose metabolism and energy metabolism [193J. 
The approach of combining 31 p and" C MRS may be used to obtain information on 
intermediates of glucose and energy metabolism in liver and skeletal muscle in cancer 
patients with or without weight loss. This is of particular interest when investigating 
muscular fatigue or loss of muscle strength in these patients. Finally, the effect of intrave-
nous ATP on liver and muscle ATP content could be measured in combination by 31 p 
MRS. 
The studies described in the present thesis clearly point out that alterations in host liver 
metabolism exist in lung cancer patients which are prognostic for the development of 
weight loss. Unravelling the underlying mechanisms of altered host metabolism is the 
starting point for successful development of therapies for weight loss in lung cancer. 
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Weight loss is a common phenomenon in lung cancer patients and is associated with 
increased morbidity and mortality (Chapter 1). A typical feature of weight loss in cancer 
is that not only fat tissue but also muscle protein is lost. Decreases in food intake cannot 
fully account for the weight loss, suggesting alterations in host metabolism. 
E[evated muscle protein degradation and endogenous glucose production have been 
observed in cancer. Muscle·derived amino acids, especially alanine, are used for g[uco-
neogenesis within the liver. It has remained unclear, however, whether gluconeogenesis 
from alanine is elevated in lung cancer patients and whether it is related with weight 
loss. Also, it is not known whether changes in hepatic glucose metabolism are associa~ 
ted with alterations in energy (ATP) metabolism in the liver of lung cancer patients. 
The present research project was aimed at obtaining quantitative information on 
gluconeogenesis from alanine and on liver energy metabolism in relation with weight 
loss in lung cancer. The following specific study questions were formulated: 
1. Are liver gluconeogenesis increased and energy status decreased in lung cancer pa~ 
tients, and are these alterations related with weight loss? 
2. Can depleted liver energy stores in advanced lung cancer patients be restored by ATP 
infusion, and does this affect glucose metabolism? 
3. Do alterations in hepatic gluconeogenesis predict subsequent weight loss in cancer 
patients? 
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In Chapter 2, whole-body turnover rates of glucose and alanine, and gluconeogenesis 
from alanine were determined in lung cancer patients with weight loss (>5% of pre-
illness stable weight) or without weight loss. Primed·constant infusions of 16,6-'H,I-
glucose and 13-13C]·L-a[anine were used. The relations between turnover rates and the 
degree of weight loss were investigated. Hea[thy control subjects without weight loss 
were included as a reference. 
Energy intake and plasma concentrations of glucose, alanine, insulin, and glucagon 
were not different between lung cancer patients and healthy subjects. Whole body 
glucose and alanine turnover, and gluconeogenesis frorn alanine were 35%, 39% and 
57% higher, respectively, in weight-losing lung cancer patients compared to weight-
stable patients and healthy subjects. The degree of weight loss was positively correlated 
with glucose and alanine turnover, as well as with gluconeogenesis from alanine. 
[n Chapter 3 the relation between elevated hepatic phosphomonoesters (PME) and 
phosphodiesters (PDE), as observed by 31 p MRS, and glucose flux and gluconeogenesis 
from alanine, as determined by turnover measurements, in lung cancer patients is 
reported. 
Patients with advanced lung cancer without liver metastases, with/without weight 
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loss and healthy control subjects were studied after an overnight fast. Liver PME concen-
trations were 6% higher in lung cancer patients compared to controls; in particular, 
patients with weight loss had significantly higher PME levels than weight-stable patients. 
Levels of PDE did not differ between the groups. PME levels were significantly correlated 
with glucose turnover and gluconeogenesis from alanine in lung cancer patients. 
In Chapter 4, changes in levels of gluconeogenic intermediates in the liver of lung 
cancer patients during continuous L-alanine infusion are reported, using simultaneous 31 P 
MRS and turnover measurements. Lung cancer patients without liver metastases 
with/without weight loss and healthy control subjects were studied during an intrave-
nous L-alanine bolus of 1.4-2.8 mmol/kg followed by continuous infusion of 2.8 mmol L-
alanine/kg/h for 90 minutes. 
During L-alanine infusion, plasma alanine concentrations increased 15 to 17-fold in 
lung cancer patients and 24-fold in healthy subjects. Whole·body glucose turnover 
slightly increased (8%) in weight-stable lung cancer patients, whereas no significant 
change in weight-losing lung cancer patients and healthy subjects were observed. Liver 
PME levels increased by 50% in healthy subjects (area under the curve) and by 87% in 
weight-stable lung cancer patients after 45-90 min of alanine infusion. In contras~ no 
significant changes in PME were observed in weight-losing lung cancer patients. Plasma 
insulin concentrations increased during L-alanine infusion in all groups. Peak plasma 
insulin levels were lower in weight-losing lung cancer patients than in weight-stable lung 
cancer patients and healthy subjects. In lung cancer patients, changes in PME and PDE 
levels during alanine infusion were inversely correlated with their respective baseline 
levels. No such relation was observed in healthy control subjects. Also, changes in PME 
during alanine infusion in lung cancer patients were inversely correlated with the degree 
of weight loss. 
I n the same protocol, it was investigated whether increasing rates of gluconeogene-
sis, stimulated by L-alanine infusion, have an effect on bioenergetics in the liver of lung 
cancer patients with or without weight loss. Results are reported in Chapter 5. Baseline 
ATP levels were reduced in weight-losing lung cancer patients and inversely correlated 
with the degree of weight loss. Pr/ATP ratios in these patients were increased, indicating 
reduced liver phosphorylation status. During L-alanine infusion, ATP levels decreased in 
all groups. In weight-losing lung cancer patients, ATP levels were lower at all time-points 
between 0-90 min of alanine infusion as compared to both weight-stable lung cancer 
patients and healthy controls. Between 60·90 min of alanine infusion, partial recovery of 
ATP was observed in both healthy control subjects and weight-stable lung cancer pa-
tients, but not in weight-losing lung cancer patients where ATP continued to decrease. Pi 
/ATP ratios were significantly elevated after 70-90 min of L-alanine infusion in weight-
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losing lung cancer patients compared to weight-stable lung cancer patients and healthy 
subjects. 
Since liver ATP levels in weight-losing lung cancer patients were decreased and infusion 
of adenosine 5'-triphosphate (ATP) had shown to increase liver ATP levels in mice, two 
studies were carried out to investigate the effect of ATP infusion on liver ATP and gluco-
se metabolism. The study described in Chapter 6 was aimed at investigating whether 
ATP infusion restores liver ATP levels and phosphorylation status in advanced lung 
cancer patients. Patients with advanced non-small cell lung cancer were studied one 
week before and at 22-24 hours of continuous ATP infusion (37-75 ~g/kg/min) after an 
overnight fast. During ATP infusion 31 p MRS·detected hepatic ATP levels in lung cancer 
patients increased from 8.8% of total MR-detectable phosphate to 12.2% during ATP 
infusion, a level similar to that in healthy subjects (11.9%). ATP levels tended to increase 
more in patients with >5% weight loss than in patients without weight loss. Although 
PIA TP ratios in weight-losing lung cancer patients decreased slightly during ATP infusi-
on, this was not statistically significant. 
In the study described in Chapter 7, the effects of ATP infusion on whole body 
glucose and alanine turnover metabolism were investigated one week before and at 22-
24 hours of continuous ATP infusion using stable isotope tracers. High-dose ATP infusion 
(75 ~g/kg/min) increased glucose turnover by 41 % and gluconeogenesis from alanine 
by 23%, whereas at lower ATP doses (37-50 ~g/kg/min) no effects were detected. The 
change in glucose turnover during ATP infusion was positively correlated with ATP dose. 
The percentage glucose derived from alanine increased from 59% to 75% at high-dose 
ATP. No change in alanine turnover was observed at any ATP dose. 
In Chapter 8 observations on gluconeogenesis and liver metabolism in patients with 
breast cancer (mean weight loss 0 ± 1 %) are described. Glucose and alanine turnover, 
and gluconeogenesis from alanine in breast cancer patients were not different compared 
to healthy subjects. Baseline liver metabolites as observed by 31 p MRS Were similar in 
both groups. I n breast cancer patients, PME levels were inversely correlated with gluco-
se production and gluconeogenesis from alanine. During L-alanine infusion, PME levels 
increased in breast cancer patients and healthy subjects, but this was only significant in 
healthy subjects. No changes in POE, ATP or Pi levels were observed during L-alanine in 
breast cancer patients. 
The study described in Chapter 9 was conducted to investigate whether high hepatic 
PME levels in cancer patients predict the development of weight loss. For this analysis, 
3! P MRS liver data of fifty-six cancer patients with various tumour types, predominantly 
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lung (n=31) and breast cancer (n=25), were pooled. Body weight, body mass index, 
upper arm circumference, and triceps skinfold thickness decreased within 3 months 
post·MRS. After adjustment for energy intake and weight loss prior to MRS, a 5% rise in 
PME significantly predicted a reduction in body weight of 1.8 ± 0.6 kg and a reduction 
in body mass index of 0.6 ± 0.2 kg/m' at 3 months after MRS. 
In conclusion, the present project demonstrates elevated glucose and alanine turnover, 
and gluconeogenesis from alanine in weight·losing lung cancer patients. Elevated PME 
levels in the liver of lung cancer patients are correlated with increased glucose flux and 
gluconeogenesis from alanine, indicating that PME levels reflect contributions from 
gluconeogenic intermediates. In weight-losing lung cancer patients, maximal levels of 
gluconeogenic intermediates within the liver have been observed. In weight·stable lung 
cancer patients gluconeogenesis is more rapidly induced by alanine infusion than in 
healthy control subjects suggesting that the first steps of the gluconeogenic pathway are 
enhanced. Altered gluconeogenic enzyme activities, possibly PEPCK, and elevated 
alanine uptake by the liver may playa role. Weight·stable breast cancer patients do not 
show the alterations in hepatic glucose metabolism as observed in lung cancer, indica-
ting that alterations in host-metabolism may be tumour-specific. Nevertheless, the obser-
vation that elevated hepatic PME levels in cancer patients of different tumour types 
predict weight loss within the following three months is consistent with the suggestion 
that elevated gluconeogenesis contributes to weight loss in cancer. 
Hepatic energy and phosphorylation status is decreased in lung cancer patients with 
weight loss. An impaired energy regenerating capacity during stimulated gluconeogene-
sis exists in these patients. Decreased hepatic ATP levels in advanced lung cancer 
patients, especially weight-losing patients, can be regenerated by intravenolls infusion of 
ATP which may contribute to improving the nutritional status in these patients. High· 
dose intravenous ATP infusion also increases glucose turnover and gluconeogenesis 
from alanine in these patients. 
The studies described in the present thesis clearly point out that alterations in host liver 
metabolisrn exist in lung cancer patients which are prognostic for the development of 
weight loss. Unravelling the underlying mechanisms of altered host metabolism will be 
the starting point for successful development of therapies for weight loss in lung cancer. 
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Gewichtsverlies komt veelvuldig voor bij patienten met longkanker. Een kenmerk van ge-
wichtsverlies bij kanker is dat er niet aileen een afname van het vetweefsel optreedt maar er ook 
spiereiwit verloren gaat. Bij de gezonde mens wordt spiereiwit tijdens (Iangdurig) vasten juist 
gespaard. Deze afname in spiereiwit leidt tot een verslechtering van de lichamelijke conditie en 
een kortere overlevingsduur bij kankerpatienten. Het ontstaan van gewichtsverlies bij 
kankerpatienten kan niet volle dig worden verklaard doordat deze minder eten dan gezonde 
personen. Er zijn aanwijzingen dat veranderingen in de stofwisseling een belangrijke rol spelen 
bij het ontstaan van gewichtsverlies. 
Bij patienten met kanker zijn een verhoogde afbraak van spiereiwit en verhoogde 
gluconeogenese, dit is de vorming van glucose (suiker, koolhydraten) uit niet-koolhydraat 
substraten in het Iiehaam, waargenomen. Glueoneogenese is een energieverbruikend proees. 
Aminozuren afkomstig uit de afbraak van spierweefsel, met name alanine, kunnen worden 
gebruikt voer glueoneogenese in de lever. Het is eehter nog onduidelijk of glueoneogenese uit 
alanine verhoogd is bij patienten met longkanker en of een verhoogde glueoneogenese 
samenhangt met gewichtsverlies. Verder zou het kunnen zijn dat een verhoogde 
gluconeogenese een effect heeft op de energiehuishouding van de lever. Het is onbekend of 
veri aging van de energiestatus van de lever sarnenhangt rnet gewiehtsverlies. 
Het doel van het in dit proefschrift beschreven onderzoek was na te gaan of de 
gluconeogenese uit alanine en de energiehuishouding in de lever afwijkend zijn bij 
longkankerpatienten met, respectievelijk zonder gewichtsverlies. De hiervoor gebruikte 
methoden zijn turnoverrnetingen met stabiele isotopen en fosfor magnetisehe resonantie 
spectroscopie (31 p MRS) van de lever. De eerste methode is gebaseerd op het meten van de 
omzettingssnelheid (turnover) van een bepaald substraat (molecuul) in het bloed door het 
"merken" van het moleCLIulmet een zwaar atoom. In dit onderzoek werden glucose en alanine 
gemeten, gemerkt met de atomen deuterium ('H) en koolstof-13 ("C). De tweede methode is 
gebaseerd op verschillen in rnagnetische eigenschappen tussen verschillende moleculen die een 
fosfor atoom bevatten. Met behulp van 31 p MRS kunnen relatieve concentraties van deze 
moleculen in specifieke organen, zoals de lever, gemeten worden. 
De onderzoeksvragen van dit proefschrift waren: 
1. Is gluconeogenese in de lever verhoogd en de energiereserve van de lever verlaagd bij 
patienten rnet longkanker, en zijn deze veranderingen gerelateerd aan gewichtsverlies? 
2. Kan een verlaagde energiestatus van de lever bij longkankerpatienten hersteld worden door 
een inluus van ATP en wat is het effect hiervan op de gluconeogenese? 
3. Voorspellen veranderingen van de gluconeogenese in de lever van kankerpatienten 
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gewichtsverlies? 
In Hoofdstuk 2 wordt een onderzoek beschreven naar de stofwisseling van glucose, alanine, 
en gluconeogenese uit alanine bij longkankerpatienten met gewichtsverlies (>5% van het 
stabiele gewicht voor de ziekte) en zander gewichtsverlies, gemeten met stabiele isotopen. Ook 
wordt beschreven of er een relatie bestaat tussen de stofwisseling van de genoemde substraten 
en de mate van gewichtsverlies. De waarden bij kankerpatienten werden vergeleken met die 
van gezonde vrijwilligers zonder gewichtsverlies. 
De voedingsinname en plasmaconcentraties van glucose, alanine, insuline en glucagon 
bleken niet te verschillen tussen longkankerpatienten en gezonde controlepersonen. De 
glucose~ en alaninetllrnover en de gluconeogenese lIit alanine bij longkankerpatienten met 
gewichtsverlies waren respectievelijk 35% , 39% en 57% hoger dan bij patienten zonder 
gewichtsverlies en gezonde vrijwilligers. De snelheid van de gilicose~ en alanineturnover, en 
gluconeogenese uit alanine was hager naarmate het gewichtsverlies ~ij longkankerpatienten 
toenam. 
Gluconeogenese uit alanine vindt voornamelijk plaats in de lever. Met behulp van 31 p MRS 
kunnen verhoogde concentraties van tllssenprodllcten van de gluconeogenese worden 
gemeten als een stijging van de phosphomonoesters (PME) en phosphodiesters (PDE) in de 
lever. In het onderzoek beschreven in Hoofdstuk 3 werd nagegaan of verhoogde PME- en 
phosphodiester (POE) concentraties samenhangen met verhoogde glucoseturnover en 
gluconeogenese uit alanine, zoals gemeten met stabiele isotopen bij longkankerpatienten en 
gezonde vrijwilligers. De PME-concentratie in de lever bij longkankerpatienten bleek 6% hoger 
te zijn dan bij gezonde controlepersonen. De PME-waarden in patienten met gewichtsverlies 
waren significant hoger dan in patienten zonder gewichtsverlies. PDE-concentraties in de lever 
waren niet verschillend tllssen de groepen. Hogere PME-concentraties in de lever bij 
longkankerpatienten gingen gepaard met een hog ere glucoseturnover en gluconeogenese uit 
alanine. Bij gezonde controlepersonen werd dit verband niet gevonden. 
In Hoofdstuk 4 wordt een dynamisch onderzoek naar concentraties van tllssenproducten van 
de gluconeogenese in de lever van longkankerpatienten beschreven. Hierin werden 31 p MRS-
metingen van de lever en tllrnovennetingen verricht tijdens een in(uus van L-alanine (bolus van 
1,4-2,8 mmoljkg gevolgd door 2,8 mmoljkgjuur gedurende 90 minuten). 
Tijdens het in(uus van l~alanine stegen de plasma alanineconcentraties met een factor 1 s~ 17 
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bij longkankerpatienten en met een factor 24 bij gezonde controlepersonen. De 
glucaseturnaver tijdens het L~alanine inflllls steeg met 8% bij langkankerpatienten zander 
gewichtsverlies, terwijl geen significante verandering werd waargenomen bij patienten met 
gewichtsverlies en gezonde controlepersonen. Na 45-90 minuten alanine infuus waren de PME-
concentraties in de lever gestegen met 500/0 bij gezande cantroles en met 87% bij 
longkankerpatienten zonder gewichtsverlies. Bij longkankerpatienten met gewichtsverlies 
werden geen significante veranderingen in PME~concentraties in de lever waargenomen. De 
plasma illsulinecollcentraties namen weliswaar bij aile groepen tijdens het L~alanine infulls toe, 
maar stegen het minst bij longkankerpatienten met gewichtsverlies. Hoe hoger de concentraties 
van PME en PDE waren in de lever van longkankerpatienten in de uitgangssituatie, des te kleiner 
waren de veranderingen in deze componenten tijdens het L~alanine infuus. Opnieuw werden 
deze relaties niet gevanden bij gezande controlepersonen. Verder waren de veranderingen in 
PME in de lever bij longkankerpatienten tijdens het L-alanine infuus kleiner naarmate het 
percentage gewichtsverlies grater was. 
Dezelfde studieopzet werd gebruikt om na te gaan of een verhoogde gluconeogenese 
tijdens alanine infuus invloed heeft op de energiehllishollding in de lever van 
longkankerpatienten Illet en zonder gewichtsverlies. Oit onderzoek wordt beschreven in 
Hoofdstuk 5. Veranderingen in concentraties van adenosine triphosphate (AlP) en anorganisch 
JI fosfaat (P,) werden gemeten met behulp van P MRS. 
Basale ATP-concentraties waren verlaagd in de lever bij longkankerpatienten met ge-
wichtsverlies. De AlP~concentraties wareiliager naannate het gewichtsverlies grater was. De 
P IATP ratio's in de lever bij longkankerpatienten met gewichtsverlies waren verhoogd, hetgeen 
duidt op een verlaagde fosforyleringsstatus (energiestatus) van de lever. Tijdens het L-alanine 
infuus daalde de concentratie van ATP in de lever bij aile groepen. Gedurende de gehele 
infuusperiode (0-90 min.) was het ATP-gehalte bij longkankerpatienten met gewichtsverlies 
significant lager dan bij longkankerpatienten zonder gewichtsverlies en gezonde 
controlepersonen. Opmerkelijk was dat bij de laatste twee groepen na 60-90 minuten een 
zekere stabilisatie van de AlP niveau's in de lever plaatsvond, maar niet bij longkankerpatienten 
met gewichtsverlies. Na 70-90 min infuus van L-alanine waren de P /ATP ratio's significant 
verhoogd bij longkanker-patienten met gewichtsverlies ten opzichte van gewichtsstabiele 
longkankerpatientell en gezonde controlepersonen. 
De volgende hvee studies werden uitgevoerd arn het effect van een infuus van AlP op de 
energiehuishouding in de lever en de glucosestofwisseling bij patienten met longkanker te 
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bestuderen. In het onderzoek beschreven in Hoofdstuk 6 werd nagegaan of een infuus van ATP 
hetATP-gehalte en de fosforyleringsstatus in de lever bij longkankerpatienten kan verbeteren. 
Dit werd onderzocht met behulp van 31 p MRS. Patienten met longkanker werden tweemaal 
onderzocht: een week vaar, resp. tijdens 22-24 uur continu ATP infuus (37-75 >lg/kg/min). Het 
ATP-gehalte in de lever bij longkankerpati~nten nam toe van 8,8% in de uitgangssituatie (ten 
opzichte van totaal MR-fosfaat) tot 12,2% tijdens het ATP-infuus. Deze laatste waarden waren 
gelijk aan die bij gezonde controlepersonen. Het ATP·gehalte nam meer toe bij patienten met 
gewichtsverlies dan bij patienten zonder gewichtsverlies. De PIA TP verhoudingen daalden licht 
tijdens het ATP-infuus, maar dit was niet statistisch significant. 
In Hoofdsluk 7 wordt het effeel van het ATP-infuus op de glucose- en alanineturnover, en 
op de gluconeogenese uit alanine beschreven. Een hoge ATp·dosis (75 >lg/kg/min) bleek bij 
longkankerpatienten een stijging in de glucoseturnover van 41 % en een stijging in de 
gluconeogenese uit alanine van 23% te veroorzaken. Lagere doses AlP (37-50 >lg/kg/min) 
hadden dit effeel niet. De toename in de glucoseturnover was afhankelijk van de AlP-dosis. 
Tijdens de hoge ATP-dosis narn het percentage glucose afkolllstig van alanine toe van 59% tot 
75%. De alanineturnover bij longkankerpatienten veranderde bij geen van de gegeven AlP-
doses. 
In Hoofdstuk 8 worden resliitaten beschreven van gluconeogenese en leverstofwisseling bij 
pam~nten met borstkanker (gewichtsverlies: 0 ± 1 %). Glucose- en alaninetllrnover en 
gluconeogenese lIit alanine bij patienten met borstkanker waren niet verschillend van die bij 
gezonde controlepersonen. Concentraties van metabolieten in de lever gerneten met 31 p 
MRS waren niet verschillend tussen de groepen. Bij borstkankerpatienten waren PME 
niveau's in de lever negatief gecorreleerd met glucoseprodllctie en gluconeogenese uit 
alanine. Lever-PME concentraties namen toe tijdens L-alanine infulis bij zowel 
borstkankerpatienten als gezonde controlepersonen, maar aileen bij de laatste groep was dit 
significant. Er werden geen verandering waargenomen in POE, ATP en Pi concentraties 
tijdens L-alanine infuus bij borstkankerpatienten. 
In de studie beschreven in Hoofdsluk 9 werd onderzocht of een hoge concentratie van 
PME in de lever bij kankerpatienten het optreden van gewichtsverlies kan voorspellen. 
Gegevens van 31 p MRS-studies van de lever bij 56 kankerpatienten met diverse tumortypen, 
voornamelijk long- (n~31) en borstkanker (n~25), werden samengevoegd voor deze analyse. 
lijdens 3 maanden na de MRS-meting namen het lichaamsgewicht, de quetelet-index, de 
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armomtrek, en de triceps huidplooi dikte af. Na correctie voor de energieinname en de 
quetelet-index ten tijde van de MRS-meting, bleek een stijging in de PME waarde van 5% 
was voorspellend voor een gewichtsafname van 1,8 ± 0,6 kg en een afname in de quetelet-
index van 0,6 ± 0,2 in 3 maanden. 
Conclusie 
Het onderzoek beschreven in dit proefschrift toont aan dat de glucose- en 
alaninestofwisseling verhoogd zijn bij longkankerpatienten met gewichtsverlies. Deze 
afwijkingen zijn afllankelijk van de mate van gewichtsverlies bij longkankerpatienten en niet 
aileen van de aanwezigheid van longkanker als zodanig. De resultaten wijzen erap clat een 
verhoogde concentratie van PME in de lever van longkankerpatienten het gevolg is van een 
verhoogcle glucoseturnover en gluconeogellese uit alanine, door een toename van-
concentraties van tussenproducten van de gluconeogenese. In de lever van longkank-
erpatienten met gewichtsverlies is cle gluconeogenese lIit alanine maximaal. Bij 
longkankerpatienten zonder gewichtsverlies zijn waarschijnlijk de eerste stappen van de 
gluconeogenese versneld. Mogelijke achterliggende mechanisrnen zijn een verhoogde 
activiteit van gluconeogenese-enzymen, met name fosfoenolpyruvaat carboxykinase, en een 
verhoogde opname van alanine in de lever vanllit het bloed. De bevindingen clat verhoogde 
PME-waarden in de lever bij kankerpatienten het gewichtsverlies in de 3 daaropvolgende 
rnaanden voorspellen wijst op een mogelijk oorzakelijk verband tussen een verhoogde 
gluconeogenese en gewichtsverlies bij patienten met long- en borstkanker. 
De ATP- en fosforyleringsstatus van de lever zijn verlaagd bij longkankerpatienten met 
gewichtsverlies. Ook bestaat er een verfllinderde capaciteit voor het herstellen van het 
energieniveau bij longkankerpatienten rnet gewichtsverlies. Een infuus van ATP kan de 
energiestatus van de lever bij longkankerpatienten verbeteren, met name in patienten met 
gewichtsverlies. Deze veranderingen kunnen een ral spelen in de gunstige effecten van ATP 
op het lichaamsgewicht zoals gemeten bij muizen. Een hoge dosis ATP veroorzaakt ook een 
toename in de gilicoseturnover en de gluconeogenese uit alanine bij patienten met 
longkanker. 
Het in dit proefschrift beschreven onderzoek toont aan zien dat er veranderingen 
bestaan in de leverstofwisseling bij patienten rnet longkanker en dat deze veranderingen 
gewichtsverlies kunnen voorspellen. Het ontrafelen van de oorzaken van deze afwijkende 
stofwisseling zou een uitgangspunt kunnen zijn voor de ontwikkeling van sllccesvolle 
therapieen tegen gewichtsverlies bij kanker. 
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